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Background: Neuroinflammation is a common feature of Alzheimer’s disease pathology, 
which is characterized by the presence of activated astrocytes and activation of the 
microglia (the brain’s resident macrophages), as well as expression of inflammatory 
cytokines & complement system activation. Recently, genome-wide association studies 
(GWAS) have shown an association of risk of sporadic AD with genes linked to innate 
immunity such as genes related to microglial functions and complement genes. The 
complement system plays an integral role in the innate immune response; however, the 
contribution of the immune system and complement activation in glial cell activation and 
other immune-related changes, such as cytokine release in AD, are not completely 
understood. Abnormally accumulated misfolded proteins in the brain stimulate different 
parts of the immune response to clear them. 
Objectives: The aim of this project was to study the potential contribution of the innate 
immune response in AD compared with control brain. This involved work to investigate 
the differences between a number of complement system proteins, astrocyte markers and 
cytokines using quantitative protein measurements and quantification of gene expression. 
Another aim was to explore the correlations of these inflammatory changes with each other 
and with AD-related protein changes and other related confounding factors.  
Method: To achieve these objectives, a range of specific inflammatory proteins and genes 
were quantified in frontal and temporal cortex post-mortem brain tissue from South West 
Dementia Brain Bank (SWDBB) from cases of neuropathologically confirmed AD and 
elderly non-demented controls. Tissue was homogenized and used in ELISA assays and 
qPCR for those measurement. To ensure all of the changes seen were originated from brain 
tissue, fibrinogen was measured as a marker of Blood-brain barrier disruption. Innate 
immune markers such as complement cascade proteins (C1q, C3), activation products 
(iC3b and TCC) and regulators (Clusterin and CFH), astrocyte marker (GFAP), pro-
inflammatory cytokines (IL-1β) were measured. Relative gene expression quantification 
was done to a variety of genes (C1QA, C3, CFH, CLU, CR1 GFAP, IL-1β and TNF-α) in 
relation to different calibrator genes.  
Results: There was no significant difference in fibrinogen levels between different groups 
of the study. Some of the complement proteins and regulators, such as C3, CFH iC3b & 
clusterin, are increased in one or both brain areas examined in the AD group compared to 
age-matched controls while others show no significant difference between the groups such 
ii 
 
as C1q and TCC, as shown in the figure. These changes were related to Aβ load or increased 
with later Braak stages. Complement genes were also upregulated in frontal brain areas in 
AD such as (C3 and CLU), while other genes were upregulated in the temporal cortex 
(C1QA, C3 and CR1). 
GFAP as a marker of astrocytes was found to be increased in the temporal cortex of AD 
patients compared to controls, while GFAP relative gene expression was upregulated in 
both frontal and temporal brain areas. Other inflammatory markers tested as pro-
inflammatory cytokines showed a significant decrease in IL-1β levels in AD in both brain 
areas compared to controls. Moreover, IL-1β relative gene expression was also 
downregulated in AD brain mRNA. 
 
 
Conclusion: Data from this study support the role of neuroinflammation as an important 
contributor to AD pathology. Results from human brain tissue are more relevant than those 
obtained from cell or animal models which may not reflect the complexity of human 
pathological changes in AD brain. The findings provide novel data in one of the largest 
cohorts selected to study the inflammatory markers by sensitive and accurate methods for 
the quantitative measurement of proteins and genes. Moreover, the main conclusion is that 
the complement system is dysregulated in AD brain, some of the complement system 
components were found to be correlated with the disease pathology according to Braak 
staging, however, further studies would be needed to confirm these preliminary results and 
to try and find neuroinflammation related therapeutic options for treating AD.
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1. Chapter 1: Introduction. 
Dementia 
Dementia is the clinical syndrome of progressive loss of cognitive abilities such as 
those involved in thinking, language, memory, and behaviour. It can be considered as one 
of the most important causes of dependency and disability (1). The most common types of 
dementia include Alzheimer’s disease (AD), vascular dementia (VaD), dementia with 
Lewy bodies (DLB), Parkinson’s disease dementia (PDD), fronto-temporal dementia 
(FTD) and mixed dementias  that often include the co-occurrence of more than one type of 
dementia-related pathology, often related to cerebrovascular pathology (2,3). 
1.1 Alzheimer’s disease (AD) 
AD is the commonest form of dementia worldwide (4), which was first described 
in 1907 (5). It is a neurodegenerative disease characterized by gradual and progressive loss 
of memory and cognitive function (6). If there are no changes to the current availability of 
treatments, the total number of people with dementia is projected to reach more than 150 
million in 2050 (1). After being studied extensively for many decades, the mechanisms 
underlying the initiation of AD and how it progresses are better understood but much still 
remains unknown. Moreover, new therapeutic approaches are required since all of those 
current available predominantly treat symptoms. Thus, the underlying progressive disease 
continues to a point beyond which the treatments are no longer effective. Another issue that 
recent trials have shown on new experimental treatments, is that all new compounds need 
to be explored in clinical trials much earlier in the course of AD, such as in cases of mild 
cognitive impairment (MCI), where the likelihood of benefit may be greater (7,8). 
1.1.1 Genetics of AD 
According to the presence, or not, of familial mutations, which largely determines 
age of onset, AD can be categorized into familial and sporadic forms. 
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1.1.1.1 Familial AD (FAD) 
Familial AD is a rare, early-onset autosomal form caused by genetic mutation in 
one of three genes related to the production of beta amyloid protein (Aβ). The first one is 
the amyloid precursor protein (APP) (9), which accounts for less than 5% of cases; the 
other two genes are presenilin gene 1 or 2 (PSEN1 or PSEN2); all of which are relatively 
rare and can be diagnosed early in life with an onset before 65 years of age. These mutations 
lead to either increased production of Aβ or increased ratio of formation of the toxic form 
Aβ (1-42) peptide to Aβ (1-40) peptide (10). PSEN1 mutations are the most common and 
leads to development of a rapidly progressing form of the disease with earlier disease onset 
than other forms (11). 
1.1.1.2 Sporadic AD 
It is the commonest form of AD and is also often referred to as late-onset AD 
(LOAD). This form generally has a later age of onset i.e. after 65 years of age. Interactions 
between environmental, and genetic factors with various hypotheses have been suggested 
in this type. Despite having complex and heterogenous causes, there is no definite causative 
genetic factor identified. 
Genes associated with LOAD 
There are many genes involved as risk factors for sporadic AD, of which 
apolipoprotein E (APOE) genotype is considered the main risk factor (12–14); a ligand 
involved in lipid transport (15). The three major gene isoforms in human are (ε2, ε3, and 
ε4) that respectively give rise to three corresponding protein isoforms ApoE E2, E3 and 
E4. APOE ε3 is the commonest isoform (16), while having the ε4 allele makes an individual 
more susceptible to develop AD by 2 to 5 fold if heterozygous and by 12 to 15 fold if they 
are carrying the less common homozygous genotype (16,17). The mechanism of APOE 
involvement in AD is still not fully understood; however, it was identified very early on 
that ApoE can bind to Aβ (18,19), and that the ε4 allele was associated with increased Aβ 
aggregation (17,20), whereas conversely, the ε2 allele has been found to be protective 
against AD. There is also the evidence that different ApoE isoforms may bind differently 
to low-density lipoprotein related protein 1 (LRP1), an ApoE receptor that also bind and 
involved in Aβ clearance (21,22). 
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A number of other genetic risk factors have been discovered by Genome Wide 
Association Studies (GWAS) that include pathway analyses. Some of these genes are 
connected with the role of immune response, including genes implicated in the function of 
microglia. They include the clusterin (CLU) gene (23), as well as TREM2, CD33, CR1, 
ABCA7 and SHIP1 (24,25)  The presence of genetic polymorphisms that are associated 
with increased risk support the idea that systemic inflammation, phagocytosis, 
neuroinflammation and immunological responses are important factors in AD risk. This 
will be discussed in more detail later. 
1.1.2 Risk factors for AD 
The incidence of AD is increasing as the population ages. Ageing, an unavoidably 
non-modifiable factor, is considered to be the main risk factor for AD. However, as 
mentioned, for the majority of AD cases, no definite cause has been identified; it appears 
to be a complex multi-factorial disease that gives rise to the progressive and irreversible 
neurodegeneration. Women also have a higher risk factor in their lifetime of AD than men, 
two-thirds of AD cases are women. One reason that has been proposed is that women 
relatively live longer than men, although there are additional biological and hormonal 
differences that may have some bearing (26,27). Moreover, there is evidence that the 
inflammatory response, including the phagocytosis by microglia in the brain is affected by 
gender differences (28,29). 
Apart from genetic factors previously mentioned, it is well known that a 
considerable number of AD cases have mixed vascular pathology and small-vessel disease 
(SVD) (30,31). Furthermore, other studies suggested that cases with mixed pathologies 
show a more progressive course of dementia (32) and tend to coincide with specific 
vascular-related co-morbidities such as diabetes (3). 
Cardiovascular disease and hypertension, which may also become more prevalent 
in older age, are also risk factors for the disease. The brain renin-angiotensin system (RAS) 
is an important regulator of blood pressure, and contributes to aspects of AD progression 
and cognitive decline (33,34). Recent epidemiological studies have linked other risk factors 
that may be related to AD and vascular dementia such as: hypercholesterolaemia, diabetes 
and smoking (35–38). Other possible risk factors for AD are environmental such as the 
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association with dietary intake (39), low level of education (40) and traumatic brain injury 
(41). 
1.1.3 Pathology of AD 
For more than three decades, there has been intensive research into the 
pathogenesis of AD (42), but how the process is initiated and progresses, and how its 
progression can be stopped, or slowed, remain unresolved. To date, drugs available for AD 
are acetylcholinesterase inhibitors (CEIs) (43). Another less frequently used drug in AD is 
Memantine (44). No single treatment was successful to stop or slow the disease progression 
in all cases, therefore, more therapeutic options continue to be explored (45). 
AD is a complex disease that can be described and divided up according to a time 
scale. Some researchers divide AD phases into (1): a ‘biochemical phase’ - the beginning 
of the two main pathological hallmarks of AD that includes the extracellular accumulation 
of Aβ and the intracellular changes that give rise to tubulin-associated unit (Tau) pathology. 
It is also known that pathological changes affecting brain regions that control memory, 
occur many years before clinically apparent symptoms of the disease i.e. the preclinical or 
prodromal stage (46,47). This is followed by (2) the ‘cellular phase’ - likely to start after 
the failure of Aβ clearance mechanisms that involves different cell types, such as neuronal 
cells, microglia and astrocytes (47), and then finally (3) the ‘clinical phase’ identified by 
the cognitive impairment caused by neuronal death and accompanied by the progressive 
symptoms of the disease and brain atrophy (48,49). Although others suggested that the 
initial biochemical phase may be preceded by or triggered by underlying early vascular 
dysfunction, potentially caused by cerebrovascular disease, which has been identified as an 
even earlier form of pathology (50).  
1.1.3.1 Beta-amyloid (Aβ) 
➢ Aβ production 
There are multiple changes that may be involved in the pathogenesis of AD 
including the formation of senile plaques by the deposition and accumulation of 
extracellular fibrillar Aβ deposits in the brain parenchyma (51,52). The ‘amyloid cascade 
hypothesis’ is a widely accepted theory for the pathogenesis of AD, which has been a key 
5 
 
focus in several decades in the development of new therapies for AD. The key essence of 
the hypothesis, which has amyloidogenic and non-amyloidogenic pathway arms, is neuron-
centric and is initiated by amyloid beta deposition that is thought to subsequently induce 
tau hyperphosphorylation, synaptic dysfunction and neuronal loss (53). 
In the amyloidogenic pathway, beta amyloid (Aβ) is formed by the sequential 
cleavage of the transmembrane protein APP via β- and then γ-secretase enzymes (54,55). 
The amyloidogenic pathway gives rise to the accumulation of soluble Aβ oligomers as 
illustrated in Figure 1-1, which has been suggested to be cleared from the brain by different 
mechanisms (56,57).  
In contrast, the non-amyloidogenic pathway that involves the processing of APP 
via α-secretase and then by γ-secretase results to produce a different longer form of Aβ. 
Imbalance between the amyloidogenic and non-amyloidogenic pathways determines the 
levels of Aβ being produced and in turn determines the extent to which oligomeric Aβ is 
produced or cleared and thus which determines whether AD progression is initiated 
(42,58). In AD, amyloid plaques are dense and called senile or neuritic plaques, caused by 
the further development of oligomeric Aβ into fibrils, usually caused by increased 
production of slightly longer forms of Aβ (Aβ42) that are insoluble and initially deposited 
in the isocortex (59) then spread to the hippocampus and entorhinal cortex (60).  
Despite considering insoluble amyloid β as the main harmful constituent in the 
disease pathogenesis (61), the soluble Aβ has been linked to synaptic disruption and 
cognitive dysfunction as an important contributor in AD pathology (62). Low molecular-
weight dissociates of soluble Aβ have been suggested to be more toxic than bigger 
oligomers (63). There remains debate as to how Aβ has its toxic effect. There is increasing 
evidence that some Aβ accumulation can be seen in brain even without any signs of 
cognitive decline suggesting that Aβ is not the only contributing factor for AD pathology 
(64). That was previously supported by the failure of clinical trials based on amyloid 
hypothesis which consider Aβ accumulation in the brain as the primary pathological event 




Figure 1-1: Alzheimer's disease pathology. This figure shows: (1) Amyloid plaques formation by 
abnormal accumulation of insoluble Aβ formed by the cleavage of transmembrane amyloid 
precursor protein (APP) and processed by the amyloidogenic β-secretase pathway or the non-
amyloidogenic α-secretase pathway, (2) Neurofibrillary tangles formation and 
hyperphosphorylation of tau protein. 
➢ Aβ clearance 
It is critical to understand the methods of clearance of soluble Aβ from the brain. 
As mentioned, unimpaired functional clearance is important to avoid extracellular Aβ 
accumulation that leads to exacerbation of AD pathology. Clearance can occur via different 
mechanisms. One such mechanism is degradation of Aβ by proteolytic enzymes such as 
neprilysin (NEP) (66,67), insulin degrading enzyme (IDE), angiotensin-converting enzyme 
(ACE) (68) or endothelin-converting enzyme (ECE) (69,70).  
Another route of clearance is the perivascular drainage of Aβ from the brain and 
its transport through the neurovascular unit (NVU) including astrocytes i.e. the blood-brain 
barrier. In this mechanism, it is also thought to involve ApoE as a chaperone protein (22), 
previously mentioned as produced by APOE in which variation is one of the largest risk 
factors for sporadic AD (71,72). Astrocytes are also involved in Aβ clearance, where they 
have been shown to be stimulated by Aβ that in turn aid its removal (73–75). The 
mechanisms by which astrocytes regulate Aβ are still debated. ApoE which is produced 
primarily by astrocytes in the central nervous system (CNS) and is also thought to play a 
cardinal, but indirect role, in Aβ regulation in this mechanism as it was shown previously 
that soluble Aβ binds poorly to ApoE E4 (75,76). 
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Another mechanism of Aβ clearance is phagocytosis by activated microglia 
through scavenger receptors or by expressing degrading enzymes (77). However, this 
mechanism may become defective over time and fail to remove Aβ from AD brain (78). 
Toll-like receptors (TLRs) in particular have been implicated in Aβ removal by activated 
microglia (79). Astrocytes can also phagocytose neurons containing Aβ (80). Furthermore, 
major complement system proteins such as C3 have also been implicated in Aβ clearance 
as seen in transgenic mice deficient in C3 component (81) and where the C3b fragment 
binding with microglia enhanced Aβ clearance (82). Thus, neuroinflammation including 
glial cells and complement activation are considered as important regulators of Aβ 
clearance in AD brain. 
1.1.3.2 Tau pathology 
Tau protein is present normally in the microtubules of neurons that stabilize the 
cell structure (83,84) and enable axonogenesis (85). In AD, the intracellular tau-related 
lesion is the second main pathological hallmark, named as neurofibrillary tangles (NFTs). 
It was shown that, in one form of transgenic AD mouse model, beta amyloid pathology 
precedes tau pathology (86), and in time promotes tau hyperphosphorylation and 
aggregation in the brain as shown in Figure 1-1. This interaction leads to formation of 
misfolded tau protein; tauopathies, disruption of normal neuronal function, and inevitable 
neuronal death and brain atrophy (87–89). Tauopathies can also occur secondary to various 
types of injuries in the brain, such as traumatic brain injury (90). 
Another suggested mechanism of Aβ and hyperphosphorylated tau protein 
propagation in AD brain is a ‘prion-like’ property that has been reported (91). Recently, 
evidence has supported this mechanism whereby brain extracts from humans with 
tauopathies can induce tau pathology in non-transgenic mice (92,93). 
➢ Neurofibrillary tangles (NFTs) 
Hyperphosphorylated tau and NFTs exhibit a characteristic sequence of 
distribution in the brain starting from the temporal cortex and hippocampus then spread to 
other parts (94). This form of pathology has been described to be divisible into six stages 
of increasing severity, correlating closely with clinical stages of dementia, as described by 
Braak & Braak 1991 (95) and is widely used to determine severity of the disease (96). 
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Misfolded tau protein is toxic and causes neuronal dysfunction via disrupting the synaptic 
function and neuronal cell death. Additionally, its aggregation due to hyperphosphorylation 
of the tau protein, can also stimulate immune responses in the brain including complement 
cascade activation (97). It seems that Aβ, particularly soluble oligomeric Aβ, can initiate 
tau changes that precede the formation of NFTs, which accelerate disease progression (98). 
This sequence of pathology has been confirmed recently by positron emission tomography 
(PET) scanning of Aβ And tau (99). 
1.1.3.3 Neuronal death and cerebral atrophy 
As previously mentioned, abnormal Aβ and tau aggregation affect neurons in AD 
brain. Accumulation of phosphorylated tau leads to cytoskeletal changes in the neurons 
starting from cortical neurons in the hippocampus and entorhinal cortex spreading into 
different areas in the brain parenchyma (100). Significant synaptic loss is also observed in 
AD brains and APOE genotypes may affect pre- and post-synaptic function (101–103). 
Possible mechanisms of neuronal death in AD brain are apoptosis induced by Aβ and 
regulated by caspases (104,105), or phagocytosis by microglial activation together with 
complement system (C1q) that mediates early synaptic loss in AD (106). Nevertheless, 
regional depletion of synapses correlates with the cognitive decline in AD brain (107). 
In addition, brain hypometabolism and decreased glucose consumption are 
suggested to be early events in some neurodegenerative diseases like sporadic AD, leading 
to neuronal and synaptic dysfunction (108), and eventually to cognitive decline and disease 
progression. Regional glucose hypometabolism can be considered as a predictor for 
progression of MCI patients into AD patients (109). Insulin resistance is also implicated in 
the pathogenesis of AD (110). It is likely that insulin signaling regulates synaptic function 
and insulin resistance in the brain increases the risk of impaired cognition (111). Moreover, 
in AD pathogenesis, mitochondrial dysfunction leads to oxidative stress (112,113). This 
occurs as a consequence of reactive oxygen species (ROS) accumulation, chemically active 
substances that cause damage of surrounding neurons (114).  
Macroscopically, a significant loss in brain tissue weight and size (101,115), 
starting with hippocampal atrophy (116) and expansion of the ventricles are seen in AD 
brains by neuroimaging or in post-mortem studies (117). 
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1.1.3.4 Brain areas affected in AD  
Different brain regions have varying and specific functions as well as protein 
expression profiles which also changes in different stages of pathological stages of AD 
(118). Braak et.al, in their landmark work for staging the neuropathological features in AD, 
described the spread of NFTs starting from transentorhinal cortex early in stages (I-II), then 
to the limbic system in stages (III-IV), and then to isocortical areas in stages (V-VI) in 
which the hippocampus is heavily involved  (95). The thalamus is involvement in 
progression of memory loss early in MCI and AD (119). 
The medial temporal area including the hippocampus is affected early in AD brain 
(120), which is the main cause of memory loss. One of the first areas affected is the 
amygdala; both amygdala and hippocampal cell loss and atrophy correlate with cognitive 
function (121). The cerebellum was thought to be relatively ‘spared’ from AD pathology, 
however, some evidence has proved its early involvement in AD pathology (122) and in 
atrophy (123). 
1.1.3.5 Cerebrovascular pathology 
Several sets of evidence have proved that the neuropathology of AD is extended 
beyond Aβ and NFTs. Changes in cerebral vasculature and its effect on the pathogenesis 
of VaD and mixed types of dementias is another important aspect of the disease and indeed 
may, according to recent evidence, be the earliest pathology evident in the development of 
AD (50). Good cerebral blood flow is essential for normal brain function and homeostasis. 
These functions are regulated and maintained by the NVU (124) which will be discussed 
further later. The vascular hypothesis considers that impaired cerebral perfusion is the main 
triggering factor for neuronal damage in AD (125). Cerebral hypoperfusion is variable 
between brain regions and correlates with Braak stages and pathology distribution (126). 
Under hypoxic conditions, pericytes and vascular smooth muscle cells could lead to 
defective Aβ clearance (127), and accumulation of neurotoxic molecules in the brain, 
which may also occur before Aβ deposition (128–131). More recently dysfunction in the 
renin angiotensin system, a major biochemical pathway in blood pressure and blood flow 
regulation, has been proposed to be an instrumental mechanism that mediates both vascular 
dysfunction, as well as more classical AD-related pathologies, in AD (34). 
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➢ Cerebral amyloid angiopathy (CAA) 
Amyloid beta deposition is also present in cerebral blood vessels, a pathology 
known as cerebral amyloid angiopathy. In late AD stages, CAA causes narrowing of small 
and medium sized cerebral vessels and impairment of the normal drainage process. It was 
thought that the APOE genotype implicated in Aβ accumulation in the blood vessels (132). 
More recent studies have highlighted the role of APOE ε4 in fibrin deposition around 
vessels and its correlated with CAA (133). These pathological events lead to blood vessel 
stiffness, reduced cerebral blood flow; with hypoperfusion and subsequent reduction in 
brain tissue oxygenation and increased likelihood of haemorrhage. CAA was also found to 
correlate with cognitive decline in AD (134). Although the role of blood-vessel Aβ is 
important, the association with APOE is still disputed with the previous reports of 
association with APOE ε4 (135). 
It is also well known that cerebral microhaemorrhage is a common feature in AD 
brain, particularly in the presence of hypertension (136). This has been shown to worsen 
cognitive function and can be seen around amyloid plaques. Homozygous APOE ε4 
patients are more likely to have brain microhaemorrhage (137). 
Furthermore, chronic cerebral hypoperfusion was proven to cause more Aβ 
deposition in APP transgenic mice brain (138), and mild or acute hypoperfusion also 
exacerbated pathology in triple transgenic mice causing a sudden increase in β-secretase 
enzyme and subsequent Aβ accumulation (139). All of these pathological changes together 
with the blood-brain barrier (BBB) disruption eventually lead to considerable and 
progressive neuronal degeneration and loss (48). 
1.1.3.6 The blood-brain barrier 
The brain is considered to be insulated from the rest of body, maintained by the 
protective function of the BBB. This is a complex cellular network comprising the NVU, 
composed of different cell types working together to maintain the brain homeostasis 
necessary for normal activity of nerve cells. The BBB (as shown in Figure 1-2) protects the 
brain parenchyma from invading dangerous insults and pathogens, and tight junctions are 
formed by endothelial cells sharing a basement lamina with pericytes and astrocytic end 
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feet surrounding the blood vessels and where perivascular microglia interact with neurons 
(140). In this context, the BBB is the first line of defence to protect the brain.  
 
Figure 1-2: Schematic representation of the Blood-Brain Barrier: showing the neurovascular 
unit which is formed by a collection of different cell types; astrocytic end feet, pericytes, endothelial 
cells, microglia and microglia interacting with neurons. 
1.1.3.6.1 The Blood-Brain Barrier in healthy brain 
In the healthy brain, cells from the peripheral circulation and large plasma proteins 
are unable to get into the brain parenchyma via the BBB. However, there is evidence that 
the BBB is disrupted in young mice and this is explained by pericyte loss (141) and with 
age in mouse models of AD (142). Similar finding during normal ageing around the 
hippocampus was seen in human brain, this age dependant leakage was verified by using a 
dynamic contrast-enhanced magnetic resonance imaging (MRI)  protocol in human brain 
(143). 
1.1.3.6.2  BBB Leakage in AD animal models 
Different studies on transgenic mouse models of AD investigated the role of BBB 
disruption in AD pathology and the inflammatory response due to this disruption. In one 
study, cerebrospinal fluid (CSF) albumin index was found to be increase early in the disease 
even before the plaque formation (144). Another showed that BBB disruption correlated 
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with the disease pathology (145). Fibrin was found in the parenchyma of AD mice brains 
and its deposition was increased by age and contributed to the pathology as a potent driver 
for inflammation that resulted in neurovascular damage (142). Neuroinflammation was 
exacerbated in those models by co-injection of Aβ and fibrinogen (146). Furthermore, in a 
different study, lipopolysaccharide (LPS)-induced peripheral inflammation in an APP 
transgenic mice model, caused BBB disruption compared to wild type mice, which 
indicates that systemic inflammation could cause AD pathology however, the exact 
mechanism of this is unclear (147). 
Contrary to this, depletion of fibrinogen from transgenic mice was proven to 
decrease the microglial activation and attenuate AD pathology. Blocking of fibrinogen with 
anti-coagulant was protective in AD mice (148). This evidence suggest that BBB disruption 
is an important contributor to AD pathology. 
1.1.3.6.3  BBB Leakage in human AD brain 
Brain homeostasis is maintained by the NVU as mentioned above. Interaction 
between different cell types maintains BBB integrity in the brain and regulates clearance 
of proteins that can induce neurotoxicity, such as Aβ42, from the brain (149). Any 
dysfunction in this system such as astrocyte dysfunction (150), endothelial cell damage 
(151), or pericyte dysfunction (129,143,152), will eventually lead to NVU dysfunction and 
BBB disruption. This failure reduces cerebral blood flow (causing hypoxia), alters 
homeostasis, and causes impairment of clearance mechanisms and proteins accumulation 
(153). 
Under pathological conditions such as neuroinflammatory disorders of the CNS, 
BBB breakdown can occur to various degrees, leading to extravasation of blood derived 
toxic materials including haemoglobin, albumin, fibrinogen or plasminogen which, when 
they accumulate, lead to a chronic inflammatory response and neuronal damage either 
directly or via increasing the oxidative stress leading to progressive neurodegeneration 
(127,143). BBB disruption can be slow and limited to the areas of AD pathology 
(151,154,155). However, the timing and the role of disrupted BBB in AD pathology is 
controversial (156–158).  
In the brain, fibrinogen is transformed into fibrin over time and this is indicative 
of excessive BBB leakage. Together with microglia, fibrinogen induces neuroinflammatory 
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response in the brain (159). Therefore, studying fibrinogen on the cellular and molecular 
level is important to highlight its role in neuroinflammation in the brain and it could 
considered as a therapeutic target needing further research (160). In this context, anti-
coagulants that block fibrin in the CNS may be of help in treating neurological diseases, 
however, excess bleeding due to their use may be problematic. 
1.1.4 Diagnosis of AD 
As previously mentioned, neuropathological changes occur in the brain many years 
before the outward appearance of symptoms that lead onto a clinical diagnosis of dementia. 
Although diagnosis of AD is based on clinical findings and neuroimaging, there is a 
growing body of work to try and find early biomarkers in plasma or CSF of AD patients. 
It is necessary to find accurate and sensitive preclinical biomarkers for AD diagnosis to 
enable both early intervention of therapy but also the development of such interventions 
before cognitive decline, or in MCI to monitor the prognosis of the disease process after 
intervention. Biofluid markers have their limitations, for example plasma markers are yet 
to give an accurate or consistent indication of brain pathology, although high throughput 
therapeutic technology has yet to come of age there. Further progress has been made using 
CSF samples for testing a small number of biomarkers, but these cannot be used regularly 
as this requires invasive techniques and which is not always amenable in various clinical 
settings. 
An early sign of AD is the gradual decline in the ability to retain new memories. 
As the disease progresses there are more signs including changes in thinking, behaviour, 
sleep disturbances and in some patients, psychological symptoms. These changes are 
variable between individuals, and in severe AD, they may interfere with daily activities 
leading to complete disability, which requires constant care  (161). 
Clinical diagnosis of dementia is challenging especially in the early stages of the 
disease. Neuropsychological tests are used in AD diagnosis to identify the state of patient’s 
cognition. Tests used as standardized methods to evaluate cognitive functions such as 
memory, attention, and language. Commonly used test is the Mini-Mental State 
Examination (MMSE) which is a score-based screening tool to detect the cognitive decline 
(162), however this method has its limitations in discriminating different forms of 
dementias (163). Other tests are ADAS-Cog. (Alzheimer’s Disease Assessment Scale-
Cognitive) (164), Short Blessed Test (Orientation-Memory-Concentration test) (165), 
Clock Drawing Test (166), and others. 
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Neuroimaging is now one of the increasingly used and well-established tools in 
AD diagnosis and follow-up. Using MRI of the brain or PET scans there are now specific 
tools of detection of abnormally accumulated proteins in the brains of living patients, using 
radiolabelled imaging agents (167).  
National Institute on Ageing and Alzheimer’s Association (NIA-AA) workgroups 
suggested dividing AD diagnosis into Preclinical AD, MCI and AD (168), as shown in 
Figure 1-3. However, recently a newer revision to classification of the disease has been 
recommended (ATN classification). This classifies biomarkers and imaging for amyloid 
beta deposition, tau deposition and neurodegeneration (169) although again its use is 
limited by the availability in clinical settings to provide all of the capacity to assess for the 
relevant clinical variables. AD can only confidentially be diagnosed by the 
histopathological examination of post-mortem tissue of the brain or in conjunction with 
knowledge of prior medical history where ongoing use of biomarkers in living persons are 
still now as accurate. The Consortium to Establish a Registry of Alzheimer’s Disease 
(CERAD) has established the protocol for the diagnosis of probable or definite AD 
according to the density neuritic plaques (170). Three pathological criteria are widely used: 
Braak tangle staging mentioned above in Section 1.1.3.2, CERAD criteria (170), or both 
combined, although again more recently there have also been some revisions to this using 
National Institute of Health (NIH-Reagan criteria) (171).  
 
Figure 1-3: Schematic Schematic figure of AD phases and diagnosis. 1) preclinical phase. 2) 




1.1.5 Treatment of AD 
Treatment of AD is very challenging. As mentioned above, there is as yet no 
effective treatment that has yet been shown to stop or even slow the progression of AD. To 
date, all available therapeutics are predominantly symptomatic which are better to be used 
in preclinical stages of the disease (172). Current research has now focused on developing 
targeted therapies against some of the downstream effects of some genes involved in the 
development of the disease e.g., APP, PSEN1 and PSEN2 to target Aβ. Furthermore, one 
of the most important aspects and challenges in the identification or development of any 
AD treatment, is to find an effective drug which can successfully cross the BBB. 
Drugs available for AD are CEIs that prevent acetylcholinesterase degradation and 
enhance the effect of the remaining transmitters at the synapse (48). CEIs used are 
Donepezil (173), Galantamine (174), and Rivastigmine (43). Another less frequently used 
drug is Memantine that inhibits the prolonged calcium influx and associated neurotoxicity 
that results from glutamate over-excitation (44). Many trials of secretases (β- and γ-) 
inhibitors have been undertaken that were found not to be efficient in lowering Aβ or 
having any therapeutic benefit to AD patients, some having many side effects that triggered 
early termination of the trials on grounds of safety (175–177). Modifying other risk factors 
such as the dietary intake, cardiovascular disease and antioxidants were also studied to 
reduce AD risk (178) and continue to be an area of ongoing interest. 
Epidemiological studies on the effect of anti-inflammatory drugs such as anti-
tumour necrosis factor (TNF) and non-steroidal anti-inflammatory drugs (NSAIDs) have 
previously shown a reduced risk of AD in rheumatoid arthritis patients (179–184). 
Nevertheless, meta-analysis studies failed to support this (185,186). Those kinds of studies, 
besides genetics, have highlighted the role of neuroinflammation in AD brain. Similar to 
other trials, anti-inflammatory drugs for clinical trials have so far failed to show a 
significant effect on AD progression (187). Some of these trials had gastrointestinal adverse 
effects or stopped due to cardiovascular problems (188).  
Different aspects of neuroinflammation, which will be discussed in more detail 
later, can be targeted in AD either by introducing new drugs or by using repurposed 
approved anti-inflammatory drugs, more drugs were included in the pipeline (189). 
However, scientists have faced many challenges in targeting the immune response, for 
16 
 
example targeting microglia in AD is very difficult, as they secrete too many different 
cytokines and chemokines (190,191). 
In order to achieve success in AD treatment, we should focus on earlier 
interventions, multi-targeting, and a better understanding of what is actually happening on 
the biological and molecular basis in AD brain.  
1.2 Immune system in the brain 
In general, the immune system is a network of specialized cells that act together in 
the body against infections and diseases. It is characterized by having two components; the 
innate and the adaptive immune response. In a recent study, there was some evidence that 
the overactive innate immune response was associated with increased risk of AD, while the 
adaptive immune response was suggested to be neuroprotective (192).  
The brain has been considered for a long time to be an immunologically privileged 
site because of the presence of the BBB, which prevents the entry of peripheral cells and 
other molecules from the blood into the CNS. However, it is now evident that there is a 
connection between peripheral and central immune systems via the lymphatic system; so 
the CNS is not completely sealed off from the rest of the body (193)  besides the BBB 
breakdown that can occur in CNS diseases.  
The innate immune response in the brain is the first line of defence against 
pathogens and abnormally accumulated proteins (194). It involves the main resident 
immune cell in the brain, the microglia and the complement system. Understanding how 
exactly the innate immunity is implicated in AD is still unclear (195). Many studies have 
linked peripheral or systemic inflammation to CNS inflammation; the peripheral immune 
response represented by the blood-derived cells greatly affects the brain function 
(156,158,196), and leads to neuroinflammation (197,198) and early involvement in AD 
pathology (MCI) (199). 
Acute phase reactants like C-reactive protein (CRP) were identified to be 
associated with increased AD risk (200), where they were found to be increased in plasma 
from AD patients (201). Furthermore, systemic infection worsens the cognitive function 
and leads to neurodegeneration (202), the mechanism by which the bacterial infection 
causes neuronal cell death is not fully understood (203). Some studies have suggested that 
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systemic infections modify the inflammatory response and enhance the neurodegenerative 
process in the brain (204). This can be mediated by the release of pro-inflammatory 
cytokines such as Interleukin 6 (IL-6) and microglial activation in the brain and is 
represented by some neuropsychiatric symptoms like delirium and sickness behaviour 
(204,205). 
Bacteria in Alzheimer’s disease 
More recently, the microbiome became an interesting area of research in AD. Oral 
and gut flora were related to increased risk of AD,  reviewed in (206). The idea that 
infectious pathogens or their toxic products are present in the brain (207) and involved in 
AD is not new. Spirochetes are one kind of bacteria thought to contribute in AD 
pathogenesis. This idea was supported by AD symptoms seen in the late stage of syphilis 
(208), and that cognitive impairment was delayed when the mouse model of AD studied 
were raised in sterile environment (209). Interestingly, amyloid is an anti-microbial peptide 
that is shown to be protective against bacteria, fungus, and viruses and hence it has been 
hypothesized to be produced in response to them. It also has some pro-inflammatory 
activities (210,211), all of which have supported the anti-microbial protection hypothesis 
in AD (212). 
Further, a possible route for the bacteria or its products to enter the brain is BBB 
breakdown due to genetic causes such as APOE variation or tumour necrosis factor alpha 
genes (TNF-α) in late onset AD (206). Nerves can be another suggested route of pathogens 
to the brain, as seen via the trigeminal route (213), or olfactory nerve and bulb (214), that 
was supported by olfactory deficits and hyposmia as early symptoms in AD patients. 
Of all modifiable risk factors, researchers linked only poor dental care during life 
indicated by tooth loss, with the increased risk of AD in identical twins that were discordant 
for dementia (215,216). Furthermore, oral bacteria seen in the peripheral blood could 
differentiate between AD and cognitively normal subjects (217,218). 
1.3 Neuroinflammation in AD 
➢ A cause or a consequence? 
There is a substantial evidence accumulating and supporting the involvement of 
inflammation in the pathogenesis of neurodegenerative diseases including AD. Despite the 
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great effort to understand this relationship, it is still not clear if inflammation is a cause, 
contributor, or a consequence of AD pathology. However, GWAS, as mentioned above in 
Section 1.1.1.2, highlighted innate immunity genes as important in AD risk, many of the 
genes detected were related to microglial function or to the complement cascade. Genetic 
information supports the contribution of immune response as a contributing factor to the 
development of the disease and not only as a consequence of the disease progression where 
its involvement may also still be relevant. It is not known exactly when neuroinflammation 
starts in AD brain. However, data from transgenic mice has suggested that the 
inflammatory process starts early before amyloid plaque formation (219). 
Abnormally accumulated misfolded proteins in the brain stimulate different parts 
of the immune response to clear them. In the last two decades, studies have investigated 
the relationship between Aβ stimulation and chronic inflammatory reaction i.e. 
neuroinflammation in AD, release of inflammatory mediators and disease progression 
(201,220–222). As association does not mean causation, neuroinflammation may reflect a 
vicious circle in the pathogenesis of AD. 
➢ Constituents of neuroinflammation: 
• Glial cell activation: astrocytes and microglia. 
• Complement cascade activation. 
• Inflammatory cytokines production. 
• Inflammasome activation. 
Neuroinflammation is characterized by the presence of reactive astrocytes and 
activation of the brain’s resident macrophages; microglia surrounding Aβ deposits (194), 
as shown in Figure 1-4, as well as complement system activation (97,223,224) in order to 
clear the plaques (179,201,225). This state of neuroinflammation is associated with the 
expression of pro-inflammatory cytokines from microglia (190,191). Conflicting results 
were seen in neuroinflammatory response in AD that can be explained by the involvement 
of the immune response in different stages of the disease and switching between 
neuroprotective and neurotoxic function of brain cells. All of these cardinal features of AD, 
besides the main pathological changes i.e. the extracellular senile plaques and intracellular 
neurofibrillary tangles, lead to the neuronal damage and loss of function (226). 
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Soluble  Aβ oligomers cause inflammation mediated by microglial activation 
(227), reactive astrocytes (228), monocytes (229) and inflammasome activation (230,231). 
This is accompanied by BBB disruption (151,155), which has been reported in different 
stages of AD (232–234).  
 
Figure 1-4: Neuroinflammatory components of Alzheimer's disease with Aβ pathology. This 
figure shows astrocytes and microglia surrounding amyloid plaques, inflammatory cytokines 
production and the complement cascade component involved in relation to BBB disruption. 
In the AD brain, the mechanism of neuronal damage in which immune response is 
implicated, is either phagocytosis or complement system activation in order to remove 
apoptotic neuronal cells. It is widely accepted that microglia can perform phagocytosis in 
AD brain. With the help of C3b complement fragment, microglia constantly survey the 
brain environment to detect pathogens, apoptotic cells or foreign materials (235), and also 
secretes inflammatory cytokines as well as ROS; this will be discussed in more detail in 
the next section. 
1.3.1 Glial cell activation 
Glial cells are the most abundant type of cells in the human brain and account for 
half of the brain cell count (236). They are divided into two main types: macroglia including 
astrocytes, oligodendrocytes as well as radial cells, and resident microglia. The harmful 
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toxic Aβ peptide accumulation stimulates glial cell activation (237); both microglia and 
astrocytes are strongly involved in the different stages of AD pathology (238). 
1.3.1.1 Microglia in AD 
Recently, microglia have been considered to be of great importance in AD 
pathogenesis, particularly with respect to the strong genetic implications of the immune 
system in sporadic AD (239,240). They are considered as the CNS resident immune cell 
type resembling the peripheral macrophages, both cell types have the same origin. (241). 
They are rapid responders and their activation helps in the defence against pathogens and 
play a key role in immune surveillance in the brain parenchyma (242,243) to respond to 
cellular damage by phagocytosis (82,222). Furthermore, microglial activation is dependent 
on the type of stimuli; for instance chronic deposition of Aβ stimulates persistent activation 
of microglial cells (243,244).  
 Multiple studies have investigated the microglial activation and dysfunction 
within AD brain, however, their role in the pathogenesis is still debated and needs further 
investigation. It is thought that the glial cell activation takes place over years before the 
clinical manifestations of AD, although the manner in which this happens may differ. 
Studies in transgenic animal models have demonstrated, variably, that microglial activation 
starts only after the plaque formation as seen by confocal imaging (245), whilst, others 
show increased microglial density even before plaque formation (246). All of this needs 
further clarification and may explain the multiple roles of microglia in different stages in 
AD brain. Microglia are heterogenous and respond to various types of stimuli not only the 
Aβ peptide, but also to the tau oligomers (247) and apoptotic neurons (248). Their relation 
to tau pathology remains to be clarified, although microglial phagocytosis at the synapse 
may play an important role in synaptic pruning and spreading tau pathology (249). It is 
now known that microglia express a large number of inflammatory cytokines and 
chemokines (190,191,250) which modify the inflammatory response and can be detected 
in the human brain and CSF (251,252). An In vitro study showed that Aβ can stimulate 




➢ How do microglia remove Aβ?  
As previously mentioned, the main trigger for microglial activation in AD is Aβ. 
Activated microglia surround the plaques within 1-2 days as seen in an AD mouse model 
(245) and their role in the rapid removal of Aβ is mediated via scavenger receptors (254). 
A sustained activation involves different mechanisms by which activated microglia 
function in late stages of AD. Microglia express cell surface receptors such as receptor for 
advanced glycation end-products (RAGE) (193,255,256), and TLRs which mediate 
binding of Aβ to microglia leading to their proliferation and phagocytosis (257,258).  
1.3.1.1.1 Microglial functions 
Microglia exert a variety of functions that may become impaired with ageing due 
to decreased motility and senescence (259). It is thought that the role microglia in the 
healthy brain is beneficial, constantly repairing the damage. However, they switch between 
neuroprotective and neurotoxic phenotypes in neurodegeneration as shown in Figure 1-5. 
The complex role of microglia in the brain makes it a difficult target for therapeutic 
approaches in AD. However, trials to target microglia complements targeting Aβ and tau 
(260). 
 
Figure 1-5: Schematic representation of microglial activation phenotypes. M1: Pro-
inflammatory or classically activated phenotype. M2: Anti-inflammatory or alternatively 
activated phenotype. LPS: lipopolysaccharides, IL: interleukins. 
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➢ Expression of cytokines  
Cytokine expression is closely related to microglial activation in AD,  in vitro, pro-
inflammatory cytokines were increased in a dose dependant manner when microglial cells 
were activated by Aβ (261). As mentioned above, the protective form of microglia secretes 
anti-inflammatory cytokines such as IL-10 and IL-4, whereas the other form expresses pro-
inflammatory cytokines. Very little is known about the competition between pro and anti-
inflammatory cytokines, the balance between both types can determine the contribution of 
microglia in AD pathology.  
➢ Phagocytosis 
The ‘never resting’ cell type is another description of microglia (262). Similar to 
macrophages in the periphery, they survey to detect pathogens and injury, such as damaged 
cells, for phagocytosis via cell surface receptors such as TLRs (79). As previously 
mentioned, this would be done by changing their morphology, retracting their processes, 
and releasing pro-inflammatory cytokines in the brain environment. 
➢ Neuronal circuit and synapses 
Under physiological conditions, microglia are involved in different functions 
including adult hippocampal neurogenesis (263,264), as well as maturation and refinement 
of the neuronal circuit by interacting dynamically with it (265). Microglia are also involved 
in synaptic pruning leading to organization and maturation of neuronal networks (266,267). 
This process is a complement dependant mechanism as seen in C3 deficient mice (268), 
thus emphasizing their contribution in synaptic elimination in AD brain (269). 
1.3.1.1.2 Microglial phenotypes 
Microglia are characterised by the ability to change their morphology, activation 
status and their remarkable plasticity following activation. Normally in the healthy brain, 
they exist in a resting state with a small cell body and long ramified processes, but are 
highly dynamic in their surveillance of the environment as mentioned above (242). Upon 
stimulation by invading threats including abnormal proteins or apoptotic cells, microglia 
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undergo morphological changes such as increased body size, shorter processes, and become 
reactive and amoeboid in shape (270). Interestingly, microglial activation increases with 
age and in early stages of AD, before the start of cognitive decline (271,272). 
Two types of activation are seen in microglia as shown in Figure 1-5, the classically 
activated form of microglia (M1; pro-inflammatory phenotype), which is stimulated by 
LPS and expresses some cell-surface activation molecules, such as major 
histocompatibility complex (MHC-II). This type is considered as the main source of pro-
inflammatory cytokines TNF-α and interleukin 1 beta (IL-1β) (244) and subsequently leads 
to a state of oxidative stress in the brain (273). 
The second type is the alternatively activated microglia (M2; anti-inflammatory 
phenotype) that releases the anti-inflammatory cytokines such as  (IL-10) and lowers the 
level of pro-inflammatory cytokines (243) to help in tissue repair. Both phenotypes 
sometimes co-occur (274), the idea that microglia switch during the course of the disease 
between the two phenotypes and change from M2 to M1 needs to be more investigated.  
Microglia, therefore, can exert an innate immune response, phagocytosis by M2 
phenotype or adaptive immune response, antigen presenting function by M1 (220). 
1.3.1.1.3 Microglia genes in LOAD 
Genetic studies in late-onset AD have identified genes other than APOE4 gene, 
many of which are related to microglial function and inflammation. These findings have 
supported the idea of microglial dysfunction as a contributing factor of AD pathogenesis. 
One of these genes is triggering receptors expressed in myeloid cells 2 (TREM2) (275).  A 
transmembrane, immune regulatory receptor protein in microglia thought to be 
neuroprotective against Aβ (276). TREM2 action is mediated by supressing inflammation, 
decreasing the pro-inflammatory cytokines (277,278) via TLR signaling, and promoting 
phagocytosis of apoptotic neurons and cellular debris (279,280) and chemotaxis by 
microglia (281).  
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Loss-of-function mutations in TREM2 are associated with increased AD risk (282), 
although the mechanism remains elusive. This prompted questions on whether TREM2 
offered biomarker possibilities in AD. Yet, soluble TREM2 (sTREM2) was unchanged in 
CSF in AD or MCI (283). Recent studies have also showed that sTREM2 was not changed 
in plasma of AD patients compared to controls or in different variant groups (284–286). 
Information about cellular expression of TREM2 in post-mortem brain tissue are limited, 
messenger RNA (mRNA) of TREM2 was significantly increased in hippocampus in AD 
(287). 
Another strong genetic risk factor for LOAD is CD33;cluster of differentiation 33 
polymorphisms; the sialic acid binding immunoglobulin type lectins (siglec) that is 
expressed by microglia and modulates the immune function. Its expression has been found 
to be increased in AD brain and to correlate with cognitive impairment and Aβ load (288). 
Both genes are related  to microglial immune response in the brain and modulate each 
other’s function (289). 
1.3.1.2 Astrocytes in AD 
Both microglia and astrocytes mediate the innate immune responses in the brain; 
astrocytes constantly survey the brain environment in a similar way to detect any harm in 
the brain. Nevertheless, the involvement of microglia in AD is thought to occur earlier than 
astrocytes that are thought to be involved later in the disease process (290). Astrocytes 
release the cytoplasmic intermediate filament proteins mainly the glial fibrillary acidic 
protein (GFAP) (291), vimentin and nestin all of which maintains astrocyte cytoskeleton, 
cell shape and BBB function.  
Additionally, diverse astroglial responses have been demonstrated in AD, this cell 
type is an important mediators for Aβ neurotoxicity and tau phosphorylation, pathological 
changes that stimulate astrocytes (237). Astrocytic response in AD brain varies from 
atrophic to hypertrophic changes. Their hypertrophic state is the neuroprotective form and 
represented by an increase in number, size and increased expression of GFAP (292,293). 
However, the neurotoxic (atrophic) form of astrocytes is stimulated by the activated 
microglia via cytokines and chemokines expression (294). Previous work has suggested 
that the astrocyte response is more prominent in some brain regions with high AD 
pathology such as the temporal cortex (295). 
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1.3.1.2.1 Astrocyte phenotypes 
Astrocytes are highly heterogenous in morphological appearance and activation 
status (296). Protoplasmic astrocytes are seen in the grey matter, while fibrous type is seen 
in the white matter (297). Under physiological conditions, they are in a resting, non-reactive 
state, but able to maintain the structure and homeostasis of the brain (298).  
In slowly progressive pathological conditions in CNS such as AD, astrocytes show 
reactivity or atrophy and undergo various morphological changes (299). Reactivity is the 
state in which astrocytes may increase in size, become hypertrophic, thickened processes, 
and overexpress GFAP, as mentioned above. It is a transient response which involves 
calcium signaling and stimulates neurotransmitter release which mediates neuronal 
functions (300). These reactive astrocytes are found close to amyloid plaques (297). The 
glial scar is another form of astrocytic change in response to severe tissue damage, which 
is irreversible and causes permanent cellular changes (298,301). 
1.3.1.2.2 Astrocyte functions 
It was thought that astrocytes were passive and a supportive cell type in the human 
brain for a long time, but later on they considered as the most functionally diverse cell type 
in the brain. They regulate immune response in brain by controlling immune cell entry 
across the BBB; as well as regulating extracellular potassium balance (302,303). Genetic 
studies show that the most prominent risk factors for developing LOAD are those genes 
expressed mainly by astrocytes such as APOE and clusterin (APOJ), both of which 




Figure 1-6: Schematic illustration of different functions of astrocyte in the human brain. 
Astrocytes maintain the brain homeostasis, a part of the neuro-vascular unit, help in the neuronal 
support, the main source of cholesterol in the brain and contribute to the neuroinflammation via 
expression of inflammatory cytokines and complement proteins. 
➢ Brain homeostasis and NVU 
In normal physiological conditions, astrocytes are the structure-maintaining cells 
in the brain that regulate the blood flow (304), and have different roles in maintaining tissue 
homeostasis (305,306). They are considered as a cardinal part of the NVU with their end-
feet surrounding blood vessels (307,308), the so-called glymphatic system which promotes 
removal of soluble proteins such as Aβ and tau proteins as well as metabolites from CNS 
parenchyma (72) as mentioned before (see section 1.1.3.6). Moreover, they control 
extracellular space volume and ion homeostasis mainly by maintaining the extracellular 
K+ levels through passive and active uptake (302). 
➢ Neuronal support 
An important role of astrocytes is seen in the development of the brain and 
providing neurons with necessary nutrients through secreting neurotrophic factors and 
neurotransmitters such as glutamate, the inhibitory glial neurotransmitter gamma-
aminobutyric acid (GABA) and acetylcholine (309,310). Those neuromodulators help in 




Moreover, astrocytes are essential in development, function and plasticity of 
neuronal circuits including synaptic formation in healthy and diseased brain (312). 
Together with oligodendrocytes, they secrete almost all cholesterol content of the brain, 
which maintains synaptogenesis via ApoE (313–315). Human astrocytes also mediate rapid 
removal of neurotransmitters from the extracellular space, maintaining synaptic 
transmission, neuronal survival and activity and avoiding excitotoxicity (316,317). 
➢ Expression of pro-inflammatory molecules 
Astrocytes help in modulating inflammation in CNS. Both astrocytes and microglia 
are major sources of cytokines in the brain (pro-inflammatory cytokines), they can produce 
complement proteins and complement receptors. Astrocytes maintain the function of the 
neurons via cytokines such as IL-1β and the specific cytokine produced: calcium binding 
protein B (S100B) (318), both of which have been implicated in the pathogenesis of AD 
(316).  
➢ Astrocytes and ApoE 
ApoE is mainly secreted from astrocytes. It is the major cholesterol carrier relevant 
to genetic risk factors for sporadic AD, which regulates astrocyte function, Aβ clearance, 
glucose metabolism, innate and adaptive immune responses, cytokine signaling as well as 
promoting synaptogenesis and neuronal survival as mentioned above (302,319,320). 
➢ Astrocytes and APOJ (clusterin) 
Clusterin is a multifunctional glycoprotein mainly produced by astrocytes (321). 
Together with ApoE, they influence Aβ metabolism in the brain and are implicated in AD 
by different mechanisms including lipid transport and immune response modulation (this 
will be discussed in detail in section 1.3.2). 
1.3.1.2.3 Role of astrocytes in AD neuroinflammation 
Many evidences suggested that astrocytes are involved in neurodegenerative 
disorders such as AD. Astrocytes can be considered as part of the cause rather than a 
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consequence of AD pathology (322), both astrocytic atrophy (323,324) and reactivity have 
been found before detectable Aβ deposition. Additionally, GFAP-positive astrocytes were 
found related to Aβ plaques in transgenic AD mice (325). Moreover, PET scanning in 
patients with mild cognitive decline, presented with astrogliosis as an early event in the 
development of AD (326). 
➢ Aβ removal by astrocytes  
In AD, astrocytes are activated and change in their response to help in Aβ 
degradation (327). Reactive astrocytes with phagocytic activity were found to encircle the 
Aβ plaques to separate the affected part from the normal healthy tissue and to engulf 
neuritic dystrophies in both patients with AD and mouse models (298,328).  
Astrocytes mediate the clearance of Aβ by multiple mechanisms, Aβ degradation 
occurs via secreting protease enzymes such as IDE, NEP, and others, as mentioned above 
in (Section 1.1.3.1). These enzymes were noted to be co-localized with GFAP; the marker 
of mature astrocytes in the brain of transgenic mice (329). Matrix metalloproteinases 
(MMPs) may also contribute to extracellular Aβ degradation via astrocytes (330). Similar 
to microglia, RAGE receptors are involved with astrocytes in mediating the immune 
response in AD brain via Aβ phagocytosis (331). 
As an important component of NVU and thanks to their projections around blood 
vessels, astroglia can regulate the vascular clearance of proteins from the brain such as Aβ 
and tau, debris, also glucose, and the toxic by-products across the BBB (332). At the 
astrocyte end feet, high expression of aquaporin 4 channel (AQP4) is thought to help in 
their clearance from the brain due to its role in water transport (333). Nevertheless, 
astrocytes are not only involved in Aβ degradation and clearance, but also in their 
production by secreting APP, supporting the link between astrocytes and AD pathology as 
a contributor, not only a consequence of the disease, however, this interaction is a complex 
process. (334). 
➢ Neuronal death in AD 
Due to the complex interplay between astrocytes and neurons, the role of astrocytes 
in AD is gaining interest. Activated microglia stimulate astrocytes via cytokines and this 
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involves C1q and classical complement pathway (CP) in AD brain. Furthermore, synaptic 
pruning is a key feature in AD pathology and astrocytes are a contributor to this as a 
response to CNS injury, they phagocytose pruned neurons. Recent accumulating evidence 
support that reactive astrocytes in AD become neurotoxic and cause astrocyte-mediated 
neurotoxicity by downregulating glutamate synthetase expression (294,335). 
➢ Metabolic dysfunction in AD 
Normally, glucose is the energy required for brain metabolism. It is stored in 
astrocytes in the form of glycogen which fuel neurons by supplying lactate (lactate shuttle) 
(336). Glycolysis in the brain has a dual action; it supports neuronal energy metabolism, 
but enhances inflammation by stimulating the neurodegenerative form of astrocytes (337). 
 In AD brain, glucose hypometabolism occurs as an early event in which reactive 
astrocytes are strongly involved, the so-called neuroenergetic theory of AD. Interestingly, 
astrocytes in the resting state consume more than the half of glucose in the brain (338). 
1.3.1.2.4 GFAP 
GFAP is a specific marker of mature astrocytes (339). It is an intermediate filament 
protein III (IF) which is highly expressed in the brain and responsible for structural support 
of astrocytes (340) and helps in astrocytic differentiation. Moreover, there are four 
isoforms, collectively called GFAP+1 in the brain, which was found to be limited to a 
subset of astrocytes with elongated processes, that are increased in number during the 
progression of AD (341). GFAP is proposed to play a role in astrocyte-
neuronal interactions. Following brain injury, astrocytes enter an activated state called 
astrogliosis, which is characterized by increase in number and size and increased 
expression of GFAP protein (340). Nevertheless, it is not clear how excatly ativated 
astrocytes contribute to GFAP upregulation. One possible mechanism is that upon 
activation, nitric oxide (NO) expression occurs from astrocytes (342). 
Aged astrocytes contain elevated levels of GFAP and S100B protein (343). It has 
been previously reported that GFAP is increased in CSF samples obtained from AD 
patients (344,345), and in AD brain tissue (295,346). Previous work has suggested that the 
astrocyte response is more prominent in some brain regions with more AD pathology, such 
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as the temporal cortex (295). GFAP expression is modulated by caspase cleavage, which 
was reported to be within the degenerating astrocytes in AD brain (347). Other suggested 
regulators to GFAP expression were: nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) signaling, neuromodulators, intracellular K+ level, and hormones 
(such as sex hormones and steroids) (348). 
1.3.2 Complement system activation 
1.3.2.1 Complement system 
The complement system (C) plays a major role in the innate immune response, 
which when activated protects our bodies against invading microorganisms, abnormal 
protein accumulation and harmful cellular debris (349). More than 40 proteins (soluble or 
membrane-bound), regulators and receptors set up the complement system, all working 
together to fight invading dangers and bridge the innate and adaptive immune responses 
(350,351). 
1.3.2.1.1 Complement Proteins 
The source of complement proteins in human body is mainly hepatic however, it 
is known that other organs and tissues can produce and initiate a local immune response in 
these organs or exacerbate the disease pathology. Native proteins are produced in the liver 
and circulate in plasma in an inactive form. They are then activated through enzyme 
complexes (convertases) in a cascade like manner, to the final common pathway that results 
in cell lysis. 
1.3.2.1.2 Complement pathways 
There are three complement pathways: the classical pathway (CP), alternative 
pathway (AP) and mannose binding lectin (MBL), as shown in Figure 1-7. All of which 
lead to sequential enzymatic activation and protein cleavage (349). The activation of any 




The classical complement pathway proteins are: C1 (fragment q, r, and s), C2, C3, 
C4, C5, C6, C7, C8 and C9. Its activation starts with binding of C1q to the immune complex 
or apoptotic cell, then cleavage of C4 generating C4a and C4b components, then C2 
cleavage and formation of C3 convertase that cleaves C3 into C3a and C3b fragments. C3a 
plays a crucial role in inflammation and immune response via the C3a receptor (C3aR) 
(352), while C3b acts as an opsonin which is involved in phagocytosis and clearance of 
immune complexes.  
After that, the activation of C5 convertase results in C5 hydrolysis into C5a and 
C5b fragments. C5a is similar to C3a in the pro-inflammatory response that induces 
chemotaxis via C5a receptor (C5aR) (353), while C5b initiates the terminal pathway and 
eventually leads to assembly of the membrane attack complex (MAC). Cell lysis occurs 
through the insertion of the pore-forming C5b-C9 complex into the cell membrane when 
present in sufficient concentrations, it is also named the terminal complement complex 
(TCC) (354). 
The alternative pathway which starts at C3 level by a direct binding of C3b to an 
activating surface such as beta amyloid (355). This pathway involves factors B and D and 
can be considered as an amplification loop for the classical pathway. As it continues in the 
same manner, the activation of one complement pathway generally leads to activation of 
the other (356). The lectin pathway starts with binding of MBL to a mannose group on the 




Figure 1-7: Complement system activation pathways. This figure shows the three different 
complement pathways (classical, alternative and mannose binding lectin pathways). 
1.3.2.1.3 Complement Regulators 
Complement system activation has a dual effect in the human body, it can be 
beneficial; nevertheless, the spontaneous activation of this cascade leads to excessive 
uncontrolled activation. The regulation of the complement activation is crucial to 
homeostasis and any disturbance of this delicate balance can result in pathological changes. 
Its dysregulation results in chronic inflammation and exacerbation of the disease pathology 
and self- destruction of tissue as seen in some inflammatory diseases. This is the reason 
why the complement system needs to be regulated and inhibited by soluble or membrane-
bound inhibitors.  
Complement activation is modulated at various levels by different regulatory 
proteins or inhibitors such C1 inhibitor, complement factor H (CFH), cluster of 
differentiation 59 (CD59), clusterin, and surface bound regulators such as complement 
receptor 1 (CR1), 2,3 and 4 (358). For instance, C1 inhibitor is an early regulator of the 
classical pathway, which inhibits C1q. CFH is the main regulator of the alternative pathway 
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via inhibiting C3 cleavage enzyme and is considered to be a leading cause in some 
inflammatory diseases such as age-related macular degeneration (AMD) (359). CD59 and 
clusterin are the regulators of the terminal complement pathway, as shown in Figure 1-7, 
more details about CFH and clusterin will be discussed in Section 1.3.2.7. 
1.3.2.2 Complement System in the brain 
1.3.2.2.1 Complement components: their source in the human brain 
The source of complement proteins in the normal and diseased brain is debatable, 
they can be formed locally by several cell types such as glial cells and neurons (360,361). 
In vitro, different cell lines from microglia, astrocytes and neurons were proven to be able 
to secrete many complement proteins (362,363). Furthermore, complement genes are also 
expressed from smooth muscle cells (364), and from microglial cells extracted from post-
mortem human brain tissue (365). Moreover, immunohistochemical studies in 
hippocampus have showed complement proteins staining on neurons (366). Normally, the 
brain is isolated by an intact BBB. However, in the course of some pathological conditions 
such as AD, it can be disrupted and plasma proteins including complement proteins may 
circulate from the peripheral blood to the CNS (143).  
1.3.2.2.2 Complement functions in the brain 
In addition to the main role of the complement system in the peripheral circulation, 
complement is thought to have also non-immune functions in the brain (367). It plays 
important roles in brain development, neurogenesis, homeostasis, and regeneration in CNS. 
Recently, many complement components were more carefully examined in psychiatric and 
neurological diseases such as AD (it will be discussed in more detail in the next section), 
in addition to its involvement in psychiatric disease such as C4 implication in the 
pathogenesis of schizophrenia (368). Moreover, some complement components like C5aR 
signaling were found to be involved in the process of neurogenesis (369). 
Complement functions in the brain were mainly highlighted by studying 
complement deficient mice. For instance, C1q and C3 have roles in synapses in brain 
development (370). C1q deficient mice are more susceptible to epileptic fits due to 
defective synaptic elimination and abnormally connected neurons in the brain (371,372). 
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C3-deficient mice were also noted to have impaired synaptic elimination from damaged 
neurons (373,374). All of which highlighted the role of C1q and C3 in synaptic function in 
the brain. 
1.3.2.3 Complement activation in Alzheimer’s disease  
Complement proteins were seen by immunohistochemical staining with amyloid 
plaques (223), neurofibrillary tangles (97) and dystrophic neurites in AD brain (224). Since 
then, it was hypothesized that the complement system may contribute to AD pathogenesis. 
However, it is still not completely understood whether complement is a cause, a 
contributing factor, or a consequence of the chronic inflammatory condition in AD. As 
mentioned above, GWAS have identified polymorphism in two complement regulator 
genes: CR1 and CLU as risk factors for sporadic AD (23). 
Activation of complement system in AD brain occurs via the classical pathway on 
amyloid plaques or with tau pathology which like Aβ, initiates a potent antibody-
independent complement system activation (97). The classical pathway will lead to 
opsonisation through C3b or by driving the inflammatory response via C3a and C5a. Its 
activation on microglia leads to cytokine expression (375) and subsequent release of 
neurotoxic substances such as free oxygen radicals, and mediates the cross talk between 
glial cells in AD brain (376).  
Both the complement system and BBB are important for brain homeostasis. 
Complement activation may contribute to BBB dysfunction as it promotes inflammation, 
which in turn is associated with increased vascular permeability (377). Nevertheless, the 
exact mechanism is not understood. Possible contributors of BBB dysfunction in the brain 
are C3a and C5a signalling pathways which involve endothelial activation (378). On the 
other hand, when BBB is disrupted it allows plasma proteins and cell recruitment to the 
brain. 
1.3.2.4 Genetics of the complement system in Alzheimer’s disease 
Large genome-wide association studies have identified 25 genetic loci, including 
two genes of innate immunity related to complement system, as previously mentioned, the 
CLU and CR1 polymorphisms (23). LOAD risk is approximately 25.5% for APOE, 8.9% 
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for CLU and only 3.8% for the CR1 polymorphism. All three genes are implicated in Aβ 
clearance from human brain, unlike the genes that are involved in familial AD, which 
involves overproduction of Aβ (23). 
Three SNPs (single-nucleotide polymorphisms) of CLU showed statistically 
significant association with AD as a genetic risk factor (379). Moreover, two different 
polymorphisms were identified for CR1, one of them in the region that is believed to be the 
binding site of C1q molecule (23). The extent of senile plaques was associated to CR1 
variants (380), more details about clusterin and CR1 in AD will be discussed later. 
Different alleles of CFH were recognized as the major risk factor in degenerative 
diseases of the eye (AMD), as discussed in Section 1.3.2.7.4 (381). It is known that AMD 
shares similar risk factors and pathological features with AD (382) such as Aβ deposition, 
inflammation and complement activation. Genetic variants of the gene encoding CFH were 
shown to be associated with cognitive decline in AD and brain atrophy (383). Despite this, 
CFH (Y402H) association with AD risk is controversial; some studies supported the 
involvement in AD pathogenesis as an important immune risk factor (384), while others 
did not (385).  
In recent genetic studies and according to the International Genomics of 
Alzheimer’s Project (IGAP), more regulatory genes of the immune response were 
discovered, such as complement receptor 2 (CR2) (25). How these complement genes and 
pathways are linked to AD pathology is not yet fully understood (172). Smaller studies 
revealed other complement risk factors in AD such as C1s, and C9. Loss of function of 
those genes leads to impairment of complement activity in the brain and loss of its ability 
to kill pathogens such as P. gingivalis. This leads to the spread of microbes to the brain via 
a disrupted BBB (386). In addition, C7 was detected as a genetic risk factor in familial AD 
(387). 
More recently, the likelihood of both peripheral and central elements to the 
involvement of complement in AD is suggested from data where low levels of C3 in plasma 
were associated with increased AD risk in a large prospective cohort preceding the 
diagnosis of AD (388). Few studies so far have investigated complement gene expression 
in post-mortem human brain tissue. It is of importance therefore, to assess complement 
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gene expression in post-mortem brains of AD patients, to provide a better understanding of 
the inflammatory response in AD at the mRNA level. 
1.3.2.5 Complement proteins in animal models of AD 
To date, most of the data about complement in AD has been obtained from animal 
models such as, transgenics, knock-outs, or from overexpressing the complement proteins 
in AD models, which do not represent the actual events in the human brain (367). Animal 
models can mimic single gene mutation in familial AD but not in the sporadic AD form. 
This is because LOAD is a complex genetic form of the disease with a large variability 
between individuals. Despite this, a considerable amount of data has been generated by 
studying those models along with complement knockout mice, which helped in further 
understanding the functions of almost all complement components (363). 
There are some differences in complement proteins between animal models and 
human. For instance, C1q in mice is less efficient in binding to Aβ than in humans resulting 
in less activation of complement in mice (389). Furthermore, the alternative complement 
pathway may have a more important role in AD mice than the classical complement 
pathway (390). 
Deficiencies in early complement components such as C1q and C3 proved to be 
neuroprotective and showed a reduced pathology in transgenic mouse model of AD, 
supporting the role of the classical complement system activation in AD (391). A recent 
study in a transgenic AD model (APP/PS1) which closely represents the AD pathological 
changes, has outlined the role of C3 protein by knocking out C3 (APP/PS1: C3 KO) in 
neurodegeneration. C3 was shown to be a protective protein against cognitive decline even 
in the presence of Aβ deposition. In addition to that, the microglial markers were decreased 
in that model and their phenotype changed suggesting that C3 has an effect on the normal 
function of microglial cells (392). 
As previously mentioned, both complement, and microglia are involved in the 
process of synaptic elimination. In this context, C1q and C3-deficient mice showed poor 
synapse elimination (371) and the AD models lacking the C3 protein APP/PS1;C3KO 
showed regional specific neuronal and synaptic loss (392). Those data links complement 
and innate immune systems in neurodegenerative pathology in mice (393).  
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1.3.2.6 Complement Proteins as biomarkers for AD diagnosis 
It is likely that treating AD with disease-modifying therapies is more efficient when 
targeted at early stages of the disease. Therefore, there is an urgent need to find biomarkers, 
ideally peripheral biomarkers because of easier access and cost, that accurately reflect the 
disease severity as well as correlate with pathological changes in AD. Previous studies have 
measured levels of different complement molecules in CSF and/or plasma of AD patients. 
However, the invasive technique to obtain CSF, limits the availability of CSF markers as 
early diagnostic tests for AD. Plasma biomarkers are easier to be regularly obtained for 
screening tests and follow-ups that enable early diagnosis and prediction of the progression 
from MCI to AD. Yet, the limited coordination of the complement system between the 
CNS and periphery in established AD may limit this approach. 
1.3.2.6.1 Complement in plasma of AD patients  
Recent studies have been successful in detecting inflammatory biomarkers in 
plasma, including complement proteins that can be indicative for early AD i.e. were 
predictive for conversion from MCI to AD (394). Plasma clusterin level is one important 
biomarker found to be predictive for cognitive decline in AD and stroke (395), and 
correlated with the overall, as well as the inflammatory, polygenic risk score of AD (396).  
Other complement proteins related to the C3 pathway in plasma were used as early 
biomarkers for predicting AD pathology. In a recent study, lower plasma C3 level predicted 
a greater risk of AD (388). CFH was detected as an AD specific marker, which is positively 
correlated with hippocampal metabolite and cognitive decline in early AD (397). In another 
proteomic study by the same group, C3 and complement factor I (CFI) levels were 
correlated with whole brain atrophy detected by neuro-imaging (398). Moreover, a 
multivariate model based on three complement proteins in plasma (clusterin, TCC and CFI) 
was highly predictive for MCI progression to AD within one year (399). 
1.3.2.6.2 Complement in CSF of AD patients  
In CSF, variable results from the measurement of complement proteins in plasma 
of AD patients have been reported. Complement C3 was increased in CSF (400) and C3 
and CFH were repeatedly associated with AD. In one study, the two complement proteins 
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were investigated in different neurodegenerative diseases like AD and Parkinson’s disease 
(PD). In that study a significant correlation was seen between increased C3 with lower 
MMSE score (401). C3 and CFH were found to be reduced in CSF of AD patients in 
another study (402). Both were also reliably associated with AD pathological changes in 
CSF like tau and Aβ 42 measurements, and can be considered as prognostic markers for 
the disease, however, exactly how they are involved in AD remains unclear (403). 
Interestingly, a normal level of clusterin in the CSF of AD patients was seen in 
some studies (404), while in others, it was increased in AD compared to controls and 
correlated with CSF tau and Aβ 42 measurements. Nevertheless, it could not be considered 
as a reliable marker for AD in CSF (405). 
1.3.2.7 Complement in AD brain  
The role of complement in AD pathology is complex. Although its role as an early 
trigger for AD pathology is unclear, when activated, complement mediates a very strong 
inflammatory response to dispose of the abnormally accumulated proteins that may lead to 
tissue destruction. Nevertheless, uncontrolled activation in the brain is dangerous in itself, 
so complement regulators work to overcome this excessive activation. Therefore, the effect 
of complement activation in brain may be dependent on the balance between its protective 
and harmful effects. Considering complement as a vital contributing factor in 
neuroinflammation, there is a need for more studies to investigate those markers in post-
mortem tissue of AD brain. 
Immunohistochemistry 
Immunostaining of complement proteins has been first detected in AD brain on 
amyloid plaques, NFT, and dystrophic neurites (196,223,406,407). Multiple complement 
fragments were seen in AD brain, activation markers such as iC3b (early stage activation 
fragment of complement system), and C9 (late stage activation protein of the cascade) on 
amyloid plaques and on neurons in AD brain (408). Immunohistochemical studies also 
suggested that C1q enhances Aβ aggregation (409) and colocalizes with activated 
astrocytes and microglia (410). Moreover, increased complement immunoreactivity with 
age was evident (391).  
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Furthermore, immunoreactivity of complement regulators was also detected in AD 
brain, such as clusterin staining on dystrophic neurites in the presence or absence of MAC 
staining (411). C5aR has been shown to be colocalized with NFT in human brain (412).  
1.3.2.7.1  C1q  
C1q is a complex protein, which together with C1r and C1s fragments, form the 
C1 complex. C1q is the recognition molecule and initiator of the classical pathway. In the 
peripheral circulation it is widely expressed by leukocytes while, in the brain, is produced 
mainly by microglia (413,414). In AD, the trigger for CP activation is the Aβ that can bind 
to C1q as seen by in vitro studies (415). That binding has previously been shown to further 
aggregate Aβ (409). 
C1 activation on the amyloid plaque leads to subsequent activation of C4 then C3 
and assembly of C3 convertase. This triggers neuroinflammation by producing pro-
inflammatory and toxic substances to neurons such as ROS in AD (416), or by production of 
anaphylatoxins (C3a and C5a), as shown in Figure 1-8. C1q has a main role in clearance of 
apoptotic cells by binding to them early in the brain pathology (417). Moreover, the 
neuroprotective role of C1q either alone or in conjugation with C3, is associated with 
phagocytic action of microglia to engulf misfolded proteins and cell debris (375,418). 
Another crucial role of C1q in the brain is synaptic elimination (371). Both C1q 
and microglia, were shown to mediate early synaptic loss in AD model (393). Moreover, 
C1q was increased early before plaque formation in association with synapses (106). When 
complement is depleted in AD mouse model, a significant reduction in glial cell activation 
was seen around the plaques as well as an increase in the synaptic marker (synaptophysin) 
compared to normally C1q expressing mice (391). All of the above confirmed the role of 
CP activation via C1q in synaptic loss and in the recruitment of glial cells to amyloid 
plaques in AD brain. 
1.3.2.7.2  Complement component 3 (C3) 
C3 is the central component of the complement cascade. It interacts with a 
considerable number of proteins and its cleavage by one of the three complement pathways 
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will lead to activation of the terminal complement pathway. C3 convertases cleave C3 into 
C3a, a soluble anaphylatoxin which stimulates the local immune response (419) and C3b 
fragment. C3b opsonizes the complement activator surface and in turn activates C5 
convertase which cleaves C5 into C5a and C5b in a similar way as for C3 cleavage. (420,421), 
as shown in Figure 1-8.  
 
 
Figure 1-8: Complement activation pathways in the brain. This figure shows C3 activation 
pathway: the central components of the complement system and the subsequence of its activation 
including (1) release of anaphylatoxins such as C3a and C5a causing neuroinflammation. (2) 
opsonization of target cells and phagocytosis by C3b. or (3) cell lysis by activation of C5 
convertases and C5b assembly of the terminal complement pathway (MAC formation). 
C3 is mainly produced by astrocytes in the CNS  and its production is stimulated 
by NFκB signaling pathway (422). C3a receptors are expressed on microglia and neuronal 
damage occurs via the action of C3a with C3aR on microglia (376). The role of C3 in the 
brain remains unclear i.e. whether C3 is protective or toxic in the AD pathology remains to 
be determined. There is evidence that C3 has a protective role in the AD mice model as C3 
deficiency showed increased AD pathology (81). In another study of human amyloid 
precursor protein (hAPP) AD mice, C3 inhibition was achieved by using soluble 
complement receptor-related protein y (sCrry); a potent inhibitor of C3 convertases. As a 
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consequence, more than two-fold increase of Aβ load was observed in treated mice 
compared to age-matched controls (393).  
C3 can also be activated by Aβ via the alternative complement pathway (355). 
Furthermore, the activity of the alternative pathway was found to be increased in AD, 
evident by increased expression of factors B and D (423). This means that the classical 
complement activation via C3 pathway in the brain can be augmented by the alternative 
pathway (the amplification loop). Elevated C3 level in CSF of AD patients has suggested 
the implication of both the alternative and lectin pathways (400), although there is no 
evidence to connect the lectin pathway with AD pathogenesis. In AD brain, C3 together 
with C1q, mediate the immune inflammatory response. C3 upregulation seen to correlate 
with cognitive decline as measured by MMSE (401). Inhibition of C1q, C3 or microglial 
receptor CR3 reduce microglial phagocytosis as well as the extent of synaptic loss (106). 
Moreover, C3 tagging of synapses lead to their loss in a C3-deficient amyloidosis model 
(392). 
1.3.2.7.3 Inactivated form of C3b (iC3b) 
Further C3 cleavage leads to formation of iC3b, which serves as a phagocytic 
ligand to invading pathogens. iC3b is the initial and proteolytic inactive breakdown 
products (BDPs) of C3b which is considered as an early activation marker of the 
complement system for both the classical and alternative pathways. It is formed by the 
action of CFH and CFI on C3b component of C3 protein (424). iC3b binds to complement 
receptor 3 (CR3): named as CD11b on antigen presenting cells, such as monocytes, 
macrophages, dendritic cells (DC) in the periphery (425), or on microglia in the brain (370). 
Early activation markers of C3 were also found in neuritic plaques in AD brain (426). 
iC3b/CR3 signaling on microglia helps in clearance of apoptotic cells and the 
sequential production of cytokines. Moreover, there is evidence to highlight the role of CR3 
on microglial cells in synaptic pruning, since blocking this pathway rescued synapses in 




1.3.2.7.4  Complement factor H (CFH)  
CFH is one of the most important regulatory proteins (Creg) in the complement 
cascade; it is a large soluble glycoprotein which regulates the alternative pathway by 
inhibiting C3 convertase enzyme. Its role is to avoid excessive complement activation via 
the amplification loop and rescue host cells from damage. CFH when binds to C3b it acts 
as a co-factor for factor I; another C3b regulator which helps in the inactivation of C3b to 
iC3b (428). In the normal brain, CFH is formed locally (429) and it is not known if this 
large molecule can cross the BBB (430). Moreover, CFH in CSF was increased  in AD 
compared to MCI patients (397). 
CFH has been linked to several human disease pathologies, as mentioned before, 
the CFH gene polymorphism is one major risk factor for AMD in the eye (359). CFH is 
also involved in AD pathogenesis (383,431). In AD brain, CFH was shown to co-localize 
with amyloid plaques and neurons (432). The involvement of CFH in AD pathogenesis 
remains unclear. The CFH polymorphism was shown to be involved in AD pathogenesis 
in some studies (384), but not others (385). In CSF of AD patients, CFH was reliably 
associated with AD pathology (403) and  increased with cognitive decline (397).  
1.3.2.7.5 Clusterin (Apolipoprotein J)  
Clusterin is also a regulator of the complement cascade. It is a multifunctional 
glycoprotein which is highly expressed in different tissues including the brain (433); glial 
cells in the brain can express the soluble proteins clusterin (321). Clusterin is a high-density 
lipoprotein which has many cellular functions in health and disease, for instance it assists 
with cholesterol transport to prevent its accumulation. It also has roles in angiogenesis, cell 
adhesion and clearance of debris by apoptosis. It also acts as a fluid phase regulator to the 
terminal complement pathway by preventing MAC assembly and so is called the 
complement lysis inhibitor (CLI) that prevent the excessive cell damage (379). 
In AD, CLU variation was associated with the risk of developing LOAD in multiple 
independent GWAS studies (23). It is expressed in different isoforms: nuclear and secreted 
forms (433). Clusterin was increased in CSF and also associated with amyloid plaques  in 
AD patients (434). In plasma, clusterin level was suggested to be a potential marker of 
predicting cognitive decline and associated with polygenic risk score in AD (396). 
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Clusterin is detected in the AD brain, but how the protein affects AD pathogenesis is 
unknown. Nevertheless, the relationship of clusterin with Aβ has been of great interest to 
AD research. It is thought to bind to the soluble and insoluble forms of Aβ and plays a role 
in its clearance (435). Furthermore, clusterin prevents Aβ fibrillization in rat brains (436). 
Under physiological conditions, clusterin facilitates Aβ clearance from the brain 
by preventing its aggregation and increasing perivascular clearance. The role of clusterin 
in Aβ clearance is similar to that of ApoE, both interact with Aβ and clear it from the brain 
to the bloodstream (17,314,437). That mechanism of Aβ clearance probably depends on 
the ratio of clusterin to Aβ levels in the brain. It correlated positively with Aβ protein 
fractions in AD brain (438). Moreover, clusterin was found to be increased in ApoE 4 
carriers with an increased co-localization with synapses; however, it is not yet known if 
clusterin has a protective or toxic effect to synapses (439). 
1.3.2.7.6 Terminal complement complex (TCC) 
TCC is a macromolecular complex which consists of a number of complement 
proteins: C5b, C6, C7, C8 and several molecules of C9. C5b initiates the terminal pathway 
and eventually leads to the assembly of MAC (354). Its action is to cause lysis of the target 
cell via the influx of ions and water to the cells leading to electrolyte imbalance and 
disturbed osmosis. Cytotoxicity occurs when MAC is present in sufficient concentrations 
via forming a pore (a ring like structure) in the lipid bilayer of the cell membrane, as shown 
in Figure 1-9 (440). The assembly of TCC is beneficial; however, robust activation will 
damage host cells, so it is regularly inhibited by different regulators such as CD59 and 
clusterin (441). 
In AD, direct complement mediated cell lysis occurs in neurons. TCC has been 
identified in neuritic plaques and neurofibrillary tangles (97,172), and co-localizes with Aβ 
in the brain (223). In AD, complement regulators are crucial for the disease process to avoid 
excessive activation or bystander lysis of neighbouring cells. For instance, CD59 is a 
membrane bound glycoprotein that protects against complement mediated lysis. Its 
deficiency has previously shown to predispose to AD. This may occur when neurons 




Figure 1-9: Membrane attack complex (MAC formation). This figure shows the activation of 
terminal components of the complement C5b, C6, C7, C8 and C9 which results in the deposition of 
MAC onto the plasma membrane of the target cells. This causes pore formation in the membrane 
preventing target cells from maintain osmosis and electrolyte imbalance and results in their death. 
1.3.2.7.7  Complement receptor type1 (CR1)  
Complement receptor 1 is a polymorphic transmembrane glycoprotein. It is the cell 
surface receptor for C3b fragment of C3 protein and C4b, and can also bind to C1q (443). 
Soluble CR1 works as a regulator of the complement cascade activation via inhibiting both 
the classical and alternative pathways. This regulatory mechanism occurs via inhibiting C3 
convertase or by providing a cofactor action to factor I. Moreover, CR1 can also regulate 
phagocytosis by the removal of immune complexes coated with C3b or C4b (444). CR1 is 
known to be expressed on erythrocytes in the periphery and helps in the clearance of 
abnormally accumulated proteins (445). However, it is also expressed by astrocytes, 
microglia and Kolmer cells in choroid plexus in the brain neurons (446,447). 
GWAS have linked CR1 polymorphisms with the risk of developing LOAD 
(23,448). The longer isoform (S) has been recognized to be the risk allele for CR1 gene in 
AD, however, the mechanism behind this is not fully understood (449,450). The role of 
CR1 with ApoE interacting to clear brain amyloid deposition is complex (451). The genetic 
risk association of CR1 with AD was evident in ApoE E4 carriers (23). However, other 
studies showed no interaction between the two genes (452).  
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It was evident that peripheral C3 and CR1 are important for systemic Aβ clearance 
from blood via complement-dependent adherence of Aβ to erythrocytes (453,454). 
Neverthless, CR1 variation was also associated with increased risk of cerebral amyloid 
angiopathy (455). In AD patients, plasma levels of soluble CR1 did not correlate with 
diagnosis (447), a slight increase in CR1 level was seen in CSF (456). 
1.3.2.8 Complement system as a therapeutic target in AD  
Complement system activation in AD is highly complex. When and how the 
complement can be targeted is likely to be very critical. To date, there is arguably no single 
complement target that may be of a benefit for the drug discovery in AD. Theoretically, 
both complement protein expression and complement activation regulators can be targeted 
in AD. More understanding of complement dysregulation in AD brain is thus mandatory 
for this purpose. Moreover, many factors are to be taken into consideration while thinking 
of complement as therapeutic target. The therapeutic agent has to be safe in the long term 
and can pass through the BBB (172). Some large therapeutic molecules can be only 
beneficial in treating AD pathology when the BBB is disrupted. 
It should be noted however, that it would not be useful to eliminate the beneficial 
effect of complement system activation. Because of the preferential inhibition of the 
negative consequences of complete activation in C5 pathway rather than positive effects of 
early complement proteins such as (C1q and C3), inhibiting of the C5 pathway might be 
considered as a potential therapeutic option in AD. Introduction of complement 
therapeutics through combining them with low molecular weight molecules such as heparin 
may be beneficial. Similar to the trial which has shown an effective reduction in Aβ load 
in mice brain by using enoxaparin (148). 
There are currently approved anti-complement drugs such as eculizumab, which is 
a humanized monoclonal antibody against C5. It prevents C5 cleavage and therefore, 
prevents the formation of MAC, are expensive and cannot pass the BBB. However, 
permeability by the BBB might not be a problem in case of AD. That was proven in some 
other neurological diseases in which eculizumab was tried and believed to cross the 
moderately impaired BBB (457). Reliable biomarkers in plasma and imaging for early 
diagnosis of the disease are now urgently needed to help select the right patient, to ensure 
study designs capture variability in the populations being studied (e.g. patient stratification) 
and the appropriate time for the intervention (172). 
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1.3.3 Cytokines expression in the brain 
1.3.3.1  Cytokines 
Inflammatory cytokines are heterogeneous proteins of different molecular weights. 
They are responsible for inflammatory reactions, cross-talk between cells and have other 
diverse cellular functions. Interleukins (ILs) represent a large group of cytokines that are 
produced by leukocytes. Other cytokines include TNFs, interferons (IFNs), transforming 
growth factors (TGFs); and finally, chemokines that can attract and activate leukocytes to 
the affected areas. Cytokines are functionally classified into pro- and anti-inflammatory 
according to their response to injury (458).  
Pro-inflammatory cytokines include IL-1β, IL-6, IL-18, TNF-α, interferon gamma 
(IFN-γ), and granulocyte-macrophage colony stimulating factor (GM-CSF), while IL-4, 
IL-10 and TGF-β are considered anti-inflammatory cytokines. It is important to maintain 
the balance between the two types of cytokines. Any imbalance may lead to or exacerbate 
pathological conditions like neurodegenerative diseases. Cytokines thus act as an important 
link between the innate and the adaptive immune response (459). 
1.3.3.2 Cytokines in the brain 
In the CNS, cytokines are produced from both glial cells and neurons 
(235,250,460). They have roles in various neurogenic and metabolic brain functions and 
help in brain development in early stages of life (303,461,462). Additionally, circulating 
cytokines produced in the periphery reach the CNS through leaky BBB (463), or even in 
healthy conditions via active and gradient-dependent transport manner (464,465). 
Nevertheless, other evidence suggests that peripheral cytokines could also promote central 
cytokines production by the brain (466). 
1.3.3.3 Cytokines in AD 
As mentioned before, neuroinflammation is one of the main events associated with 
AD where microglial activation has been reported in both AD patients and animal models 
(243). Activation of microglia upon Aβ binding to its surface, induces pro-inflammatory 
cytokines gene expression, leading to elevation of pro-inflammatory cytokines (467,468). 
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Since cytokines represent key components in neuroinflammation, great attention has been 
paid to explore the association between cytokines and AD pathogenesis. Accumulation of 
cytokines, such as IL-1β (469), IL-6 (470) and TGF-β (471) around amyloid plaques was 
evident in AD brains. Despite being inconclusive, measurement of cytokines level in serum 
and/or CSF revealed tendency towards elevation of both pro- and anti-inflammatory 
cytokines in AD patients (472). 
How cytokines play their role in AD and whether they are a consequence, or an 
initiating factor are still a debate. However, similar to Aβ, pro-inflammatory cytokines were 
increased in response to tau overexpression in rat models (473,474). All of this suggested 
that cytokine expression could be a secondary event initiated by Aβ and tau in AD. 
However, other studies supported the role of cytokines as a cause by triggering brain Aβ 
and tau phosphorylation (475). Moreover, many individual genetic studies and meta-
analyses have linked different cytokine gene polymorphisms with AD risk such as IL-1β 
(476–479). 
1.3.3.3.1 Role of pro-inflammatory cytokines in AD pathogenesis 
Pro-inflammatory cytokines secreted by glial cells, especially the classically 
activated microglia (M1) in the brain such as IL-1β, IL-6 and TNF-α, promote 
neuroinflammation by different mechanisms. 
➢ IL-1β and AD 
IL-1β is one of the IL-1 cytokine family (480). Its production depends on the 
activation of some transcription factor such as NF-κB (481). Initially, it is released in an 
inactive ‘pro-form’. Then, the inflammasome activates caspase-1 protease that cleaves the 
pro-form of IL-1β to the mature and bioactive form (482,483). Several polymorphisms of 
the IL-1β gene have been associated with AD risk (476,479). One polymorphism was 
associated with a more delayed onset of the disease and reduced amyloid plaques and 
NFTs, particularly in patients lacking the APOE ε4 allele (477). The inflammasome is 
another part of the innate immune response which has also been proven to be involved in 
AD via interaction with microglia and the subsequent release of pro-inflammatory 
cytokines such as IL-1β (484). Inflammasome action is also related to MAC of the 
complement system (485). 
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Numerous reports have explained the role of IL-1β in neuroprotection. It has been 
suggested that soluble oligomeric Aβ can enhance the maturation of pro-IL-1β in microglia 
through ROS-dependent mechanism (486). Nevertheless, IL-1β overexpression can 
prevent Aβ clearance (487), and increase BBB permeability leading to more deposition of 
Aβ in the brain (488).  
Other studies showed that sustained IL-1β overexpression was found to 
paradoxically reduce Aβ-related pathology via promoting microglial degradation or APP 
cleavage (489–491). Therefore, an interactive relationship between IL-1β expression and 
Aβ deposition was suggested i.e. Aβ deposits can be both a trigger and a result of IL-1β 
expression in AD patients. Additionally, IL-1β can induce microglial chemotaxis as 
evidenced by lower recruitment of microglia in Interleukin- 1 receptor (IL-1R) deficient 
mice (230). 
IL-1β is one of the most widely studied molecules in the plasma of AD patients. It 
was reported to be increased in a recent meta-analysis that compared AD to healthy controls 
(492). Immunohistochemical examination of AD brain tissue revealed that glial cells 
express IL-1β in a higher concentration in the hippocampus (493). Numerous studies also 
confirmed overexpression of IL-1β produced by microglia and astrocytes around Aβ 
plaques (494,495). 
Interestingly, administration of IL-1 receptor antagonist (IL-1ra) or anti-IL-1β 
antibody was found to hinder IL-1β signaling, decrease tau pathology and improve the 
cognitive function (496,497). 
➢ TNF-α and AD 
TNF-α has been reported to have variable effects on AD risk and pathogenesis. 
Concerning genetic polymorphisms, TNF-α variants have been associated with AD risk 
(498) although this was not supported in recent GWAS. Yet, the polymorphism of this gene 
was shown to affect the susceptibility for AD in certain populations, especially among 
carriers of the APOE ε4 allele  (499). Its role in AD seems to be protective as well as toxic. 
This dual effect might be explained by the presence of two types of receptors. TNF receptor 
1 activation stimulates accumulation of Aβ and Aβ-induced neuronal death (500,501), 
while TNF receptor 2 seems to oppose the induced damage of receptor 1 (502).  
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Furthermore, a therapeutic trial of short term anti-TNF-α treatment proved to have 
some positive effect on cognition, probably by alleviating Aβ pathology in AD mice (503) 
or when used to treat other inflammatory disorders such as rheumatoid arthritis, (184). 
➢ IL-6 and AD 
Polymorphisms of IL-6 gene have been targeted by many studies to explore their 
role in AD pathogenesis (504). IL-6 variation was also found to be associated with levels 
of clusterin in CSF of AD patients (505). Moreover, studies showed that IL-6 promotes Aβ 
and NFTs accumulation (506–508). In plasma of AD patients, IL-6 was not changed as 
shown by a recent meta-analysis study (492). 
1.3.3.3.2 Role of anti-inflammatory cytokines in AD pathogenesis  
Ant-inflammatory cytokines are secreted by glial cells especially the alternatively 
activated microglia (M2) in the brain such as IL-4, IL-10 and TGF-β, as shown in Figure 
1-5. Their role is protective, and they antagonize the inflammatory response of pro-
inflammatory type. The imbalance between both types may lead to pathological condition 
in the CNS such as AD  (261).  
➢ IL-4 and AD 
IL-4 is one of the anti-inflammatory cytokines that can suppress the inflammatory 
reaction in AD. Treatment of AD animal models with IL-4 has reduced the accumulation 
of Aβ and improved the cognitive function (509). That neuroprotective effect was found to 
be mediated via promoting expression of scavenger receptor CD36 and Aβ degrading 
enzymes such as NEP and IDE, and thus the microglial clearance of Aβ (510). Moreover, 
IL-4 can supress TNF-α expression, while major histocompatibility complex class 2 (MHC-
II) expression by microglia was promoted (511). 
➢  IL-10 and AD 
Despite having CNS anti-inflammatory and neuroprotective function, the exact 
role of IL-10 in AD is not fully known. Contradictory reports have shown that IL-10 
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expression may have a role in enhancing neurogenesis and cognition (512), or increase Aβ 
accumulation and worsen cognitive dysfunction in AD mice models (513). 
➢ TGF-β and AD 
TGF-β gene polymorphism promotes risk of AD in patients with mild cognitive 
dysfunction (514). In other studies, its polymorphism was positively linked to the severity 
of cerebral amyloid angiopathy and increased plaque pathology suggesting an additional 
contribution to vascular dementia (515,516). There is also evidence that suggests a 
neuroprotective role in AD, since its deficiency in AD brains lead to Aβ accumulation  and 
promoted neurodegeneration in AD mice (517). In addition to that, the protective effect of 
TGF-β was seen when the treatment with TGF-β was successful against Aβ-induced 
neurotoxicity (518). 
1.3.3.4 Cytokines as diagnostic biomarkers for AD 
Varying results had been reported regarding the usefulness of pro- and anti-
inflammatory cytokines as diagnostic markers in AD. Cytokines have been attractive as 
potential disease predictors due to their repeated reports of association with AD. One of 
earliest attempts was performed by Ray et.al., who proposed a blood panel of 18 plasma 
biomarkers containing multiple cytokines and used it for diagnosis of AD and MCI with 
nearly 90% accuracy (519). Nevertheless, the stability and the reproducibility of this model 
were both debated (520,521). Later, two other models of plasma protein panels were used 
and proven to have more reproducibility and diagnostic accuracy (522,523).  
Promising results were obtained from different studies; where increased IL-6 level 
was shown to be a reliable associate with cognitive impairment in AD (524), and TNF-
receptor 1 has been selected among 25 inflammatory protein as a reliable biomarker for 
diagnosis of AD patients (525). 
1.3.3.5 Cytokines as therapeutic target in AD 
Neuroinflammation and its role in the pathogenesis of AD is crucial to understand, 
but as yet remains unclear. However, numerous strategies have been adopted to modulate 
those cytokines and modify the disease course. Therapeutic trials have been proposed to 
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target cytokines as an important immune pathways such as TNF-α. Etanercept, a TNF-α 
inhibitor used for rheumatoid arthritis, showed a clinical improvement after its peri-spinal 
injection (526), however, other parenteral routes were less effective (527,528).  
A study of infliximab, another TNF-α monoclonal antibody on APP/PS1 double 
transgenic mice resulted in a significant decrease in amyloid plaques and tau 
phosphorylation (529). Additionally, minocycline, which is a tetracycline derivative with 
anti-IL-6 and anti- TNF-α properties, showed promising results upon its use in transgenic 
mouse models of AD. It decreased the cortical tau aggregation and amyloid pathology 
(530,531), as well as improving the behavioural symptoms (532). However recently a phase 
II trial in AD patients found no benefit of minocycline and a higher dose was poorly 
tolerated (64). 
Melatonin is another pro-inflammatory cytokine modulator that has anti-IL-1β, 
anti-IL-6 and anti-TNF-α activity. It improved the cognitive function of rats (533). 
However, contradictory results have been also reported regarding its positive clinical effect 
in AD patients (534,535). Other promising trials for AD included IL-1ra that proved to be 
successful in treatment of rheumatoid arthritis and cortical infarcts (496,497,536), and p40-
neutralizing antibodies, an anti-psoriasis drug that inhibits IL-12 and IL-23 signaling (537).   
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1.4 Aims and Hypothesis 
 Our understanding of the complexities and heterogeneous functions of 
neuroinflammation in general have improved due to increased research and this has helped 
our understanding of how this applies to neurodegenerative diseases. Yet many gaps remain 
in our knowledge and many findings in the literature on inflammation in AD plasma, CSF 
or brain are conflicting. The changes in the peripheral blood or even in CSF do not 
necessarily reflect the processes that take place in the AD brain. Furthermore, mouse 
models of AD, which much research to-date has been undertaken on, mimic only some 
aspects of the disease pathology but not the whole complexity of the human brain or the 
many factors of LOAD. 
In contrast, there have been few post-mortem studies undertaken thus far, wherein 
the most accurate diagnosis is possible, to investigate the inflammatory markers in AD 
brain. Of the few undertaken, many have included small sample sizes. Therefore, studying 
neuroinflammation in more detail, and in larger better characterised cohorts is still needed 
to try and find potential targets for the prevention of AD that may aid the development of 
new therapies.  
1.4.1 Study hypothesis  
My overall hypothesis is that the innate immune response, particularly the 
complement system, pro-inflammatory cytokines, and glial activation, are dysregulated, 
especially in areas of greater AD pathology, and that this is associated with the severity of 
the disease. 
1.4.2 Study aims 
To study the potential contribution of the innate immune response in AD and 
compare with control brain. This involved work to investigate the differences between a 
number of complement system proteins, astrocyte markers and cytokines using quantitative 




More specifically, the aims of this investigation were as follows: 
• To measure specific inflammatory proteins and genes in homogenised frontal and 
temporal cortex post-mortem brain tissue from South West Dementia Brain Bank 
(SWDBB) from cases of neuropathologically confirmed AD and elderly non-
demented controls. 
• To correlate these inflammatory proteins with other AD-related protein marker 
data that was previously collected in the same cohort within the Dementia Research 
Group (DRG) and was available for analysis from other projects. 




2. Chapter 2: Materials and General Methods. 
2.1 Materials 
2.1.1 Consumables and chemicals 
Table 2-1: Details of consumables and reagents used and commercial suppliers. 
Item Supplier 
Absolute ethanol (EtOH) Fisher Scientific 
Aprotinin Sigma-Aldrich 
Assay-on-demand (AOD) Applied Biosystems 
Blotting chromatography paper (3MM) 
Whatman, GE Healthcare, 
Life Sciences 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
Citric acid (monohydrate) Fisher Scientific 
DEPC (diethyl pyro-carbonate) treated water Ambion, Thermo Fisher 
Disposable scalpels Swann Morton 
DNase I recombinant, RNase-free (bovine 
pancreas) 
Roche Diagnostics 
DPX (distyrene/xylene) mountant for histology 
(slides mounting medium) 
Sigma-Aldrich 
Enhanced chemiluminescence (ECL), medium and 
high sensitivity 
GE Healthcare, Life 
Sciences 
Eppendorphs, reaction tubes (0.2 ml, 0.5 ml, 2.0 ml) Grenier Bio-one 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Falcon tubes VWF Chemicals 
Filter cartridges for collection tubes (RNA 
isolation)  
Thermo Fisher Scientific 
FluorSaveTM reagent (aqueous mounting medium 
for use with fluorescent tracers) 
Merck Millipore 
Fujifilm corporation™ RX NIF sheet x-ray film Fisher Scientific 
Glycerol  Sigma-Aldrich 
55 
 
Glycine Fisher Scientific 
Glycogen, molecular biology grade Thermo Scientific 
Haematoxylin Vector Laboratories 
High-binding costar 96- well plates  R&D Systems 
Hydrogen peroxide 100 volume (> 30% w/v) Fisher Scientific 
MaxiSorp, Nuc-immuno U shape 96 wells for 
enzyme linked immunosorbent assays (ELISA) 
plates 
Thermo Scientific 
Methanol Fisher Scientific 
MicroAmp™ optical 384-well reaction plate with 
barcode 
Applied Biosystems 
Microscope slides Cellpath 
Mini-PROTEAN®TGX™ Gel, 10 wells (4–20% 
precast gels) 
Bio-Rad 
Nitrocellulose membrane (protran BA83 
membranes) 
Whatman GE Healthcare 
Life Sciences 
Normal goat, horse and rabbit serum blocking 
solution (2.5%) 
Vector Laboratories 
PAP pen Vector Laboratories 
Peroxidase substrate reagent pack for ELISA R&D Systems 
Phenylmethylsulphonyl fluoride (PMSF) Sigma-Aldrich 
Phosphate buffered saline (PBS) Sigma-Aldrich 
Polyester films (ELISA adhesive plate sealer) VWR Chemicals 
Pre-stained protein ladder (PageRuler Plus) Thermo Scientific 
RNase free collection tubes (2.0ml) Ambion, Thermo Fisher 
RNase Zap® RNase decontamination solution Invitrogen, Thermo Fisher 
Screw cap centrifuge tubes (2.0ml) Alpha Laboratories 
SIGMAFAST™ OPD (o-phenylenediamine 
dihydrochloride tablets) ELISA substrate 
Sigma-Aldrich  
Silica beads  Biospec 
Slides coverslips Cellpath 
Sodium bicarbonate (NaHCO3) Fisher Scientific 
Sodium carbonate (Na2CO3) Fisher Scientific 
Sodium chloride (NaCl) Fisher Scientific 
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Sodium dodecyl sulphate (SDS) Fisher Scientific 
Stop solution for ELISA (sulphuric acid) 
R&D Systems, Sigma-
Aldrich 
Streptavidin conjugated to horseradish-peroxidase 
(HRP) 
R&D Systems 
Sudan black B stain Sigma-Aldrich 
TaqMan fast advanced master mix Applied Biosystems 
Thioflavin S practical grade Sigma-Aldrich 
Tris base (Tris hydroxymethyl)-aminomethane Fisher Scientific 
Tris-HCL Fisher Scientific 
Triton X-100 Sigma-Aldrich 
Tween-20  VWR Chemicals 
Western blot sponges Bio-Rad 
β-Mercaptoethanol Fisher Scientific 
2.1.2 Equipment 
Table 2-2: Details of equipment used and commercial suppliers. 
Item  Supplier 
Agilent bioanalyzer (2100) Agilent Technology 
Bench top centrifuge VWR 
Electrical air displacement pipette Xplorer, Eppendorf 
Horizontal microplate shaker  
(Titramax 100) 
Heidolph Instruments 
Incubator (37ο C) /Oven (60ο C) Memmert 
Luminex® 100/200 TM Luminex Corporation 
Magnetic plate separator Luminex Corporation 
Magnetic stirrer (SB161) Stuart Scientific 
Mechanical homogeniser (Precellys 24) 
Stretton Scientific, Bertin 
Technologies 
Microplate reader (FLUOstar OPTIMA)  BMG Labtech 
Microscope (ApoTome.2) Zeiss Research Microscopy 
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Microscope (Cell observer spinning disc 
confocal microscope)  
Zeiss Research Microscopy 
Mini gel tanks for western blotting (WB) Life Technologies, Thermo Fisher  
Nanodrop (ND-1000) Labtech 
QuantStudio (12K flex) RT-PCR  Applied Biosystems 
Refrigerated centrifuge (4οC), Micro star 
17R 
Pendragon Scientific, VWR 
Thermal cycler for PCR Biometra TRIO, Analytik Jena 
Viia 7 RT-PCR system Applied Biosystems 
Vortex mixer Jencons Scientific, VWR 
Western blot system and PowerPac 300 
electric supply  
Bio-Rad 
2.1.3 Solutions used 
Table 2-3: Constituents of the regularly used solutions. 
Solution Components 
1% SDS lysis buffer 
1% SDS, 0.1 M tris HCL (pH 6.0), 0.05 M 
sodium chloride,1μM PMSF and 1μg/ml 
aprotinin. 
Antigen retrieval for 
immunohistochemistry (IHC) 
(citrate-EDTA buffer) 
10 mM Citric acid, 2 mM EDTA and 0.05% 
Tween-20 (pH 6.2) in dH2o. 
Blocking and antibody buffer 
for WB 
5% Normal serum and 0.5% Triton X-100 in PBS. 
Coating buffer for ELISA 
0.1 M/L sodium carbonate and 0.3 M/L sodium 
bicarbonate (pH 9.6). 
ELISA washing buffer 0.05% Tween-20 (pH 7.4) in PBS. 
Gel running buffer (10X) 
0.25 M Tris base, 1.02 M glycine and 1% (w/v) 
SDS. 
Gel transfer buffer (10X) 0.25 M Tris base and 1.92 M glycine. 
Gel transfer buffer (1X) 
20% methanol, 10% transfer buffer (10X) and 
70% distilled water. 
Loading buffer for WB samples 
(SDS reducing buffer)  
0.5 M Tris-HCL (pH 6.8), 25% glycerol 10% 
weight volume (w/v) SDS and 0.5% (w/v) 
bromophenol blue. 
Phosphate buffered saline  
(pH 7.4) 
0.15 M sodium chloride,1.9 mM sodium 
dihydrogen orthophosphate 1-hydrate and 7.5 mM 
di-sodium hydrogen orthophosphate. 
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Quenching buffer for IHC 3% Hydrogen peroxide (30% w/v) in methanol. 
WB blocking buffer 5% BSA in PBS in 0.1% Tween-20. 
WB washing buffer (PBS-T) 0.1% Tween-20 (pH 7.4) in PBS. 
2.1.4 Laboratory assay kits used 
Table 2-4: Details of kits used, commercial suppliers and contents of the kits. 
Item (Kit) Supplier  Contents 
DuoSet Ancillary 




96- well plates, sealers, colour reagent A 
& B, Stop solution, coating buffer, 
reagent diluent, wash buffer, PBS pack 
and carbonate-bicarbonate buffer pack. 





EZ-Link plus activated peroxidase, 
sodium cyanoborohydride solution, and 
quenching buffer (pH 9). 





20X Enzyme mix (MuLV and RNase 
inhibitor protein) and 2X RT buffer mix 
(includes dNTPs, random octamers, and 
oligo dt-16). 
High sensitivity 
quantikine ELISA kit 
for human IL-1β 
R&D Systems 
(HSLB00D) 
• 96 well microplate coated with a 
monoclonal antibody specific for 
human IL-1β. 
• Recombinant human IL-1β protein. 
• Conjugated polyclonal antibody 
against human IL-1β for as detection 
antibody. 
• Assay diluent and calibrator diluent. 
• Streptavidin conjugated to HRP. 
• Wash buffer- chromogen A and B- 
plate sealer and stop solution. 
Human Fibrinogen 




• Pre-coated plates with capture 
antibody. 
• Standard protein. 
• Detection antibody (reagent A & B). 
• Reagent diluents. 









One drop (30μl) DAB chromogen 
concentrate to 1 ml of DAB diluent, mix 







Premixed Kit A) for 
IL-1β, IL-6 & TNF-α 
R&D Systems,  
(FCSTM09) 
• Standard cocktail (recombinant human 
cytokines IL-1β, IL-6 and TNF-α). 
• Premixed magnetic microparticle 
cocktail. 
• Biotin-antibody cocktail. 
• Streptavidin-PE. 
• Wash buffer concentrate. 
• Calibrator diluent (RD6-40). 
• Microparticle diluent. 
• Biotin-Ab diluent. 
• Flat-bottomed 96-well microplate, 
mixing bottles and foil plate sealers. 
PARIS kit (Protein 




• Cell disruption buffer. 
• Cell fractionation buffer. 
• 2X lysis/binding solution.  
• Wash buffer 1 and 2, collection tubes, 
elution solution and filter cartridges. 




• Agilent RNA 600 Nano ladder. 
•  Dye concentrate, marker, and gel 
matrix. 
Sp-Xray developer 










• Protein dye reagent (Brilliant blue G, 
0.35mg/ml, in phosphoric acid and 
methanol). 
• Protein standard solution (human 
albumin, 0.3 mg/ml in saline with 0.1% 
sodium azide as a preservative). 
VECTASTAIN 





2 drops (100μl) reagent A and 2 drops 
(100μl) reagent B in 5 ml PBS, prepared 
and set at room temperature (RT) for 30 




2.1.5 Primary antibodies used 
Table 2-5: Details of primary antibodies used, suppliers and application in the thesis. In-house 
antibodies generated, characterized, and validated in laboratories of complement biology group 





Clonality Supplier  Application 
6E10 Mouse Monoclonal 









C1q Rabbit  Polyclonal In-house antibody 
Sandwich ELISA, 
WB     
C3 Rabbit Polyclonal 
In-house, Protein G 
purified antibody 
Sandwich ELISA 





C3b/iC3b Mouse Monoclonal In-house (C3/30) 
Immunofluorescence 
(IF) 
CFH  Mouse  Monoclonal OX24 antibody (539) Sandwich ELISA 
CFH  Mouse  Monoclonal 
In-house (35H9-HRP) 
labelled antibody (538) 
Sandwich ELISA 




Clusterin Mouse Monoclonal 
R&D Systems  
(DY5874-15) 
Sandwich ELISA 






























IBA1 Goat Polyclonal Abcam (Ab5076) IHC 









TCC Mouse  Monoclonal 
In-house, anti-C8, E2-
HRP labelled antibody 
(538,540) 
Sandwich ELISA 
TCC Mouse Monoclonal 
Hycult Biotech, aE11 
(HM2167)  
Sandwich ELISA 
2.1.6 Secondary antibodies used 




Clonality Supplier Application 











ELISA, WB, IF 



























2.1.7 Recombinant proteins used: 
Table 2-7: Details of protein standard used in sandwich ELISA and WB. In-house proteins 
generated in laboratories of Complement Biology Group in Cardiff University. 
Protein Type Supplier 
C1q Human affinity purified C1q protein In-house 
C3 Human affinity purified C3 protein CompTech. (A138) 
CFH Human purified FH protein In-house 
Clusterin Recombinant human clusterin R&D Systems (DY5874-15) 
Fibrinogen Recombinant human protein 
Cloud-Clone Corp. (KSA193 
Hu01) 
GFAP Recombinant human GFAP R&D Systems (DY2594-05) 
iC3b Human affinity purified iC3b protein CompTech. (A115) 
IL-1β Recombinant human protein R&D Systems (HSLB00D) 
TCC Human affinity purified protein In-house 
2.1.8 Primers used in RT-PCR 
Table 2-8: Details of TaqMan assay on demand (AOD) of genes of interest and calibrator genes 
used. NCBI =National Centre of Biotechnology information, Hs = Homo sapiens (species for which 
the assay was designed is a human origin), m1 = assay whose probe spans an exon junction and will 













Beta Actin ACTB Hs99999903_m1 NM_001101.3 77 
Clusterin CLU Hs00156548_m1 NM_001831.3 65 
Complement C1q A 
chain 
C1QA Hs00381122_m1 NM_015991.2 87 
Complement 
component 3 
C3 Hs00163811_m1 NM_000064.3 88 
Complement factor H CFH Hs00164830_m1 NM_000186.3 60 




Glial fibrillary acidic 
protein 





















Interleukin 1 beta IL-1β Hs01555410_m1 NM_000576.2 91 
Neuron specific enolase 
NSE 
(ENO2) 
Hs00157360_m1 NM_001975.2 77 





Tumour necrosis factor 
alpha 
TNF-α Hs99999043_m1 NM_000594.3 85 
2.1.9 Software package used 
Table 2-9: Software used for statistical analyses 
Item Supplier 
GraphPad version 6 (PRISM) GraphPad software, Inc. San Diego, CA, USA 
ZEN blue imaging software  Zeiss Research Microscopy 
2.2 Post-mortem human brain tissue 
2.2.1 Tissue acquisition 
Post-mortem human brain tissue was obtained from the Human Tissue Authority-
licenced South West Dementia Brain Bank, (SWDBB, HTA license number: 12273) with 
ethical approval for the described work authorized under the tissue bank ethics number 
08/H0106/28 (North Somerset and South Bristol Committee). Brains were obtained post-
mortem, the left hemisphere was sliced into coronal sections and immediately stored at -
80οC. The right hemisphere was fixed in formalin to be sliced and embedded in paraffin 
blocks from which tissue sections were made for diagnosis.  
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2.2.2 Cohort selection 
Clinically and pathologically validated AD cases with LOAD diagnosis (33 cases) 
and age matched controls (31 subjects). 
The control group comprised males (n= 19), and females (n= 12) and the AD group, 
males (n= 10) and females (n= 23). The age of the control group ranged from 43 to 95 years 
(mean 78.1, standard deviation (SD) 11.0), and the AD group ranged from 69 to 96 years 
(mean 81.6, SD 6.34). The mean post-mortem delays were 43.2 hours (SD 29.24) for the 
control group and 49.8 hours (SD 28.2) for the AD group.  
AD cases were diagnosed according to criteria given in Section 2.3 according to 
the NIA-AA guidelines (171); all details of the cohort are given in Table 3-1. 
➢ Exclusion criteria: 
• Controls with any history of cognitive decline. 
• Controls with Braak stage III (for possibility of early AD changes). 
• Cases with apparent onset of AD before 65 years. 
• Cases with a reported history of familial AD or a mixed dementia at diagnosis. 
➢ Brain regions studied:  
• Frontal cortex: Brodmann areas (BA) 8/9. 
• Temporal cortex (BA) 21/22.  
2.2.3 Brain tissue homogenization 
Previously dissected frozen brain tissue from selected areas of frontal cortex and 
temporal cortex (grey matter only), was homogenized by the addition of 1 ml SDS lysis 
buffer into a 2 ml screw cap tube containing brain tissue (200 mg) with 8-10 silica beads. 
Samples were homogenized at 6,000 x g of 3D lysis motion using a Precellys 24® 
homogenizer for 2 x 15 seconds, then centrifuged for 10 minutes at 13,000 x g at 4°C. The 
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supernatant was separated into individual aliquots. Aliquots were stored at -80°C until 
used. 
2.2.4 Tissue used for post-mortem simulation study 
Simulation of post-mortem delay was done by selecting tissue samples from 
donations with short post-mortem delay and then undertaking a series of parallel 
incubations that allowed exposing the tissue to increasing post-mortem delays at room RT 
or 4οC for up to 72 hours then stored in -80οC. Simulated post-mortem samples were then 
homogenised as previously described and measured using identical assay conditions to 
examine the possible effect of post-mortem delay. To achieve this, 10 pieces of the same 
tissue sample were dissected and stored as shown in Table 2-10. 
Table 2-10: Simulated post-mortem brain tissue. RT= room temperature. 











2.3 Neuropathological characteristics of the cohort 
Neuropathological assessment of the cohort used in this study had been carried out 
previously; the diagnosis involves assessment of Braak staging and Aβ load in conjunction 
with assessment of prior medical history. Data were available in the Medical Research 
Council (MRC) brain bank databases for SWDBB 
All brains underwent a routine neuropathological assessment, AD diagnosis was 
made for subjects who had a clinical history of dementia, and had the neuropathological 
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characteristics of ‘definitive AD’ according to CERAD; the Consortium to Establish a 
Registry for Alzheimer’s Disease (170). 
2.3.1 Braak tangle staging 
Braak staging is the quantification of neurofibrillary tangles (NFT) in six stages 
within the entorhinal cortex, hippocampal region and cortex  to assess pathological 
progression, and which has been shown to correlate  with cognitive decline (95). Stages are 
combined (0-II), (III-IV) and (V-VI) in this thesis for the purposes of data analysis to 
represent the NFT distribution in entorhinal, limbic (including hippocampus) and 
isocortical stages and also to reflect stages of absent, mild, and severe pathology, 
respectively. 
2.3.2 APOE genotyping 
APOE isoforms of the subjects in the cohort were previously assessed as a part of 
other studies within the Dementia Research Group (DRG), using extracted DNA from each 
brain and followed by PCR and restriction fragment length polymorphism as previously 
described (541). 
2.3.3 Aβ parenchymal load 
Parenchymal Aβ load was previously measured as part of a previous routine 
characterisations of brain donations within the research group in (SWDBB) and calculated 
by using computer-assisted image analysis using a Leica DM microscope and Histometrix 
software (Kinetic Imaging, Nottingham UK).  
The percentage field fraction of immunoreactivity for Aβ was calculated in 30 
randomly selected regions from three different brain areas in cerebral cortex (frontal, 
temporal, and parietal sections) by measuring the area fraction immunopositive for Aβ, as 
previously validated and described (542,543). 
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2.4 Total protein measurement 
Total protein concentration was measured using a commercial total protein kit 
(TP0100, Sigma-Aldrich). Following the manufacturer’s guidelines: brain homogenates 
were diluted (1 in 20) in 0.85% sodium chloride. 250 μl of the brilliant blue dye diluted (1 
in 5) in dH20, was added to U-bottom shape 96 well microplate. Diluted samples (5 μl) in 
duplicate, standard and blank (5 μl of 0.85% sodium chloride) were then added to the dye 
and incubated for 2 minutes. Absorbance values were detected at 595 nm on the FLUOstar 
Optima plate reader; the absorbance is proportional to the protein content in the sample, 
blank readings were subtracted, and results were analysed. 
2.5 Sandwich ELISAs for proteins of interest 
2.5.1 Fibrinogen sandwich ELISA  
Post-mortem human brain homogenates made with SDS buffer as described 
(Section 2.2.3) from AD cases and age-matched controls were tested for fibrinogen using 
a human anti-fibrinogen antibody pair (KSA193Hu01, Cloud-Clone Corp). Following 
manufacturer's instructions and after optimisation of ELISA conditions, 100 μl of capture 
antibody (mouse monoclonal anti-human fibrinogen) was diluted in PBS and pipetted into 
each well, then incubated overnight at 4οC.  
After washing with washing buffer (PBS- 0.05% Tween 20), non-specific sites 
were blocked by 300 μl freshly prepared blocking buffer (PBS with 5% BSA) in each well 
for 2 hours at RT. Aliquots of homogenates (diluted 1 in 100 of reagent diluent) and serial 
dilutions of recombinant human fibrinogen standard (100 μl) in duplicate were incubated 
in each well for 2 hours at RT; blanks contained only PBS.  
Following washing, 100 μl of detection antibody (Biotin-conjugated mouse 
monoclonal anti-fibrinogen antibody) was diluted in reagent diluents and incubated in each 
well for 2 hours at RT. Subsequently, 100 μl of HRP conjugated streptavidin enzyme was 
added and incubated for 20 minutes in the dark. After washing, 100 μl of horseradish 
substrate was added and incubated for 20 minutes in the dark at RT. 50 μl of sulfuric acid 
stop solution was then added into each well. The plate was read in the microplate reader at 
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wavelength 450 nm. Results of this experiment are interpreted, analysed, and discussed in 
detail in Chapter 3. 
2.5.2 GFAP and clusterin sandwich ELISAs 
Post-mortem human brain SDS homogenates from AD cases and age-matched 
controls were tested for GFAP and clusterin using antibody pairs (R&D Systems), 
following manufacturer's instructions, after optimisation of ELISA conditions. 100 μl of 
capture antibody was diluted to the recommended working concentration in PBS and 
pipetted into each well, then incubated overnight at RT. After washing with washing buffer, 
non-specific sites were blocked by 300 µl freshly prepared blocking buffer in each well for 
1-2 hours at RT. 
 Aliquots of homogenates (diluted 1 in 80 for GFAP and 1 in 200 for clusterin in 
reagent diluent) and serial dilutions of recombinant human proteins in duplicate were 
incubated in each well for 2 hours at RT; blanks contained only PBS.  
Following washing, detection antibody 100 µl, diluted in reagent diluents to the 
recommended working concentration, was incubated in each well for two hours at RT, then 
100 µl of HRP conjugated streptavidin enzyme was added and incubated for 20 minutes in 
the dark (R&D systems).  
After washing, 100 µl of horseradish substrate was added and incubated for 20 
minutes in the dark at RT. 50 µl of sulfuric acid stop solution (R&D systems) was added 
into each well before reading the plate absorbance in the microplate reader at wavelength 
450 nm. Results of these experiments are interpreted, analysed, and discussed in detail in 
Chapter 4 and Chapter 6. 
2.5.3 Complement proteins sandwich ELISAs (using in-house antibodies) 
These set of experiments were done under supervision of Professor Paul Morgan 
in the Complement Biology Group at the Institute of Infection and Immunity at Cardiff 
University. In-house antibodies were generated, characterized, validated and tested in 
ELISAs which had been optimised previously on AD patients plasma assays in his 
laboratories and published previously in (394,396,399,538). All complement assays were 
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re-optimized for homogenized brain samples. Serial dilutions of brain homogenates were 
then tested to choose the optimal dilution for each assay, more details about complement 
protein assays are included in Table 4-1. 
Complement protein levels were measured by sandwich ELISAs, developed after 
optimisation using a mixture of in-house and commercial antibodies. 96-well Maxisorp 
plates were coated with 50 μl capture antibody; (as shown in Table 2-5) in carbonate-
bicarbonate buffer (pH 9.4). After washing with washing buffer, non-specific sites were 
blocked by 100 μl freshly prepared blocking buffer in each well for 1-2 hours at room 
temperature. 
Aliquots of homogenates diluted in reagent diluent; (details in Table 4-1) and serial 
dilutions of standard 50 μl in duplicate were incubated in each well; blanks contained only 
the coating buffer. Following washing, 50 μl of detection antibody (as shown in Table 2-5) 
diluted in reagent diluents to optimised working concentration, was incubated in each well 
for one hour.  
Subsequently, specific secondary antibody (anti-mouse or anti-rabbit antibodies) 
was incubated for one hour in a 37oC incubator (as shown in Table 2-6). After washing, 50 
μl of chromogenic substrate orthophenylenediamine (SIGMAFAST™ OPD) was added 
and incubated in the dark at RT until the colour had developed and then stopped by the 
addition of 50 μl of stop solution (10% sulfuric acid) into each well. The plate was then 
read in the microplate reader at 492 nm absorbance. Positive controls (spiked brain samples 
with known amount of purified protein) were included in complement ELISAs to 
standardize assays. 
2.5.4 IL-1β Sandwich ELISA (High sensitivity ELISA kit) 
Post-mortem human brain SDS homogenates from AD cases and age-matched 
controls were tested for IL-1β by Quantikine high sensitivity ELISA kit (HSLB00D, R&D 
Systems). Following manufacturer's instructions, 50 µl of assay diluent was added to each 
well in pre-coated microplates with capture antibody against IL-1β, then aliquots of 
homogenates (100 µl diluted 1 in 8 in calibrator diluent) and serial dilutions of standard in 
duplicate were added and incubated for two hours at RT on a horizontal orbital microplate 
shaker set at 500 ± 50 rpm; blanks contained only calibrator diluent.  
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Following washing, human IL-1β conjugate (200 µl), diluted in reagent diluents 
was incubated in each well for 1 hour at RT on the microplate shaker, then 200 µl of HRP-
conjugated streptavidin enzyme was added and incubated for 30 minutes, covered, on the 
shaker. After washing, 200 µl of horseradish substrate was added and incubated for 30 
minutes in the dark at RT on the benchtop. 50µl of sulfuric acid stop solution was added 
into each well before reading the plate absorbance in the microplate reader at wavelength 
450 nm. Results of this experiment are interpreted, analysed, and discussed in Chapter 7. 
2.5.5 Interpretation of results and statistical analysis 
A standard curve was carried out (non-linear 4-parameter regression or log 
transformed) by plotting absorbance values collected from each assay against the 
concentrations of standards, and the concentrations of unknown samples (after subtracting 
the blank reading) were determined using this standard curve for each assay. Results were 
interpreted and corrected to total protein concentrations measured for all samples. 
Intra- and inter-assay coefficient of variations (CV) were checked for each assay. 
This was carried out using plasma samples from healthy individuals (in complement assays 
only) and brain lysates (in all assays including complement assays) to compare plates and 
ensure the CVs are below 10%. This was done to confirm that the plate-to-plate variation 
is minimal; CV= (standard deviation/ mean) x 100. 
Results were statistically analysed using GraphPad version 6 (PRISM). Data were 
first tested for normality by the Kolmogorov-Smirnov one-sample test. For normally 
distributed data, the unpaired t-test was used and where data were not normally distributed, 
a non-parametric test (Mann-Whitney test) was used for analysis. Linear correlations were 
assessed using Pearson's correlation if normally distributed data or Spearman’s test if not. 
Comparison of groups was tested by one-way analysis of variance (ANOVA) followed by 
post-hoc Tukey’s test if normally distributed data or if not, Kruskal-Wallis test followed 




2.6 Horseradish peroxidase labelling for primary antibodies 
HRP-labelling was carried out using EZ-Link plus activated peroxidase kit, 
according to manufacture instructions. HRP was added to 1 mg/ml of in-house primary 
antibody and incubated for two hours at room temperature (RT), then 10 μl of 
cyanoborohydride was added and incubated for 20 minutes at RT; 20 μl of quenching buffer 
was then added and incubated for 20 minutes at RT. HRP-labelled antibody then was 
aliquoted and stored in -20οC until used. HRP-labelling was done for the detection 
antibodies in some of the in-house complement ELISAs (C3, iC3b, CFH and TCC assays) 
in Chapter 4.  
2.7 SDS-PAGE and western blotting  
Western blotting was used to detect proteins of choice in post-mortem human brain 
tissue. Denatured proteins were first separated by molecular weight for western blotting by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) then transferred 
to nitrocellulose membrane for further detection of specific proteins. Precast 
polyacrylamide Bio-Rad gels (4–20% Mini-PROTEAN®TGX™ Gel) were used. 
2.7.1 Sample preparation for SDS-PAGE and WB 
Selected brain samples (5-25 μg of total protein), some plasma samples (for in-
house antibodies diluted 1 in 100), purified proteins (1-5 μg/ml) and protein ladder 
(PageRuler prestained protein ladder) were prepared in either reduced or non-reduced 
conditions (5% SDS lysis buffer or 5% β-mercaptoethanol in SDS) immediately before 
loading in a fume hood in an assay dependant dilution. Samples were then heated in 95°C 
for five minutes to denature the proteins and loaded in each well (25 μl), the gel was placed 
in tank full of 1X running buffer at 100-120V for 60 minutes, prepared as shown Table 2-2 
and Table 2-3. 
2.7.2 Western blotting 
The transfer of proteins was then carried out from the gel to nitrocellulose 
membrane, using an electrophoretic transfer cell assembled cassette (Mini Trans-Blot), 
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according to the manufacturer’s instructions. This was then placed in the transfer cell tank 
with 1X blotting buffer prepared as shown in Table 2-2 and Table 2-3 with a magnetic stir 
bar, and an ice pack to cool the cassette during protein transfer and placed on a magnetic 
stirrer at 100-120 V for 60 minutes.  
2.7.3 Protein detection  
The nitrocellulose membrane was washed in PBS-Tween 20 on a shaking platform, 
blocking buffer (5% BSA in PBS) was incubated overnight in the cold room (4oC) with 
shaking, the membrane was washed three times (3 x 15 minutes), the primary antibody was 
added in appropriate dilution and the membrane was incubated for an hour with shaking. 
After washing (3 x 15 minutes), the peroxidase labelled secondary antibody was then added 
in appropriate dilution for an hour before development. This was followed by washing (6 
x 15 minutes).  
Chemiluminescence for band detection was then carried out in a dark room. ECL 
western blotting detection reagents; (substrate reagents) were added to the membrane for 
(1 to 5 minutes), which was then exposed to X-ray film (Fujifilm Corporation™). The 
image was then developed in X-Ray developer solution the bands were visible. The film 
was then transferred to X-Ray fixer solution (Champion Imaging); and finally rinsed in 
water and left until dry. Antibody concentrations and concentrations of brain lysate-
purified proteins and sometimes plasma samples used were assay dependant (according to 
the results of optimisation experiments). 
2.8 Quantitative RT-PCR  
Real time polymerase chain reaction (RT-PCR) was done in this study for a number 
of selected genes of interest (C1QA, C3, CFH, CLU, CR1, GFAP, IL-1β, and TNF-α) and 
selected calibrator genes (GAPDH, β-ACT, RPL13, NSE, HPRT1). Results are interpreted, 
analysed, and discussed for complement genes in Chapter 5, GFAP in Chapter 6 and 
cytokine genes in Chapter 7. 
Ribonucleic acid (RNA) was extracted from post-mortem human brain tissue, 
tested for quantity and quality. DNase-I treatment was carried out on RNA samples to 
eliminate genomic DNA (gDNA). Reverse transcription (RT) was performed on RNA 
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samples to obtain complementary deoxyribonucleic acid (cDNA), PCR was then performed 
for cDNA to detect mRNA expression as shown in Figure 2-1). 
 
Figure 2-1: Schematic diagram showing steps done in quantitative RT-PCR experiments. The 
figure shows the main steps used in relative gene quantification including RNA extraction from 
selected brain tissue, reverse transcription of RNA to cDNA and finally the measurement of mRNA 
expression and analysis of relative gene expression of genes of interest calibrated against selected 
calibrator genes. 
2.8.1 Brain tissue homogenization for RNA isolation 
Another tissue homogenisation process was necessary for the RNA isolation. 
Frozen brain tissue (3-5 mm3) from frontal cortex (BA 8/9) and temporal cortex (BA 21/22) 
was used to measure mRNA expression of genes of interest. Tissue was homogenized by 
adding 300 μl of cell disruption buffer into a 2 ml screw cap tube containing brain tissue 
with 5-6 silica beads. Samples were homogenized at 6,000 x g using a (Precellys 24® 
homogenizer) for 2 x 15 seconds, then kept for 5-10 mins on ice and centrifuged for 10 
minutes at 10,000 x g at 4°C to clarify samples.  
74 
 
2.8.2 RNA extraction:  
All tubes, pipette tips and reagents used in RNA extraction were RNase-free and 
the benchtop surface was decontaminated regularly by RNase Zap solution to avoid DNA 
contamination. 
Total RNA was extracted using PARIS kit (Invitrogen), the upper aqueous phase 
was separated from homogenized samples and mixed with 300 μl of lysis buffer and an 
equal volume of ethanol, this was mixed gently by pipetting 3-4 times, then the mixture 
was applied to a filter cartridge assembled in a collection tube and centrifuged for 1 minute 
at 10,000 g at RT. The flow-through was discarded, 700 μl of wash solution 1 was added 
to the filter cartridge, which was centrifuged for 1 minute and the flow-through was 
discarded. All steps were done on ice. The RNA pellet was then washed twice, the 
centrifugation step was repeated and the flow-through was discarded. The filter cartridge 
was then moved to a fresh collection tube, then resuspended in 50 μl of hot (95oC) elution 
solution and re-spun for 30 seconds, RNA samples were transferred to -80οC until used.  
2.8.3 RNA quantification:  
The yield and relative purity of total RNA in samples was assessed in duplicate by 
measuring 260 nm and 280 nm using a spectrophotometer (Nanodrop; ND-1000); the 
samples used in PCR were selected at wavelength 260/280 nm range (1.8 to 2.2).  
2.8.4 RNA quality measurement:  
The Agilent bioanalyzer (2100) was used to determine the quality of RNA 
extracted from the tissue by using an RNA 6000 Nano-kit. The technique is based on 
microcapillary electrophoresis which separates different molecules by their size and 
determines the ratio of the 28S and 18S of RNA fragments and calculates RNA integrity 




Figure 2-2: RNA quality measurement for RNA samples by the Agilent Bioanalyzer.  A) shows 
a gel image of RNA (8 samples with variable RIN quality), B) Bioanalyzer electropherogram of one 
RNA sample shows intact fragments of RNA (18S and 28S ribosomal peaks), and L is ladder. 
This algorithm is designed to provide quantitative information about the general 
state of RNA samples, the score for RNA quality from zero (the most degraded) up to 10 
(the least degraded) RNA (544). As shown in Figure 2-2, the 28S/18S ratio can be detected 
by dividing the area under the peaks and this ratio should be around 2, however, the 
standard of 2 for an rRNA ratio is difficult to obtain in clinical samples especially in post-
mortem tissue. Obtaining high quality RNA extracted from post-mortem human brain 
tissue is challenging; RNA can be easily degraded as it has a free hydroxyl group which is 
prone to hydrolysis. 
2.8.5  DNase-I treatment  
Up to 10 μl of each RNA sample was incubated in incubation buffer containing 
MgCl2, NaCl, CaCl2 and HCL and 2 μl DNase-I (recombinant DNase I, Roche) to 
eliminate any gDNA. The mixture was then incubated at 37°C for 60 minutes followed by 
heat inactivation at 90°C for 5 minutes. The samples were then spun down and transferred 
to -80°C immediately.  
2.8.6 RNA cleaning-up protocol 
RNA samples were added to 1/10 volume of sodium acetate, 2.5 volume of cold 
ethanol (100%) and 1 μl of glycogen for RNA precipitation; these were then incubated for 
30 minutes at -80οC, then thawed and centrifuged for 20 minutes at 10,000 g at 4οC. The 
supernatant was then discarded, and the precipitated RNA washed in cold ethanol (70%) 
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and centrifuged again for 5 minutes. The supernatant was then discarded, and the pellet 
dried for at least two minutes until invisible and was re-suspended in DEPC-treated water. 
This protocol was used to improve total RNA purity (260/280 nm absorbance).  
2.8.7 Reverse transcription (RT) 
Equal amounts of RNA extracted from samples (300 ng) were converted to single 
stranded cDNA by using the High-capacity RNA-to-cDNA kit (Applied Biosystems). The 
RT reaction mixture (20 μl for each reaction) was calculated (as shown in Table 2-11) and 
aliquoted in tubes, then briefly centrifuged to spin down the contents. This was then 
incubated at 37οC for 1 hour in a PCR thermal cycler (Biometra TRIO), followed by heat 
inactivation at 95οC for 5 minutes and then a holding stage at 4οC. The cDNA was then 
stored at -20οC until used; cDNA is more stable chemically than RNA. A ‘no RT’ reaction 
was included in each RT experiment to be tested in PCR runs as a control and to exclude 
the presence of gDNA. 
Table 2-11: Components of reverse transcription reaction. 
Components 
Volume per reaction 
+RT reaction -RT reaction 
2X RT Buffer Mix 10 μl 10 μl 
20X RT Enzyme Mix 1 μl -- 
RNA sample Up to 9 μl Up to 9 μl 
Nuclease-free water Up to 20 μl Up to 20 μl 
Total per reaction 20 μl 20 μl 
2.8.8 Probes used in quantitative PCR 
All probes used in this study were TaqMan assay on demand; which are 
specifically designed with a sequence complementary to an internal region of the gene of 
interest; (specific area of cDNA). Moreover, the selected probes should not be able to detect 
any gDNA, with a short amplicon in size; (less than 200 base pairs). More information 
about probes used is shown in (Table 2-9). 
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2.8.9 Quantitative RT-PCR 
Real time qPCR was carried out using a fast-advanced master mixture (10μl for 
each reaction) containing all components (as shown in Table 2-12), was made on ice and 
pipetted into 384 well plates. Plates were sealed with optical adhesive film and centrifuged 
briefly to eliminate air bubbles.  














5 μl 0.5 μl 3 μl 1.5 μl 10 μl 
NTC 5 μl 0.5 μl 3 μl 1.5 μl water 10 μl 
PCR system used (QuantStudio 12K flex Real- Time PCR, Applied Biosystems), 
in the follow profile: 
1. Hold stage: 50οC for 2 minutes to prevent false positive amplification. 
2. Hold stage 95οC for 2 minutes for polymerase activation. 
3. PCR cycles (40 cycles); denature step 95οC for 1 second and anneal/extend 
step 60οC for 20 seconds in each cycle. 
Cycle threshold (Ct) values were obtained for each gene which represents the RT-
PCR cycle at which the fluorescent signal intensity of the amplified target gene reaches an 
arbitrary threshold (line set within the exponential phase of PCR reaction), and the relative 
change in gene expression was calculated as discussed in Section 2.8.11. 
All reactions were performed in triplicate. Replicates with a standard deviation 
(SD) more than 0.3 were excluded from the analysis. A no-template control sample (NTC) 
was tested in each PCR run for each TaqMan assay to detect PCR contamination and 
exclude primer dimer formation. However, this problem is not common with TaqMan 
assays.  
Pipetting was carried out using an electrical air displacement pipette based on a 
positive-displacement principle for more accurate aspiration and dispensing of the master 
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mixes (Xplorer, Eppendorf). Air bubbles were avoided by not mixing the reagent while 
pipetting and by a short spin of the PCR plates before the run started. 
2.8.10 Selection of calibrator genes for relative gene expression  
One of the most important steps in relative quantification of gene expression is to 
select a stable, highly expressed calibrator gene in the disease process and in the study 
samples, to be used to normalise the results. Since the brain tissue contains a range of cell 
types, it is usually assumed that the suitable calibrator gene would be that with an equal 
expression by all cell types. Putative calibrator genes were therefore tested in this study 
(GAPDH, β-ACT, RPL13 and HPRT1) to be validated and used in relative quantification 
of gene expression. 
2.8.11 RT-PCR analysis 
The 2-ΔΔCT method for relative quantification of gene expression: 
Gene expression in the selected frontal and temporal areas was calculated relative 
to the calibrator genes by 2-ΔΔCT method (545). The 2-ΔΔCT values were calculated in control 
and AD compared to the average control value normalized to the calibrator gene and the 
results were interpreted as the fold change in target gene mRNA levels in AD relative to 
controls; (as shown in the equations below). 
➢ Equation 2-1: ΔCT value 
                 𝚫𝐂𝐭 𝐯𝐚𝐥𝐮𝐞 = Ct (Target gene) − Ct (Calibrator gene).            
➢ Equation 2-2: ΔΔCT value 
𝚫𝚫𝐂𝐭 𝐯𝐚𝐥𝐮𝐞 =  ΔCt Test sample − mean (ΔCt Control samples). 
➢ Equation 2-3: Fold change 
𝐅𝐨𝐥𝐝 𝐜𝐡𝐚𝐧𝐠𝐞 =  (2 − ΔΔCT). 
 The geometric mean for each group was then calculated and used to perform 




2.9 Immunostaining  
2.9.1 Immuno-peroxidase staining (IHC) 
2.9.1.1 Tissue preparation 
Sections 7 μm in thickness were cut from paraffin-embedded blocks of frontal 
cortex and used for immunohistochemical staining. 
2.9.1.2 Immunohistochemical staining of paraffin sections  
Sections were dewaxed in an oven at 60οC for 1 hour, then in immersed in xylene 
(2 x 3 minutes), hydrated in 100% ethanol (2 x 3 minutes), and immersed in quenching 
buffer, then immersed in 3% hydrogen peroxide in methanol (40 minutes) to block 
endogenous peroxidase reactivity. The tissue was washed in running tap water (10 
minutes), then the heat-mediated antigen retrieval pre-treatment was performed if required 
for 10 minutes by immersing sections in citrate acid with EDTA boiled for 2 minutes.  
The sections were then washed again in the running water before being equilibrated 
in PBS. A PAP pen was used to draw a circle around the fixed tissue, then non-specific 
binding was blocked by incubation in the appropriate blocking serum (20% for 1 hour). 
The slides were then drained and incubated in different dilutions of the primary antibody 
overnight at 4οC. 
 Sections were rinsed the next day in PBS (2 x 3 minutes) and incubated with 
appropriate biotinylated secondary antibody (1 hour), followed by a PBS rinse twice and 
then incubated in previously prepared avidin-biotin complex VectaElite (ABC) (20 
minutes). The washing step was repeated then staining was detected by the chromogen 
DAB (1 to 5 minutes), after washing in running tap water for 10 minutes. 
 The sections were then counterstained with hematoxylin for nuclei staining (20 
seconds) and washed again in running water (10 minutes), dehydrated, cleared, and 
mounted in DPX mounting medium, left to dry and imaged. All solution constituents are 
included in Table 2-3, 2-4. 
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2.9.2 Immunofluorescence staining (IF) 
2.9.2.1 Tissue preparation 
Sections 7 μm in thickness were cut from paraffin-embedded blocks; frontal 
regions were used. 
2.9.2.2 Double immunofluorescence staining of paraffin sections  
Sections were dewaxed in an oven at 60οC for 1 hour, then in xylene (2 x 3 
minutes), hydrated in 100% ethanol (2 x 3 minutes), 90% ethanol (2 x 3 minutes) then 70% 
ethanol (2 x 3minutes). The tissue was washed in running tap water (10 minutes).  
Sections were first stained with thioflavin S (ThioS) for (30 minutes) to stain 
amyloid plaques, washed in 70% ethanol (5 minutes), then the heat-mediated antigen 
retrieval pre-treatment was performed if required (20 minutes) by immersing sections in 
citrate acid with EDTA boiled for 2 minutes. Sections were washed in PBS (3 x 5 minutes), 
then a PAP pen was used to draw a circle around the fixed tissue. Non-specific binding was 
then blocked by incubation in the appropriate blocking serum 20% (1 hour); the slides were 
drained and incubated in the primary antibody overnight at different dilutions at 4οC. 
 Sections were rinsed the next day in PBS (2 x 3 minutes) and incubated with 
appropriate secondary antibody (1 hour), followed by rinsing twice in PBS and then 
incubation in Sudan black B stain to eliminate auto-fluorescence. Sections were then 
washed in 70% ethanol and twice in PBS (each 3 x 5 minutes) and mounted in mounting 
medium (FluorSave). These were left to dry, and images were viewed by confocal 
microscope, captured, and merged using ZEN blue software. All solution constituents are 
included in Table 2-3, 2-4. This experiment was done to localize the major complement 
activation products; C3b/iC3b in the amyloid plaques of AD brain sections. Images of this 
experiment are shown in Chapter 4 (Section 4.4.1). 
2.10 Luminex-based cytokines assay (multiplex cytokines detection) 
AD cases and age matched controls homogenized in 1% SDS lysis buffer samples 
were tested for analytes of interest using a pre-mixed standard cocktail. All reagents were 
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prepared according to the manufacturer’s instructions (R&D). 100 µl of homogenates and 
serial dilutions of recombinant human proteins in duplicate were incubated with 25 µl 
diluted microparticle cocktail in each well of the microplate for 3 hours at RT on a shaker 
set at 800 ± 50 rpm; blanks contained only calibrator diluent. Using a hand-holding 
magnetic device separator, designed to accommodate a microplate, plate washing was 
carried out by applying the magnet to the bottom of the microplate, for 1 minute before 
removing the liquid. 100 µl of wash buffer was added and the beads allowed to settle at the 
bottom of the plate for one minute, then this step was repeated for three times. 
 Following washing, 50 µl of biotin antibody cocktail, diluted in reagent diluents, 
was added, and incubated in each well for 1 hour at RT on a shaker set at 800 ± 50 rpm. 
After washing, 50 µl of streptavidin-PE was added and incubated for 30 minutes at RT on 
a shaker as before.  The microplate was securely sealed with a foil cover in all steps of the 
experiment as the microparticles are sensitive to light. After washing, the microparticles 
were resuspended in 100 µl of wash buffer in each well and incubated for 2 minutes at RT 
on the shaker, again set at 800 ± 50 rpm. A reading was taken within 90 minutes using the 
Luminex-200 and detection of the target was set at 50 beads per region.  Calibration and 
validation of the Luminex machine was carried out every time prior to running of the assay. 
The data were analysed as the median fluorescence intensity (MFI).  
Interleukins (IL-1β, IL-6) and tumour necrosis factor alpha (TNF-α) were 
measured by the human multiplex cytokine kit, using magnetic microparticles and were 
detected by luminex-200. After many trials and optimisation, no results were obtained from 
this experiment, kit was not sensitive enough to detect cytokines level in different 
concentration of SDS brain lysate. The only cytokine measured in the cohort was IL-1β by 
the high sensitivity quantikine ELISA kit, as discussed in detail in Chapter 7.
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3. Chapter 3: Cohort Analysis & Investigations 
of Neuropathological Changes of Alzheimer’s 
Disease. 
3.1 Introduction 
AD is the commonest type of dementia (1) characterized by two main pathological 
changes, the Aβ accumulation and tau pathology. It is also known that these changes occur 
many years before clinically apparent symptoms of the disease and memory loss (46,47), 
as previously described in detail in Section 1.1.3. Those abnormally accumulated misfolded 
proteins in the brain stimulate different parts of the immune response to clear them 
(475,546). Therefore, studying these pathological changes in relation to neuroinflammation 
is an important step in understanding the immune response in AD. 
The BBB is formed by endothelial cells, pericytes and astrocytic end feet also 
called NVU as mentioned previously in Section 1.1.3.6 (124). It acts as a dynamic, 
physiological, and pathological barrier to isolate and protect the brain from the harmful 
substances such as plasma proteins, and to maintain CNS homeostasis; therefore, disruption 
of the BBB leads to neuropathological changes.  
Increased BBB permeability can occur to various degrees in different 
neuropathological diseases, such as AD (547). This impairment can occur gradually and be 
limited to the areas of the pathology (151,154,155). Moreover, the role of disrupted BBB 
in AD pathology is controversial (156–158), and the timing of its disruption remains 
elusive, however, some evidence shows that BBB disruption was found to occur early, even 
before the plaque formation in a transgenic mouse model of AD (Tg2576 mice) (144). 
The leakage of plasma proteins into the CNS stimulates the inflammatory response 
in the brain parenchyma; albumin, fibrinogen as well as fibrin are deposited in the brain 
from the peripheral blood when the BBB is disrupted in certain neurological diseases such 
as multiple sclerosis (MS) (159), and AD (145). As an indicator of BBB integrity, CSF 
albumin index was found to be correlated with CSF/plasma ratio indicating greater access 
of peripheral proteins to the CNS in AD patients, and that was also correlated with the 
disease progression measured by MMSE (145). However, it is not exactly known how these 
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proteins affect the neuronal degeneration in the brain. This may occur due a chronic 
inflammatory response from their deposition or via oxidative stress which cause neuronal 
damage leading to progressive neurodegeneration (127,143). 
Fibrinogen is a protein involved in the coagulation process, in the brain it is 
transformed and accumulated as its insoluble form (fibrin) (548), both can bind to Aβ (549). 
Fibrin deposition has been shown to enhance neuroinflammation in a mouse model of AD 
and deposition increased with age and correlated positively with Aβ load (142).  
In human brain, fibrinogen has been used as reliable marker of BBB disruption 
(160). Fibrinogen activates microglia (159,550) binds to amyloid beta (551), contributes to 
astrocyte scar formation (552), as well as having a role in cross-talk between neurons and 
glial cells; however this is poorly understood. In CNS, the inflammatory role of fibrinogen 
is thought to be mediated via the complement receptor (CR3 or CD11b/CD18) expressed 
on microglia (550). 
Further studies are required to address the role of fibrinogen in neuroinflammatory 
response in the brain and it is important to study this protein as an active player in the 
disease rather than a marker of BBB disruption. Anti-coagulants and fibrinogen inhibitors 
are considered as putative therapeutic targets for AD, however, it might also be useful to 
study the communication between the brain, immune system and the vasculature as a target 
for therapeutic intervention in AD (160).  
3.2 Study aim  
The aim of the experiments described in this chapter was to: 
• Analyse the cohort selected for protein study. 
• Measure the total protein concentration in all homogenised brain samples of the 
cohort.  
• Measure fibrinogen levels in SDS homogenized brain tissue (frontal and temporal 
cortices) by quantitative analysis using sandwich ELISA in AD and age-matched 
controls.  
• Correlate the fibrinogen levels with AD pathological changes (Aβ load and Braak 
staging; previously measured by colleagues as a part of separate studies). Further 
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to this, to assess the relationship of fibrinogen levels with potential factors and 
cohort variables such as age, gender, post-mortem interval (PMI) and APOE 
genotypes.  
• Assess BBB disruption in these cases, and to elucidate whether the changes seen 
in the inflammatory markers measured in this cohort originated from the brain itself 
or was due to increased permeability from the peripheral blood. 
3.3 Methods  
3.3.1 Cohort description 
This cohort includes clinically and pathologically validated AD cases with LOAD 
diagnosis (33 cases) and age matched controls (31 subjects), more details about the cohort 
in Section 2.2.2 and Table 3-1. Frontal and temporal brain tissue homogenates were used, 
as described in Section 2.2.3 in the general methodology (Chapter 2). 
Table 3-1: Cohort data, comparison of control and AD groups, number, age at death, sex, post-
mortem interval (PMI), Braak staging, APOE genotyping. 
 Control group AD group 
Number  31  33  
M/F  19/12  10/23  
Age at death 
Range: (43-95 years)  
Mean: 78.2 years  
SD: 11.0 
Range: (67-96 years) 
Mean: 81.6 years 
SD: 6.3 
PMI  
Range: (3-106 hours)  
Mean: 43.1 hours  
SD: 29.2 
Range: (5-99 hours)  
Mean: 49.8 hours  
SD: 28.2  
Braak Staging  
(stage 0) = 4 controls  (stage III) = 2 AD  
(stage I) = 6 controls  (stage IV) = 3 AD  
(stage II) = 20 controls  (stage V) = 13 AD  
Unknown = 1 control  (stage VI) = 15 AD  
APOE genotypes  
ε (2.3) = 4 controls  
ε (3.3) = 22 controls  
ε (2/3) = 2 AD  
ε (3/3) = 7 AD  
ε (3/4) = 3 controls  ε (2/4) = 1 AD  
ε (4/4) = 1 control  ε (3/4) = 17 AD  
Unknown = 1 control ε (4/4) = 6 AD  
85 
 
3.3.2 Total protein measurements of the cohort 
Total protein concentration in post-mortem human brain homogenates from the 
frontal (BA 8/9) and temporal cortices (B/A 21/22) was measured using Total Protein kits 
(Sigma-Aldrich) in duplicate, following the manufacturer’s guidelines as described in 
Section 2.4. This was necessary to allow adjustments made on protein measurements in 
each sample.  
3.3.3 Immunohistochemical staining method of amyloid beta 
Sections 7 μm in thickness were cut from paraffin-embedded blocks from the 
frontal cortex (female patient diagnosed with AD, aged 73 years at death and Braak stage 
V), and stained with (3μg/ml) mouse monoclonal antibody (6E10) against β-amyloid 
(BioLegend) at 4οC overnight, and goat anti-mouse antibody with dilution 1 in 1000 (R&D 
systems), was used as a secondary antibody for 1 hour at RT. Sections were pre-treated 
with citric acid buffer for antigen retrieval and stained by using the protocol outlined in 
Section 2.9.1 .  
3.3.4 Fibrinogen ELISA method 
Fibrinogen protein level was measured in SDS homogenates from the frontal and 
temporal cortices, by sandwich ELISA using a protocol detailed in Section 2.5.1 using a 
fibrinogen antibody pair kit (Cloud-Clone Corp). Following manufacturer's instructions, 
brain homogenates were diluted 1 in 100 and tested in duplicate. Results were calculated 
from a seven-point standard curve and then adjusted to total protein concentration in the 
homogenate. 
3.3.5 Statistical analysis  
Results were first tested for normality by the Kolmogorov-Smirnov one-sample 
test.  For normally distributed data, the unpaired t-test was used and where data were not 
normally distributed, a non-parametric test (Mann-Whitney test) was used for analysis. 
Linear correlations were assessed by using Pearson's correlation if normally distributed 
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data or Spearman’s test if not. Comparison of groups was tested by ANOVA followed by 
Tukey’s post-hoc test if normally distributed data, or if not, Kruskal-Wallis test followed 
by post-hoc Dunn’s multiple comparison test. Results were analysed statistically using 
Prism GraphPad version 6. Statistical significance was defined as p < 0.05. 
3.4 Results  
3.4.1 Primary analysis of the cohort  
The age of the control group ranged from 43 to 95 years (mean 78.2, SD 11.0), and 
the AD group ranged from 67 to 96 years (mean 81.6, SD 6.3). There was no significant 
difference in age between control and AD groups (P value = 0.23), as assessed by unpaired 
t-test and shown in Figure 3-1 (A). 
The PMI of the control group ranged from 3 to 106 hours (mean 43.1, SD 29.2), 
and the AD group ranged from 5 to 99 hours (mean 49.8, SD 28.2). There was no significant 
difference in PMI between control and AD groups (P value = 0.34), as assessed by unpaired 
t-test and shown in Figure 3-1 (B). 
 
Figure 3-1: Comparison of age at death (years) and PMI (hours) in control and AD groups of 
the cohort. A) Age analysis: no significant difference was seen between the groups (P value = 
0.23). B) PMI analysis: no significant difference was seen between the groups (P value = 0.34). 
The mean and SD are displayed. 
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3.4.2 Measurements of protein levels  
3.4.2.1 Total protein measurement of the cohort 
There was no significant difference in total protein concentration between either 
the frontal cortex control (mean 4.9, SD 0.68) and AD group (mean 4.89, SD 0.73) (P value 
= 0.95), or in the temporal cortex, between the control (mean 4.6, SD 0.87) and AD group 
(mean 4.7, SD 0.92) (P value = 0.77), by Mann-Whitney test.  
No significant difference was seen between frontal and temporal cortices in the 
control group (P value = 0.11), by Mann-Whitney test, or in the AD group (P value = 0.31), 
by unpaired t-test. All protein measurements given in the experiments of the following 
chapters are adjusted for total protein to account for any variations in sample concentration. 
 
Figure 3-2: Total protein concentration (mg/ml) in brain homogenates. A) Frontal cortex: no 
significant difference was seen between the groups (P value = 0.95). B) Temporal cortex: no 
significant difference was seen between the groups (P value = 0.77). 
3.4.2.2 Amyloid beta deposition in AD brain by IHC  
Frontal cortex brain tissue sections were stained with 6E10 mouse monoclonal 
antibody against human β-amyloid (1-16 amino acids residue) and scattered extracellular 
beta amyloid plaque deposition was seen in AD sections, in comparison to the negative 






Figure 3-3: Representative image of beta amyloid IHC staining with anti β-amyloid (1-16) 
mouse monoclonal antibody (6E10). Frontal sections: A, B, C) Brain tissue of a definite AD 
female patient aged 73 years at death, Braak stage V: showing scattered amyloid plaques 
stained by 6E10. D) Negative control section: only secondary antibody was used. Scale bar = 
50μm. 
3.4.2.3 Fibrinogen protein levels in AD brain tissue  
3.4.2.3.1  Comparison of fibrinogen levels between AD cases and 
controls  
Fibrinogen protein was measured in frontal and temporal cortices by sandwich 
ELISA and results were adjusted to total protein concentration for each case. The data were 
tested for normality and were not normally distributed, therefore a non-parametric 
statistical test was used (Mann-Whitney test) for analysis.  
There was no significant increase in fibrinogen concentration (ng/mg total protein) 
between controls (mean ± standard error of the mean (SEM) = 319 ± 38.6) and AD (mean 
± SEM = 284.7 ± 40.6) in the frontal cortex (P value = 0.42), or in the temporal cortex in 
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control tissue (mean ± SEM = 281 ± 46.83) compared to AD (mean ± SEM = 386.3 ± 46.8) 
and (P value = 0.13), as shown in  
Figure 3-4. No significant differences were seen between frontal and temporal 
cortex in the control or AD groups (P value = 0.38 & 0.15 respectively) in fibrinogen 
concentration, as assessed by Mann-Whitney test. 
 
 
Figure 3-4: Fibrinogen protein levels in human brain tissue (ng/mg total protein). A) Frontal 
cortex: no significant difference was seen (P value = 0.42), B) Temporal cortex: no significant 
difference was seen (P values = 0.13) between control and AD groups by Mann-Whitney test. 
3.4.2.3.2 Relationship between fibrinogen levels, age at death and 
gender  
There are some potential factors that might affect fibrinogen protein levels. These 
include age at death and gender. Age at death did not correlate significantly with fibrinogen 
concentrations when groups analyzed by Pearson’s correlation test separately or for the full 
cohort: i.e. (P value = 0.24, Pearson’s r = 0.16) in the frontal homogenates, and in the 
temporal homogenates by Spearman’s correlation test (P value = 0.66, Spearman’s r = 
0.06), as shown in Figure 3-5. Summary statistics for these data are also presented in the 





Figure 3-5: Correlation plots of fibrinogen concentration (ng/mg total protein) with age (years) 
in A) Frontal cortex: no significant correlation was seen (P value = 0.24, Pearson’s r = 0.16). 
B) Temporal cortex: no significant correlation was seen (P value = 0.66, Spearman’s r = 0.06). The 
continuous line represents the best fit of the linear regression and the dashed lines represent 95% 
confidence interval (CI) of the regression line. 
Fibrinogen concentrations were compared in control group males (n= 19) and 
females (n= 12) and AD group males (n= 10) and females (n= 23). No significant 
differences between the groups were seen in the frontal cortex when analyzed by one-way 
ANOVA test (P value = 0.77), or in the temporal cortex, when analyzed by one-way 
ANOVA (P value = 0.36). Similarly, post-hoc Tukey’s test for multiple comparison 
showed no significant difference in fibrinogen levels in any of the groups (Figure 3-6). 
 
Figure 3-6: Concentration of fibrinogen in males versus females (ng/mg total protein). 
A) frontal cortex: no significant differences were seen between groups (P value = 0.77). 
B) Temporal cortex: no significant differences were seen between groups (P value = 0.36). 
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3.4.2.3.3 Relationship between fibrinogen levels and PMI  
In the frontal cortex, no significant correlation was seen in the control or AD 
groups (P value = 0.23 & 0.057 respectively), Pearson’s r = (0.23 & 0.36) with PMI 
respectively, or for the full cohort (P value = 0.08, Pearson’s r = 0.23), as assessed by 
Pearson’s correlation test and shown in Figure 3-7 (A). 
In the temporal cortex, similarly, no significant correlation was seen in the control 
or AD group (P value = 0.11 & 0.79), Spearman’s r = (0.31 & 0.05) with PMI respectively, 
or when control and AD groups were combined (P value = 0.19, Spearman’s r = 0.18), as 
assessed by Spearman’s correlation test and shown in Figure 3-7 (B). 
 
Figure 3-7: Correlation plots of fibrinogen concentration (ng/mg total protein) with PMI 
(hours). A) Frontal cortex: no significant correlation with PMI (P value = 0.08, Pearson’s r = 0.23). 
B) Temporal cortex: no significant correlation with PMI (P value = 0.19, Spearman’s r = 0.18). 
The continuous line represents the best fit of the linear regression and the dashed lines represent 
95% confidence interval (CI) of the regression line. 
3.4.2.3.4 Relationship between fibrinogen levels and AD pathology  
Aβ load 
Parenchymal Aβ load was available from the MRC and SWDBB database for 32 
of the 33 cases in the AD group. Correlation of fibrinogen concentration with Aβ load in 
AD was explored. No significant correlation was seen in the frontal cortex (P value = 0.97, 
Pearson’s r = 0.005), or in the temporal cortex (P value = 0.83, Pearson’s r = 0.04) with Aβ 




Figure 3-8: Correlation between fibrinogen concentration and Aβ load in AD group in 
A) Frontal cortex: no significant correlation seen (P value = 0.97, Pearson’s r = 0.005) 
B) Temporal cortex: no significant correlation seen (P value = 0.83, Pearson’s r = 0.04). The 
continuous line represents the best fit of the linear regression and the dashed lines represent 95% 
confidence interval (CI) of the regression line. 
Braak tangle staging 
Comparison of fibrinogen concentration across the three groups of Braak stages 
(0-II = 31 controls, III-IV = 5 AD, V-VI = 28 AD) was performed. In the frontal cortex, no 
significant difference was seen between groups (P value = 0.39), as assessed by one-way 
ANOVA test followed by Tukey’s post-hoc test, or in the temporal cortex (P value = 0.24), 
as shown in Figure 3-9. 
 
Figure 3-9: Fibrinogen concentration in different Braak stages. A) Frontal cortex: no 
significant difference was seen between groups, one-way ANOVA test (P value = 0.39). 
B) Temporal cortex: no significant difference was seen between the groups, Kruskal-Wallis test (P 
value = 0.24). 
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3.4.2.3.5 Relationship between fibrinogen levels and APOE genotype  
Fibrinogen concentration was compared in the full cohort grouped according to the 
number of APOE ε4 allele (35 negative, 21 heterozygous and 7 homozygous; information 
taken from MRC brain bank database for SWDBB), analyzed by using Kruskal-Wallis test. 
There was no significant difference in fibrinogen concentration between the groups in the 
frontal or temporal cortex (P value = 0.057 & 0.13), respectively. A difference was seen in 
the frontal cortex but did not reach statistical significance, as shown in Figure 3-10 (A). 
AD groups with ε4 and without ε4 were analyzed and no significant differences were seen 
between the groups in the frontal and temporal cortex (P value = 0.61 & 0.62), respectively. 
 
Figure 3-10: Concentration of fibrinogen (ng/mg total protein) in controls and AD with or 
without an APOE 4 allele. A) Frontal cortex: no significant difference was seen between the 
groups (P value = 0.057). B) Temporal cortex: no significant difference was seen between the 
groups (P value = 0.13). 
3.5 Discussion 
Here, fibrinogen levels were measured to assess possible BBB leakage in post-
mortem human brain tissue from AD and aged-matched controls. There were no differences 
seen in fibrinogen levels in frontal or temporal homogenates between AD (n = 33) and age-
matched controls (n = 31). In another unpublished study (Dr. Hannah Tayler-Personal 
communication) from the Dementia Research Group, a significant increase was seen in 
fibrinogen concentration in the frontal cortex in the AD group (n = 94) compared to age-
matched controls (n = 57). Statistical significance of the difference might be explained by 
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the bigger cohort size or due to the presence of mixed vascular pathology in cases, however, 
in this study all cases were pure AD and mixed pathology was excluded from the cohort.  
Interestingly, other studies have shown that in CSF, the fibrinogen precursor 
protein gamma-A chain was increased in AD and MCI compared to controls and was 
increased with the disease severity (553). Increased plasma fibrinogen level has been 
reported to be positively correlated with cognitive decline and increased risk of AD 
(554,555).  
In these analyses of other potential factors that might confound the results, I found 
no effect of age at death, gender, or PMI on fibrinogen levels in the brain area examined, 
however, it must be acknowledged this is a small cohort of limited age range. In another 
study of a cohort of n = 23, which encompassed a range of age groups from 20 to 79 years, 
after removal of the youngest group (anomalous due to cause of death), the fibrinogen load 
showed a significant positive relationship with age in both the grey and white matter (556). 
Further to this, fibrinogen deposition increased with age in mouse models of AD (142). In 
another study of BBB permeability using contrast-enhanced MRI in different brain areas, 
in non-cognitively impaired adults, an age dependant increase in BBB permeability was 
evident only in the hippocampus and the caudate nucleus (143).   
Accumulating evidence links fibrinogen and Aβ deposition in AD mice, suggesting 
a possible interaction that accelerates the amyloid pathology (549). A positive correlation 
of fibrin levels with both Aβ1-40 and Aβ1-42 load in isolated hippocampal and cortical 
homogenates and its deposition was increased by age and contributed to the pathology, that 
further supported the proposed role of fibrin and fibrinolysis in the progression of amyloid-
β pathology (142). However, no correlation was seen in post-mortem homogenates in 
fibrinogen concentration with Aβ load in the frontal or the temporal cortex. Moreover, no 
significant difference was seen when the cohort is grouped by different Braak stages. 
Fibrinogen concentration in the frontal cortex appeared to be higher in the 
homozygous APOE ε4 group compared to the heterozygous and to the group that had no 
ε4 allele. However, that increase did not reach the statistical significance (P value = 0.057). 
Previous studies have highlighted the role of the APOE ε4 allele in increasing fibrinogen 
deposition. Fibrinogen deposition assessed by IHC was increased in AD tissue compared 
to controls in a much larger study of 15 brain areas in 58 brains. The authors reported a 
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significant increase in  those individuals homozygous for APOE ε4 (133). The data 
indicated that in ε4/ε4 individuals there was increased fibrinogen in blood vessels with 
oligomeric Aβ present.  It is possible that the current cohort was too small to detect this 
association as might be suggested by the P value of 0.057, which is just over the cut-off for 
significance. Another possible cause as mentioned above is that all cases were pure AD 
unlike that study which included CAA with AD. More investigation of the relationship 
between fibrinogen and APOE would therefore be warranted, whilst studying the 
mechanism by which different APOE isoforms might contribute to different levels of 
fibrinogen will provide further understanding of AD pathogenesis. 
Miners et al. found a significant increase in fibrinogen level in the parietal white 
matter (precuneus) in post-mortem AD tissue (n = 49) compared to controls (n = 37) (557). 
Interestingly, in a recent study of the relationship between extravascular fibrinogen and 
pathology in white matter, fibrinogen levels were also found to be no different between 
normal and AD brain and no association was found with fibrinogen and Aβ or 
hyperphosphorylated tau levels (558). There was, however, an association between 
increased fibrinogen with severity of small vessel disease, suggesting a link between BBB 
disruption and fibrinogen load, but not in AD. It was concluded that fibrinogen was a 
marker of small vessel disease not AD (558), which the absence of differences found in the 
present study is consistent with. 
Finally, microhaemorrhage is common with AD (559). In this cohort, there was 
one control subject and two AD cases which had reported causes of death related to 
cerebrovascular accidents such as cerebellar and brain stem haemorrhage and cerebral 
infarctions. Although this is a small number of cases, fibrinogen concentration was not 
elevated in those brain samples. One avoidable consideration in the type of experiments 
described here is the possible contamination of the brain samples with blood during the 
brain removal or during dissection of the tissue. As many precautions as were possible were 
taken to avoid this. It worth noting that it may not be ideal to consider fibrinogen as a single 
marker of BBB disruption, insoluble fibrinogen-human serum albumin deposition in 
human brain may be a better approach to diagnose BBB disruption (560). Furthermore, to 
ensure that alteration in fibrinogen in the brain is originated from brain not from differences 
in blood content, fibrinogen can be adjusted to haemoglobin content and micro-vessels 
content  (557). 
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3.6 Summary and conclusions 
➢ There was no significant differences in total protein concentration between the 
control and AD group in the frontal or the temporal cortex. 
➢ Fibrinogen protein was not changed in AD tissue in either the frontal or temporal 
cortices compared to age matched controls. 
➢ Fibrinogen protein showed no significant difference between the frontal and the 
temporal cortex in both control and AD groups. 
➢ Fibrinogen protein level was not affected by age or delayed PMI in brain tissue. 
➢ Fibrinogen protein level was not correlated with Aβ load or with NFT (Braak 
stages) in the frontal or the temporal cortex. 
➢ APOE ε4 status did not show significant difference in the frontal or the temporal 
cortex although there was an increase which did not reach statistical significance 




4. Chapter 4: Complement Proteins in 
Alzheimer’s Disease. 
4.1 Introduction 
The complement system is considered an important part of the innate immune 
response in the human body. It is comprised of more than 30 proteins, enzymes, receptors, 
and regulators which act in a cascade-like manner to activate one of several different 
complement system pathways: the classical pathway, the alternative pathway, and the lectin 
pathway, see Section 1.3.2. 
Activation of any of these complement pathways will lead to an inflammatory 
response by release of anaphylatoxins and chemokines, apoptosis, and complement 
mediated cell lysis. Two decades ago, evidence was accumulating to address the role of 
complement proteins in AD; immunohistochemical staining showed complement proteins 
on amyloid plaques (223), neurofibrillary tangles (97) and dystrophic neurites in AD brain 
(224). Since then, it has been hypothesized that activation of the complement system may 
contribute to AD pathology, but the extent of this contribution in disease development 
and/or progression in the brain is still unclear. 
Proteins involved in the complement system are expressed in the brain by both 
glial cells and neurons (350). Most of the data from complement studies in AD were 
obtained from transgenic mice and in vitro studies. The components of the classical and the 
alternative pathways has been reported in Alzheimer’s disease (423). 
Complement is activated via the classical pathway in amyloid plaques leading to 
opsonization through C3b or by driving an inflammatory response in the glial cells via C3a 
and C5a. Moreover, its activation on microglia leads to cytokine expression (375) and 
subsequent release of neurotoxic substances such as free oxygen radicals. Furthermore, 
complement activation  mediates the cross talk between astrocytes and microglial cells in 
the AD brain (376). Additionally, similar to Aβ, the presence of tau pathology in AD has 





 The role of complement in AD pathogenesis and progression is complex and needs 
more investigation. It needs to be determined whether complement activation is a cause of 
the disease progression, as has been suggested from interpretations of GWAS data whereby 
genes involved in innate immunity are associated with increased risk for AD, including the 
polymorphism of complement receptor 1 (CR1) and (CLU) genes.  
Various longitudinal studies have explored complement biomarkers in plasma for 
AD. Recently, the likelihood of there being both peripheral and central elements to the 
involvement of complement in AD was evident from data where low levels of C3 in plasma 
was associated with increased AD risk in a large prospective cohort preceding the diagnosis 
of AD (388). CFH was reported as a biomarker for AD, which is increased in blood, and 
correlates with disease severity (397,561). Increased plasma CFH was also considered as a 
biomarker for predicting early AD pathology (397). In another proteomic study, C3 and 
CFI levels increased with the whole brain atrophy detected by neuro-imaging (398).  
Other studies have shown that plasma clusterin level is highly significantly 
correlated with Aβ load and predictive for cognitive decline in AD (562). A recent study 
suggested that plasma clusterin levels are elevated late in the progression of the disease and 
do not precede it, and that higher clusterin levels in plasma were associated with higher AD 
risk only in older participants of their study (395). Moreover, clusterin plasma level was 
correlated with the polygenic risk score of AD as well as the inflammatory specific AD 
polygenic risk score (396). 
Different complement proteins were studied in CSF from AD patients (402). 
However, little is known about complement proteins expression in post-mortem brain 
tissue, and what limited work that has been done to date relates to C1q and Cd4 having 
been seen in amyloid plaques in superior frontal AD brain area (223), while TCC 
colocalized with dystrophic neurites in the hippocampus (563). 
Many animal models have been generated to mimic some aspects of the 
neuropathological changes of AD. However, none have successfully reproduced the full 
and broad complexity and variability of those seen in human brain tissue which are thought 
to arise from a combination of genetic and environmental factors. Thus, further assessment 
of complement proteins and their regulators in post-mortem brains is an important and as 
yet unmet research need for understanding their role in the innate immune response in 




4.2 Study aim 
The aim of the experiments described in this chapter was to measure the levels of 
a selected set of complement system proteins in post-mortem SDS homogenized tissue 
from AD brains and controls from the frontal and temporal cortices. The complement 
protein levels measured were: (C1q, C3), complement regulators (CFH, clusterin), early 
activation marker (iC3b) and terminal complement component (TCC) levels. The aim was 
to explore how these markers correlated with AD pathological changes (Aβ load and Braak 
tangle staging previously measured by colleagues as a part of separate studies). Further to 
this, the relationship with potential factors and cohort variables such as (age, gender, PMI 
and APOE genotypes) was also explored. Another aim of the present study was to see 
possible co-localization of the complement activation products; C3b/iC3b with the amyloid 
plaques of AD brain using double immunofluorescence. 
4.3 Methods 
4.3.1 Study cohort 
The details of the cohort used to measure complement proteins by ELISA is similar 
to that in the previous chapter and described in (Table 3-1). Homogenized brain samples, 
prepared as previously described in Section 2.2.3, were made from BA 8/9 frontal cortex 
and BA 21/22 temporal cortex from clinically and pathologically validated AD cases with 
LOAD diagnosis (33 cases) and age matched controls (31 subjects). The full cohort was 
used in all ELISAs except in C3 assay (only 16 controls and 16 AD were measured) and 
that was due to reagent availability. 
The brain homogenates used were age-matched, the control group (mean ± SD = 
78.2 ± 1.98) and AD group (mean ± SEM =81.6 ± 1.10) and similarly matched for PMI: 
the control group PMI (mean ± SEM = 43.1 ± 5.25) and AD group PMI (mean ± SEM = 




4.3.2 Complement proteins measurement by sandwich ELISA 
Complement protein levels were measured in brain homogenates by sandwich 
ELISA using a protocol detailed in Section 2.5.2 and 2.5.3, using commercial or in-house 
antibodies as listed in (Table 2-5 and 2-6). Samples were tested in duplicate and results 
were calculated from a seven-point standard curve, then adjusted according to total protein 
measurement in the homogenates. Intra- and inter-assay CV values were checked for each 
assay to make certain that variation was less than 10% by selected brain lysate. That 
ensured a minimal plate-to-plate variation. Assays were developed previously on plasma 
samples in Complement Biology Group (Cardiff University), then optimised for brain 
samples. Serial dilutions of brain homogenates were then tested to choose the optimal 
dilution for each assay. 
Results were first tested for normality by the Kolmogorov-Smirnov one-sample 
test. For normally distributed data, the unpaired t-test was used and if not, the non-
parametric test (Mann-Whitney test) was used for analysis. Results were analysed 
statistically using Prism GraphPad version 6; linear correlations were assessed by using 
Pearson's correlation if normally distributed data or Spearman’s test if not. Comparison of 
groups was tested by one-way analysis of variance (ANOVA) followed by Tukey’s post -
hoc test if normally distributed data or if not, Kruskal-Wallis test followed by post hoc- 




Table 4-1: Complement proteins ELISA conditions used in post-mortem human brain tissue. This table shows details of ELISA steps for complement 
protein assays. It shows the type and concentration of (capture and detection antibodies, blocking solution, standards, and brain lysates). In-house complement 
assays were developed tested and optimized in Complement Biology Group (538,540). 
Protein Standard Capture antibody Blocking Brain lysates Detection antibody 
C1q 
In-house human 
purified C1q protein, 
(62.5 ng/ml) then 1 in 2 
serial dilutions. 
Mouse monoclonal 
antibody against human 
C1q (Hycult biotech), (2 
µg/ml), one hour at 37°C 
incubator. 
2% BSA, 
one hour at 
RT 
40-fold dilution in 
1% BSA in PBS, 1.5 
hours at 37°C 
incubator. 
In-house rabbit polyclonal antibody against 
human C1q, (1µg/ml), one hour at 37°C 
incubator, followed by peroxidase conjugated 
goat anti-rabbit antibody, 1:2000 dilution for one 
hour at 37°C incubator. 
C3 
Purified human C3 
protein (CompTech), (1 
µg/ml) then 1 in 2 serial 
dilutions. 
In-house protein G 
purified, polyclonal 
antibody against human 
C3 (5 µg/ml), overnight 
at 4°C. 
2% BSA, 
one hour at 
RT 
40-fold dilution in 
1% BSA in PBS, 1.5 
hours at 37°C 
incubator. 
In-house mouse monoclonal antibody, PC3-HRP 
(labelled in-house) against human C3, 1:500 
dilution for one hour at 37°C incubator. 
CFH 
In-house human 
purified FH protein, 
(500 ng/ml) then 1 in 2 
serial dilutions. 
In-house OX24 mouse 
monoclonal antibody. 
against human CFH (5 
µg/ml), overnight at 4°C. 
2% BSA, 
one hour at 
RT 
20- fold dilution in 
1% BSA in PBS, 1.5 
hours at 37°C 
incubator. 
In-house mouse monoclonal antibody, 35H9-
HRP (labelled in-house) against human CFH, 
1:1000 dilution for one hour at 37°C incubator. 
iC3b 
Purified human iC3b 
protein (CompTech), (5 
µg/ml) then 1 in 2 
Serial dilutions.  
In-house rat monoclonal 
antibody, Clone: 9 
against human iC3b, (5 
µg/ml), one hour at 37°C 
incubator. 
5% BSA, 
one hour at 
RT 
10-fold dilution in 
2% BSA in PBS, 1.5 
hours at 37°C 
incubator. 
Mouse monoclonal antibody, bH6-HRP (labelled 
in-house) against activated human C3 (Hycult 




clusterin protein (R&D 
systems), (50 ng/ml) 
then 1 in 2 Serial 
dilutions. 
Mouse anti human 
clusterin antibody (R&D 
systems) (2 µg/ml), 
overnight at RT. 
2% BSA, 
one hour at 
RT 
200-fold dilution in 
1% BSA in PBS, 2 
hours at RT. 
Biotinylated mouse anti human clusterin antibody 
(R&D systems) (1µg/ml), two hours at RT. HRP 
conjugated streptavidin (1 in 200) for 20 minutes 
at RT in dark. 
TCC 
In-house TCC protein, 




antibody against human 
TCC (aE11 Hycult 
biotech) (5 µg/ml), 
overnight at 4°C. 
3% BSA, 
one hour at 
RT 
10-fold dilution in 
2% BSA in PBS1.5 
hours at 37°C 
incubator. 
In-house, mouse antibody against C8, E2-HRP 





4.3.3 Double Immunofluorescent staining method for complement and 
amyloid plaques in AD brain 
The protocol used in double immunofluorescent staining is outlined in Section 
2.9.2.2 in the general methodology. Sections 7 μm in thickness were cut from paraffin-
embedded blocks from the frontal cortex from control and AD sections. Sections used to 
co-localize the complement activation products; C3b/iC3b in the amyloid plaques of AD 
brain.  
This was done by immersing all brain sections in a fluorescent dye (ThioS) for 
detecting the amyloid plaques for 30 minutes, then the heat-mediated antigen retrieval pre-
treatment was performed (20 minutes) in citrate acid with EDTA. Sections were then 
stained with (3μg/ml) C3/30 antibody; a specific mouse monoclonal antibody against 
C3b/iC3b (in-house, CBG- Cardiff) at 4οC overnight, and a goat anti-mouse antibody with 
dilution 1 in 1000 (Jackson- ImmunoResearch), was used as a secondary antibody for 1 
hour at RT. Sudan black B stain was applied to the sections to eliminate auto-fluorescence. 
4.4 Results 
4.4.1 Complement co-localization with amyloid plaques in AD brain 
Double immunofluorescent staining for control and AD frontal brain sections 
showed co-localization of C3b/iC3b; activation products of the complement protein C3 
stained with C3/30 monoclonal antibody (red) within the amyloid plaques stained with 
ThioS (green) in AD sections, as shown in Figure 4-1 (C and D), compared to control brain 
section; where no amyloid plaques was seen in Figure 4-1 (A). AD brain section with no 
C3/30 antibody (negative control), showed only the amyloid plaques (green) but not 





Figure 4-1: Representative double immunofluorescent staining of C3b/iC3b complement 
proteins within amyloid plaques. A) Control tissue: non-demented male, aged 82 at death and 
Braak stage II, the image shows no plaques. B, C, D) AD tissue: demented female patient, aged 77 
years at death and Braak stage V. B) Negative control section: stained with ThioS (green) and the 
secondary antibody only was used; no C3/30 antibody, the image shows amyloid plaque stained by 
ThioS (green) only. C and D) AD sections: showing amyloid plaque stained with ThioS (green), 
and C3b/iC3b stained with C3/30 monoclonal antibody (red), co-localize with the plaque. Scale bars 
are shown for each slide. 
4.4.2 C1q protein levels in AD brain tissue 
4.4.2.1 Comparison of C1q levels between AD cases and controls   
C1q protein was measured in frontal and temporal homogenates by sandwich 
ELISA and results were adjusted to total protein concentration for each case. The data were 
tested for normality and were not normally distributed, therefore a non-parametric 
statistical test was used (Mann-Whitney test) for analysis.  
There was no significant difference in C1q levels (ng/mg total protein) between 
controls (mean ± SEM = 24.9 ± 2.7) and AD (mean ± SEM = 24.9 ± 1.5) in the frontal 




SEM = 26.7 ± 1.9) in the temporal cortex (P value = 0.66), as assessed by Mann-Whitney 
test and shown in Figure 4-2.  
A closer examination of regional differences for C1q protein levels revealed no 
significant differences between the frontal and the temporal cortex in the control or AD 
group (P value = 0.46 & 0.45 respectively), as assessed by unpaired t-test. 
 
Figure 4-2: C1q protein levels in human brain tissue (ng/mg total protein). No significant 
difference was seen between control and AD groups in A) Frontal cortex: Mann-Whitney test (P 
value = 0.21), or in B) Temporal cortex: Mann-Whitney test (P value = 0.66). 
4.4.2.2 Relationship between C1q levels, age at death and gender  
There are some potential factors that might affect C1q protein levels, such as age 
at death and gender, were assessed. No significant correlation between age at death and 
C1q levels was seen in any of the groups when analysed separately or for the full cohort (P 
value = 0.22, Spearman’s r = 0.15) in the frontal homogenates, or in the temporal 
homogenates by Spearman’s correlation test (P value = 0.97, Spearman’s r = - 0.004), as 
shown in Figure 4-3. Summary statistics for these data are also presented in the Appendix 





Figure 4-3: Correlation plots of C1q concentration (ng/mg total protein) with age at death 
(years) in A) Frontal cortex: no significant correlation with age (P value = 0.22, Spearman’s r = 
0.15). B) Temporal cortex: no significant correlation with age (P value = 0.97, Spearman’s r = -
0.004). The continuous line represents the best fit of the linear regression and the dashed lines 
represent 95% confidence interval (CI) of the regression line. 
 
C1q concentrations were compared in control group males (n= 19) and females (n= 
12) and AD group males (n= 10) and females (n= 23). No significant difference in C1q 
concentrations was seen in the frontal cortex when analyzed by Kruskal-Wallis test 
followed by post hoc- Dunn’s multiple comparison test (P value = 0.22), or temporal cortex 
(P value = 0.67). Summary statistics for these data are also presented in Appendix II, Table 
9-4. 
 
Figure 4-4: Concentration of C1q (ng/mg total protein) in males versus females. A) frontal 
cortex: no significant difference was seen (P value = 0.22). B) Temporal cortex: no significant 




4.4.2.3 Relationship between C1q levels and PMI  
In the frontal cortex, no significant correlation was seen in the control or AD 
groups (P value = 0.66 & 0.54 respectively), Spearman’s r = (0.08 & -0.1) with PMI 
respectively, or for the full cohort (P value = 0.9, Spearman’s r = -0.01), as assessed by 
Spearman’s correlation test and shown in Figure 4-5 (A). 
In the temporal cortex, similarly, no significant correlation was seen in the control 
or AD group (P value = 0.76 & 0.46), Spearman’s r = (-0.05 & 0.13) with PMI respectively, 
or when control and AD groups were combined (P value = 0.9, Spearman’s r = -0.01), as 
assessed by Spearman’s correlation test and shown in Figure 4-5 (B). 
 
Figure 4-5: Correlation plots of C1q levels (ng/mg total protein) with PMI (hours). A) Frontal 
cortex: no significant correlation with PMI (P value = 0.9, Spearman’s r = -0.01). B) Temporal 
cortex: no significant correlation with PMI (P value = 0.9, Spearman’s r = -0.01). The continuous 
line represents the best fit of the linear regression and the dashed lines represent 95% confidence 
interval (CI) of the regression line. 
4.4.2.4 Relationship between C1q levels and AD pathology  
Aβ load 
Parenchymal Aβ load was available from the MRC and SWDBB database for 32 
of the 33 cases in the AD group. Correlation of C1q levels with Aβ load was explored. No 




temporal cortex (P value = 0.77, Pearson’s r = 0.05), as assessed by Pearson’s correlation 
test and shown in Figure 4-6. 
 
Figure 4-6: Correlation between C1q levels and Aβ load in AD group. A) Frontal cortex: no 
significant correlation seen (P value = 0.08, Pearson’s r = 0.3). B) Temporal cortex: no significant 
correlation seen (P value = 0.77, Pearson’s r = 0.05). The continuous line represents the best fit of 
the linear regression and the dashed lines represent 95% confidence interval (CI) of the regression 
line. 
Braak tangle staging 
Comparison of C1q levels across the three groups of Braak stages (0-II = 31 
Controls, III-IV = 5 AD, V-VI = 28 AD) was performed. In the frontal cortex, a significant 
difference was seen between groups (P value = 0.008), as assessed by Kruskal-Wallis test. 
Group V-VI was significantly higher than group III-IV with post-hoc Dunn’s test for 
multiple comparison, while no significant difference was seen between the groups in the 
temporal cortex (P value = 0.08), as assessed by Kruskal-Wallis test followed by post-hoc 





Figure 4-7: C1q levels in different Braak stages. A) Frontal cortex: a significant increase in 
C1q concentration in Braak stage V-VI group was seen compared to III-IV group, Kruskal-Wallis 
test (*P value = 0.008). B) Temporal cortex: no significant difference was seen between the 
groups, Kruskal-Wallis test (P value = 0.08). 
4.4.2.5 Relationship between C1q levels and APOE genotype 
C1q levels was compared in the full cohort grouped according to the number of 
APOE ε4 alleles (35 negative, 21 heterozygous and 7 homozygous; information taken from 
MRC brain bank database for SWDBB), analyzed by using Kruskal-Wallis test. There was 
no significant difference in C1q levels between the groups according to APOE genotypes 
in frontal or temporal cortex (P value = 0.87 & 0.86), respectively, as shown in Figure 4-8.  
AD group was also analysed as groups with and without ε4 and no significant differences 
were seen between the groups in the frontal and temporal cortex (P value = 0.96 & 0.67), 
respectively. 
 
Figure 4-8: Concentration of C1q (ng/mg total protein) in controls and AD with or without an 
APOE 4 allele. A) Frontal cortex: no significant difference was seen between the groups (P value 





4.4.3 C3 protein levels in AD brain tissue 
4.4.3.1 Comparison of C3 levels between AD cases and controls  
C3 protein was measured in frontal and temporal cortices from only 16 controls 
and 16 AD cases from the cohort and that was due to the availability of insufficient amounts 
of in-house detection antibody. This was performed by sandwich ELISA and the results 
were adjusted to total protein concentration for each case. The data were tested for 
normality and were normally distributed, therefore, unpaired t-test was used for analysis.  
There was no significant difference in C3 levels (ng/mg total protein) between 
controls (mean ± SEM = 168.8 ± 19.7) and AD (mean ± SEM = 260.8 ± 33.8) in the frontal 
cortex (P value = 0.29), while a significant increase was seen in AD (mean ± SEM = 246 
± 36.3) compared to controls (mean ± SEM = 166.4 ± 22.2) in the temporal cortex, (P value 
= 0.025), as assessed by unpaired t-test and shown in Figure 4-9. 
A closer examination of regional differences for C3 protein levels revealed no 
significant differences between the frontal and the temporal cortex in the control or AD 
group (P value = 0.5 & 0.41), respectively, as assessed by unpaired t-test. 
 
Figure 4-9: C3 protein Levels in human brain tissue (ng/mg total protein). A) Frontal cortex: 
no significant difference was seen between control and AD groups, unpaired t-test (P value = 0.29), 





4.4.3.2 Relationship between C3 levels, age at death and gender  
There are some potential factors that might affect C3 protein levels, such as age at 
death and gender, were assessed. The age of this smaller control group ranged from 64 to 
95 years (mean 75.2, SD 10), and similarly for the smaller AD group ranged from 74 to 96 
years (mean 81.8, SD 6.8).  No significant correlation between age at death and C1q levels 
was seen in any of the groups when analysed separately or for the full cohort i.e. (P value 
= 0.27, Pearson’s r = -0.22) in the frontal homogenates, or in the temporal homogenates by 
Pearson’s correlation test (P value = 0.9, Pearson’s r = 0.02), as shown in Figure 4-10. 
Summary statistics for these data are also presented in the Appendix II, Table 9-3. 
 
Figure 4-10: Correlation plots of C3 concentration (ng/mg total protein) with age at death 
(years) in A) Frontal cortex: no significant correlation with age (P value = 0.27, Spearman’s r = -
0.22). B) Temporal cortex: no significant correlation with age (P value = 0.9, Spearman’s r = 0.02). 
The continuous line represents the best fit of the linear regression and the dashed lines represent 
95% confidence interval (CI) of the regression line. 
 
Comparison of C3 protein level in male and female groups, control group males 
(n= 13), and females (n= 3) and AD group males (n= 3) and females (n= 13). Groups were 
too small in number and no significant differences were seen in the frontal cortex (P value 
= 0.14), or in the temporal cortex (P value = 0.35), when analyzed by Kruskal-Wallis test. 
Similarly, post-hoc Dunn’s for multiple comparison showed no significant difference in C3 
levels in any of the groups (Figure 4-11). Summary statistics for these data are also 





Figure 4-11: Concentration of C3 (ng/mg total protein) in males versus females. A) frontal 
cortex: no significant difference was seen (P value = 0.14). B) Temporal cortex: no significant 
difference was seen (P value = 0.35). 
4.4.3.3 Relationship between C3 levels and PMI  
In the frontal cortex, no significant correlation was seen in the control or AD 
groups (P value = 0.5 & 0.24), respectively, Pearson’s r = (0.2 & -0.3) with PMI 
respectively, or for the full cohort (P value = 0.9, Pearson’s r = -0.003), as assessed by 
Pearson’s correlation test and shown in Figure 4-12 (A). In the temporal cortex, similarly, 
no significant correlation was seen in the control or AD group (P value = 0.45 & 0.77), 
Pearson’s r = (-0.2 & -0.008) with PMI respectively, as assessed by Pearson’s correlation 
test or when control and AD groups were combined (P value = 0.3, Spearman’s r = 0.2), as 
assessed by Spearman’s correlation test and shown in Figure 4-12 (B). 
 
Figure 4-12: Correlation plots of C3 levels (ng/mg total protein) with PMI (hours). A) Frontal 
cortex: no significant correlation with PMI (P value = 0.9, Pearson’s r = -0.003). B) Temporal 
cortex: no significant correlation with PMI (P value = 0.3, Spearman’s r = 0.2). The continuous line 
represents the best fit of the linear regression and the dashed lines represent 95% confidence interval 




4.4.3.4 Relationship between C3 levels and AD pathology 
Aβ load 
Parenchymal Aβ load was available from the MRC and SWDBB database for 15 
of the 16 cases in AD group. Correlation of C3 levels was explored in relation to Aβ load. 
In the frontal cortex, there was a significant positive correlation by using Pearson’s 
correlation (P value = 0.02, Pearson’s r = 0.6), while C3 levels did not show any significant 
correlation in the temporal cortex with Aβ load (P value = 0.25, Pearson’s r = 0.3). 
 
 
Figure 4-13: Correlation between C3 concentrations and Aβ load in AD group. A) Frontal 
cortex: a significant positive correlation was seen (*P value = 0.02, Pearson’s r = 0.6). B) Temporal 
cortex: no significant correlation was seen (P value = 0.25, Pearson’s r = 0.3). The continuous line 
represents the best fit of the linear regression and the dashed lines represent 95% confidence interval 
(CI) of the regression line. 
Braak tangle staging 
Comparison of C3 concentration was once more considered in three groups of 
increasing tau pathology according to Braak stages (0-II = 16 Controls, III-IV = 3 AD, V-
VI = 13AD) in controls and AD. No significant difference was seen between three groups 
of Braak stages in the frontal cortex (P value = 0.51), while in the temporal cortex, C3 
concentration was found to be significantly different between groups (P value = 0.04), as 
assessed by one-way ANOVA test. However, post-hoc Tukey’s test for multiple 






Figure 4-14: C3 concentration in different Braak stages. A) Frontal cortex: no significant 
difference was seen between groups, one-way ANOVA test (P value = 0.51). B) Temporal cortex: 
a significant difference was seen between the groups, one-way ANOVA test (*P value = 0.04). 
4.4.3.5 Relationship between C3 levels and APOE genotype 
C3 concentration was also examined in the cohort grouped according to the number 
of APOE ε4 alleles (15 negative, 11 heterozygous and 4 homozygous). There were so few 
cases and controls to look at this, the analysis was done by using one-way ANOVA test; 
there was no significant difference between the groups in the frontal (P value = 0.58), or 
the temporal cortex (P value = 0.27), followed by Tukey’s post -hoc test which did not 
show any differences either, as shown in Figure 4-15. 
 
Figure 4-15: Concentration of C3 (ng/mg total protein) in controls and AD with or without an 
APOE 4 allele. A) Frontal cortex: no significant difference was seen between the groups (P value 





4.4.4 CFH protein levels in AD brain tissue 
4.4.4.1 Comparison of CFH levels between AD cases and controls  
CFH protein was similarly measured in both the frontal and temporal cortices from 
the full cohort by sandwich ELISA and the results were adjusted to total protein 
concentration for each case. The data was also similarly tested for normality and was not 
normally distributed, therefore, Mann-Whitney test was used for analysis.  
There was no significant difference in CFH concentration between controls (mean 
± SEM = 203 ± 15) and AD (mean ± SEM = 229 ± 14.5), in the frontal cortex (P value = 
0.14), while there was a significant increase in AD group (mean ± SEM = 265 ± 21) (P 
value = 0.03) compared to control group (mean ± SEM = 210 ± 16) in the temporal cortex, 
as shown in Figure 4-16. 
On investigation for regional differences, no significant differences were seen 
between frontal and temporal cortex in the control or AD group (P value = 0.73 & 0.23), 
respectively, as assessed by Mann-Whitney test. 
 
Figure 4-16: CFH protein levels in human brain tissue (ng/mg total protein). A) Frontal cortex 
shows no significant difference between control and AD groups, by Mann-Whitney test (P value = 
0.14), while in B) Temporal cortex: a significant increase was seen in AD tissue, by Mann-Whitney 





4.4.4.2 Relationship between CFH levels with age at death and 
gender 
Similar examinations to those of the other markers showed that there were no 
significant correlations between age at death and CFH levels were seen in the frontal for 
control group or AD group when combined i.e. (P value = 0.15, Spearman’s r = -0.17), as 
shown in Figure 4-17 (A). In the frontal AD tissue, there was a significant negative 
correlation between CFH protein levels and age (P value = 0.04, Spearman r = -0.35). In 
the temporal cortex, no significant differences were seen in the groups when analysed 
separately or when the full cohort was analysed i.e. (P value = 0.69, Spearman’s r = -0.05), 
as shown in Figure 4-17 (B). Summary statistics for these data are also presented in the 
Appendix II, Table 9-3. 
 
Figure 4-17: Correlation plots of CFH concentration (ng/mg total protein) with age at death 
(years) in A) Frontal cortex: no significant correlation with age (P value = 0.15, Spearman’s r = -
0.17). B) Temporal cortex: no significant correlation with age (P value = 0.69, Spearman’s r = -
0.05). The continuous line represents the best fit of the linear regression and the dashed lines 
represent 95% confidence interval (CI) of the regression line. 
 
Comparison of CFH concentration was also undertaken according to gender, 
control group males (n= 19), females (n= 12) and AD group males (n= 10), females (n= 
23). There was no significant difference seen in the frontal cortex between the groups when 
analyzed separately or for the full cohort (P value = 0.3), while in the temporal cortex, there 
was a significant difference between the groups by Kruskal-Wallis test (P value = 0.03), 
and post-hoc Dunn’s test revealed a significant increase in AD in female compared to 






Figure 4-18: Concentration of CFH in males versus females (ng/mg total protein). A) frontal 
cortex: no significant difference was seen between groups (P value = 0.3). B) Temporal cortex: a 
significant difference was seen between groups (*P value = 0.03), females of AD group was 
significantly higher than females of control group by Kruskal-Wallis test followed by Post-hoc 
Dunn’s test. 
4.4.4.3 Relationship between CFH levels and PMI  
The correlation of CFH levels with PMI for both control and AD groups was 
explored. It was evident that there was no correlation with PMI in any of the groups. In the 
frontal cortex, no significant correlation was seen in the control or AD groups (P value = 
0.4 & 0.057), respectively, Spearman’s r = (-0.13 & -0.3) with PMI respectively, or for the 
full cohort (P value = 0.12, Spearman’s r = -0.19), as shown in Figure 4-19 (A). 
In the temporal cortex, no correlation in the control or AD group (P value = 0.8 & 
0.45), Spearman’s r = (0.04 & -0.13) with PMI respectively, or when control and AD 





Figure 4-19: Correlation plots of CFH levels (ng/mg total protein) with PMI (hours). 
A) Frontal cortex: no significant correlation with PMI (P value = 0.12, Spearman’s r = -0.19). 
B) Temporal cortex: no significant correlation with PMI (P value = 0.8, Spearman’s r = -0.02). The 
continuous line represents the best fit of the linear regression and the dashed lines represent 95% 
confidence interval (CI) of the regression line 
4.4.4.4 Relationship between CFH levels and AD pathology 
Aβ load 
The correlation of Aβ neuropathology and CFH protein in AD tissue (32 cases) 
was undertaken, there were no correlations found either in the frontal cortex (P value = 0.9, 
Spearman’s r = 0.01), or in the temporal cortex with Aβ load (P value = 0.49, Spearman’s 
r = 0.12), as shown in Figure 4-20. 
 
Figure 4-20: Correlation between CFH concentrations and Aβ load in AD group. A) Frontal 
cortex: no significant correlation was seen (P value = 0.9, Spearman’s r = 0.01) B) Temporal 
cortex: no significant correlation was seen (P value = 0.49, Spearman’s r = 0.12). The continuous 
line represents the best fit of the linear regression and the dashed lines represent 95% confidence 




Braak tangle staging 
Comparison of CFH concentration in three Braak groups, representative of 
worsening of neuropathology (0-II, III-IV, V-VI), was explored across the controls and AD 
cases using the Kruskal-Wallis test. No significant difference was seen between three 
groups of Braak stages in either the frontal cortex (P value = 0.18) or the temporal cortex 
(P value = 0.08), as shown in Figure 4-21. 
 
Figure 4-21: CFH concentration in different Braak stages. A) Frontal cortex: no significant 
difference was seen between the groups (P value = 0.18) by Kruskal-Wallis test. B) Temporal 
cortex: no significant difference was seen between the groups (P value = 0.08) by Kruskal-Wallis 
test. 
4.4.4.5 Relationship between CFH levels and APOE genotype 
CFH levels was compared in the full cohort grouped according to the number of 
APOE ε4 alleles (35 negative, 21 heterozygous and 7 homozygous) As with previous 
markers there was no significant difference between the groups in the frontal (P value = 
0.77) or the temporal cortex (P value = 0.46), as assessed by Kruskal-Wallis test and shown 





Figure 4-22: Concentration of CFH (ng/mg total protein) in controls and AD with or without 
an APOE 4 allele. A) Frontal cortex: no significant difference was seen between the groups (P 
value = 0.77). B) Temporal cortex: no significant difference was seen between the groups (P value 
= 0.46), by Kruskal-Wallis test. 
4.4.5 iC3b protein levels in AD brain tissue 
4.4.5.1 Comparison of iC3b levels between AD cases and controls  
iC3b protein was measured in 31 controls and 33 AD cases across both brain 
regions by sandwich ELISA and results were adjusted as with other markers to total protein 
concentration for each case. The data was tested for normality and was not normally 
distributed, therefore, Mann-Whitney test was used. In this case there was a significant 
increase in iC3b concentration in AD cases (mean ± SEM = 184.6 ± 19.7), compared to 
controls (mean ± SEM = 129.8 ± 13.3) in the frontal cortex (P value = 0.02), and in AD 
group (mean ± SEM = 197.6 ± 20.6) compared to control group (mean ± SEM = 97.5 ± 
12.2), in the temporal cortex (P value < 0.0001), as shown in Figure 4-23. 
Examination of regional differences for iC3b levels showed that there were no 
significant differences between frontal and temporal cortex in the control or AD group (P 





Figure 4-23: iC3b protein levels in human brain tissue (ng/mg total protein). A significant 
increase was seen in AD tissue compared to controls in A) Frontal cortex: Mann-Whitney test 
(*P value = 0.02) and in B) Temporal cortex: Mann-Whitney test (***P value < 0.0001). 
4.4.5.2 Relationship between iC3b levels with age at death and 
gender  
Age did not correlate significantly with iC3b concentration in the frontal or the 
temporal cortex, for control group or AD group either in the frontal cortex when analysed 
separately or for the full cohort i.e. (P value = 0.4, Spearman’s r = 0.1), or in the temporal 
cortex when analysed separately or for the full cohort (P value = 0.8, Spearman’s r = -0.02), 
as shown in Figure 4-24. Summary statistics for these data are also presented in the 
Appendix II, Table 9-3. 
 
Figure 4-24: Correlation plots of iC3b concentration (ng/mg total protein) with age at death 
(years) in A) Frontal cortex: no significant correlation (P value = 0.4, Spearman’s r = 0.1). 





Comparison of iC3b concentration was also examined according to gender (control 
group males (n= 19), females (n= 12) and AD group males (n= 10) females (n= 23)). No 
significant differences were found in the frontal cortex between the groups when analyzed 
separately or when combined (P value = 0.14), as shown in Figure 4-25. However, 
investigation by Kruskal-Wallis test of the temporal cortex similar to CFH showed there 
was a significant difference (P value = 0.0008), and post-hoc Dunn’s test revealed a 
significant increase in AD female tissue compared to control female tissue. Summary 
statistics for these data are also presented in Appendix II, Table 9-4. 
 
Figure 4-25: Concentration of iC3b in males versus females (ng/mg total protein). A) frontal 
cortex: no significant difference was seen between groups (P value = 0.14). B) Temporal cortex: 
a significant difference was seen between groups (**P value = 0.0008), females of AD group was 
significantly higher than females of control group by Kruskal-Wallis test followed by Post-hoc 
Dunn’s test. 
4.4.5.3 Relationship between iC3b levels and PMI  
Correlation of iC3b levels with PMI was assessed for both control and AD groups. 
Unlike some of the differences found for age and gender for some comparisons, there was 
no correlation with PMI in any of the groups. In the frontal cortex, no significant correlation 
was seen in the control (P value = 0.5, Pearson’s r = 0.1), or AD group (P value = 0.4, 
Spearman’s r = -0.14), with PMI, or for the full cohort (P value = 0.96, Spearman’s r = 
0.005), as shown in Figure 4-26 (A). 
In the temporal cortex, no correlation in the control (P value = 0.6, Pearson’s r = -
0.09), or AD group (P value = 0.5 Spearman’s r = -0.01), or when combined (P value = 0.8, 





Figure 4-26: Correlation plots of iC3b levels (ng/mg total protein) with PMI (hours). 
A) Frontal cortex: no significant correlation with PMI (P value = 0.96, Spearman’s r = 0.005).  
B) Temporal cortex: no significant correlation with PMI (P value = 0.8, Spearman’s r = -0.01). The 
continuous line represents the best fit of the linear regression and the dashed lines represent 95% 
confidence interval (CI) of the regression line. 
4.4.5.4 Relationship between iC3b levels and AD pathology 
Aβ load 
Parenchymal Aβ load in correlation with iC3b levels was explored. There was no 
significant correlation between Aβ load and iC3b protein in AD tissue (32 cases) when 
analyzed either in the frontal (P value = 0.6, Spearman’s r = 0.09), or in the temporal cortex 
(P value = 0.3, Spearman’s r = -0.17), as shown in Figure 4-27.  
 
Figure 4-27: Correlation between iC3b levels and Aβ load in AD group. A) Frontal cortex: no 
significant correlation seen (P value = 0.6, Spearman’s r = 0.09). B) Temporal cortex: no significant 
correlation seen (P value = 0.3, Spearman’s r = -0.17). The continuous line represents the best fit of 





Braak tangle staging 
Comparison of iC3b levels across the three groups of Braak stages (0-II = 31 
Controls, III-IV = 5 AD, V-VI = 28 AD) was performed. In the frontal cortex, no significant 
difference was seen between groups (P value = 0.07), as assessed by Kruskal-Wallis test, 
however, in the temporal cortex iC3b concentration was significantly different between 
groups, Kruskal-Wallis (P value = 0.02). Group V-VI was significantly higher than group 
0-II with Kruskal-Wallis test followed by post-hoc Dunn’s test for multiple comparison, as 
shown in Figure 4-28. 
 
Figure 4-28: iC3b concentration in different Braak stages. A) Frontal cortex: no significant 
difference was seen between the groups, Kruskal-Wallis test (P value = 0.07). B) Temporal cortex: 
a significant difference was seen between the groups, Kruskal-Wallis test (*P value = 0.02). 
4.4.5.5 Relationship between iC3b levels and APOE genotype 
iC3b levels was compared in the full cohort grouped according to the number of 
APOE ε4 alleles (35 negative, 21 heterozygous and 7 homozygous) analyzed by using 
Kruskal-Wallis test. There was no significant difference in iC3b levels between the groups 
according to APOE genotypes in frontal or temporal cortex (P value = 0.07), as shown in 
Figure 4-29 (A).  
There was however an evidence of a significant difference between groups in the 




iC3b concentration than group with no ε4 allele. This difference was detected after using 
post-hoc Dunn’s test for multiple analysis, as shown in Figure 4-29 (B). 
 
Figure 4-29: Concentration of iC3b (ng/mg total protein) in controls and AD with or without 
an APOE 4 allele. A) Frontal cortex: no significant difference was seen between the groups (P 
value = 0.07). B) Temporal cortex: a significant increase was seen between the groups (*P value = 
0.024). 
4.4.5.6 Relationship between iC3b levels and CFH levels 
It was interesting to see if there was any correlation between CFH and iC3b levels. 
In the frontal cortex, a significant correlation was seen in the control and AD groups (P 
value = 0.0015 & 0.001 respectively), Pearson’s r = (0.54 & 0.54) with CFH levels 
respectively, and in the full cohort (P value < 0.0001, Pearson’s r = 0.5), as assessed by 
Pearson’s correlation test and shown in Figure 4-30 (A). 
In the temporal cortex, similarly, a significant correlation was seen in the control 
and AD group (P value = 0.0003 & 0.0014), Pearson’s r = (0.61 & 0.53) with CFH levels 
respectively, and when control and AD groups were combined (P value = 0.0001, Pearson’s 






Figure 4-30: Correlation between iC3b levels and CFH levels. A) Frontal cortex: a significant 
correlation seen (P value < 0.0001, Pearson’s r = 0.5). B) Temporal cortex: a significant correlation 
seen (P value = 0.0001, Pearson’s r = 0.58). The continuous line represents the best fit of the linear 
regression and the dashed lines represent 95% confidence interval (CI) of the regression line.  
4.4.6 Clusterin protein expression in AD brain tissue 
4.4.6.1 Comparison of clusterin levels between AD cases and 
controls 
Clusterin protein was measured in frontal and temporal homogenates by sandwich 
ELISA and results were adjusted to total protein concentration for each case. The data were 
tested for normality and were normally distributed, therefore a parametric statistical test 
was used (unpaired t-test) for analysis.  
A significant increase was seen in clusterin levels (μg/mg total protein) in AD 
(mean ± SEM = 1.9 ± 0.14) compared to controls (mean ± SEM = 1.5 ± 0.12) in the frontal 
cortex (P value = 0.03). In the temporal cortex, a significant increase was also seen in AD 
(mean ± SEM = 2.0 ± 0.12) compared to controls (mean ± SEM = 1.7 ± 0.1) and (P value 
= 0.048), as assessed by unpaired t-test and shown in Figure 4-31.  
Although there were disease-associated differences there were no significant 
differences between the frontal and the temporal cortex in the control or AD group (P value 





Figure 4-31: Clusterin protein expression in human brain tissue (μg/mg total protein). A 
significant increase was seen in AD tissue compared to controls in A) Frontal cortex: by unpaired 
t-test (*P value = 0.03), and in B) Temporal cortex: by unpaired t-test (*P value = 0.048). 
4.4.6.2 Relationship between clusterin levels with age at death and 
gender 
There are some potential factors that might affect clusterin protein levels, such as 
age at death and gender. No significant correlation between age at death and clusterin levels 
was seen in any of the groups when analysed separately or for the full cohort (P value = 
0.18, Spearman’s r = 0.16) in the frontal homogenates, or in the temporal homogenates by 
Spearman’s correlation test (P value = 0.15, Spearman’s r = 0.18), as shown in Figure 4-32. 
Summary statistics for these data are also presented in the Appendix II, Table 9-3. 
 
Figure 4-32: Correlation plots of clusterin concentration (ng/mg total protein) with age at 
death (years) in A) Frontal cortex: no significant correlation with age (P value = 0.18, Spearman’s 
r = 0.16). B) Temporal cortex: no significant correlation with age (P value = 0.15, Spearman’s r = 
0.18). The continuous line represents the best fit of the linear regression and the dashed lines 




 Similar comparison of clusterin concentration according to gender (control group 
males (n= 19), females (n= 12) and AD group males (n= 10) and females (n= 23)) showed 
no significant differences in the frontal cortex in any of the groups when analyzed 
separately, or when control and AD were combined i.e. (P value = 0.18), or in the temporal 
cortex in any of the groups when analyzed separately, or when combined i.e. (P value = 
0.23), as assessed by Kruskal-Wallis test followed by post hoc- Dunn’s multiple 
comparison test and shown in Figure 4-33. Summary statistics for these data are also 
presented in Table 9-4 
 
Figure 4-33: Concentration of clusterin (μg/mg total protein) in males versus females. A) 
frontal cortex: no significant difference was seen (P value = 0.18). B) Temporal cortex: no 
significant difference was seen (P value = 0.23). 
4.4.6.3 Relationship between clusterin levels and PMI  
Correlation of clusterin concentration with PMI was assessed for both control and 
AD groups. Similar to age at death and gender, there was no correlation with PMI in any 
of the groups of the cohort. In the frontal cortex, no significant correlation was seen in the 
control or AD groups (P value = 0.12 & 0.09 respectively), Spearman’s r = (0.2 & -0.3) 
with PMI respectively, or for the full cohort (P value = 0.8, Spearman’s r = -0.01), as shown 
in Figure 4-34 (A). 
In the temporal cortex, similarly, no significant correlation was seen in the control 
or AD group (P value = 0.75 & 0.16), Spearman’s r = (0.05 & -0.2) with PMI respectively, 
or when control and AD groups were combined (P value = 0.4, Spearman’s r = -0.09), as 





Figure 4-34: Correlation plots of clusterin levels (μg /mg total protein) with PMI (hours). 
A) Frontal cortex: no significant correlation with PMI (P value = 0.8, Spearman’s r = -0.01). 
B) Temporal cortex: no significant correlation with PMI (P value = 0.4, Spearman’s r = -0.09). The 
continuous line represents the best fit of the linear regression and the dashed lines represent 95% 
confidence interval (CI) of the regression line. 
4.4.6.4 Relationship between clusterin levels and AD pathology 
Aβ load 
Looking at the parenchymal Aβ load and clusterin protein levels in AD tissue (32 
cases), there was no significant correlations found either in the frontal (P value = 0.6, 
Pearson’s r = 0.09), or in the temporal cortex (P value = 0.6, Pearson’s r = 0.08), as assessed 
by using Pearson’s correlation test and shown in Figure 4-35. 
 
Figure 4-35: Correlation between clusterin concentrations and Aβ load in AD group. 
A) Frontal cortex: no significant correlation was seen (P value = 0.6, Pearson’s r = 0.09). 
B) Temporal cortex: no significant correlation was seen (P value = 0.6, Pearson’s r = 0.08). The 
continuous line represents the best fit of the linear regression and the dashed lines represent 95% 




Braak tangle staging 
Comparison of clusterin levels across the three groups of Braak stages (0-II = 31 
Controls, III-IV = 5 AD, V-VI = 28 AD) was performed. In the frontal cortex, a significant 
difference was seen between groups (P value = 0.04). Group V-VI was significantly higher 
than group 0-II. In the temporal cortex clusterin concentration was also significantly 
different between groups (P = 0.004), as assessed by one-way ANOVA test. Furthermore, 
in this comparison group V-VI was significantly higher than group 0-II and group III-IV 
with post-hoc Tukey’s test for multiple comparison and shown in Figure 4-36. 
 
Figure 4-36: Clusterin concentration in different Braak stages. A) Frontal cortex: a significant 
difference was seen between groups, Kruskal-Wallis test (*P value = 0.04). B) Temporal cortex: a 
significant difference was seen between the groups, one-way ANOVA test (*P value = 0.004). 
4.4.6.5 Relationship between clusterin levels and APOE genotype 
Clusterin levels was compared in the full cohort grouped according to the number 
of APOE ε4 alleles (35 negative, 21 heterozygous and 7 homozygous). There was no 
significant difference in clusterin levels between the groups according to APOE genotypes 
in frontal cortex (P value = 0.9), as assessed by one-way ANOVA test and shown in Figure 
4-37 (A).  
There was no evidence of significant difference between groups in the temporal 
cortex (P value = 0.2) by using Kruskal-Wallis test and then by post-hoc Dunn’s test for 





Figure 4-37: Concentration of clusterin (μg /mg total protein) in controls and AD with or 
without an APOE 4 allele. A) Frontal cortex: no significant difference was seen between the 
groups (P value = 0.9). B) Temporal cortex: no significant difference was seen between the groups 
(P value = 0.2). 
4.4.7 TCC protein expression in AD brain tissue 
4.4.7.1 Comparison of TCC levels between AD cases and controls  
Finally, the terminal complement protein complex (TCC), was measured in frontal 
and temporal cortices from 31 controls and 33 AD cases by sandwich ELISA and results 
were adjusted to total protein concentration for each case. The data was tested for normality 
and was found to be normally distributed prompting the need to use the unpaired t-test.  
There was no significant difference in TCC levels (ng/mg total protein) between 
controls (mean ± SEM = 541.2 ± 34.2) and AD (mean ± SEM = 585 ± 41.8) in the frontal 
cortex (P value = 0.42) or between controls (mean ± SEM = 609.1 ± 49.2) and AD (mean 
± SEM = 698.6 ± 56.2) in the temporal cortex (P value = 0.24), as assessed by unpaired t-
test and shown in Figure 4-38.  
On a related exploration of regional differences for TCC no significant difference 
was seen between frontal and temporal cortex in either the control or AD group (P value = 





Figure 4-38: TCC levels in human brain tissue (ng/mg total protein). No significant difference 
was seen between the groups in A) Frontal cortex: by unpaired t-test (P value = 0.42), or in B) 
Temporal cortex: by unpaired t-test (P value = 0.24). 
4.4.7.2 Relationship between TCC levels with age at death and 
gender 
Similar to the previous analyses, age at death and gender were assessed. No 
significant correlation between age at death and TCC levels was seen in any of the groups 
when analysed separately or for the full cohort (P value = 0.6, Spearman’s r = 0.06) in the 
frontal homogenates, or in the temporal homogenates by correlation test (P value = 0.79, 
Pearson’s r = 0.03), as shown in Figure 4-39. Summary statistics for these data are also 
presented in the Appendix II, Table 9-3. 
 
Figure 4-39: Correlation plots of TCC concentration (ng/mg total protein) with age at death 
(years) in A) Frontal cortex: no significant correlation with age (P value = 0.6, Spearman’s r = 
0.06). B) Temporal cortex: no significant correlation with age (P value = 0.79, Pearson’s r = 0.03). 
The continuous line represents the best fit of the linear regression and the dashed lines represent 




Comparison of TCC concentration according to gender (control group males (n= 
19), females (n= 12) and AD group males (n= 10) and females (n= 23)) showed no 
significant differences in the frontal cortex in any of the groups when analyzed separately, 
or when control and AD were combined i.e. (P value = 0.29), by using Kruskal-Wallis test 
and then by post-hoc Dunn’s test for multiple analysis, as shown in Figure 4-40 (A), or in 
the temporal cortex in any of the groups when analyzed separately, or when combined i.e. 
(P value = 0.65), as assessed by one-way ANOVA test followed by post hoc- Tukey’s 
multiple comparison test and shown in Figure 4-40 (B). Summary statistics for these data 
are also presented in Appendix II, Table 9-4. 
 
Figure 4-40: Concentration of TCC (ng/mg total protein) in males versus females. A) frontal 
cortex: no significant difference was seen (P value = 0.29) by Kruskal-Wallis test. B) Temporal 
cortex: no significant difference was seen (P value = 0.65) by one-way ANOVA test. 
4.4.7.3 Relationship between TCC levels and PMI  
Correlation of TCC concentration with PMI was assessed for both control and AD 
groups. Similar to age at death and gender, there was no correlation with PMI in any of the 
groups of the cohort. In the frontal cortex, no significant correlation was seen in the control 
or AD groups (P value = 0.88 & 0.16 respectively), Pearson’s r = (-0.03 & 0.2) with PMI 
respectively, or for the full cohort (P value = 0.5, Spearman’s r = -0.07), as shown in Figure 
4-41 (A). In the temporal cortex, similarly, no significant correlation was seen in the control 
or AD group (P value = 0.8 & 0.7), Pearson’s r = (0.03 & 0.05) with PMI respectively, or 
when control and AD groups were combined (P value = 0.74, Spearman’s r = -0.04), as 





Figure 4-41: Correlation between TCC concentrations and PMI load in AD group. A) Frontal 
cortex: no significant correlation was seen (P value = 0.5, Spearman’s r = -0.07). B) Temporal 
cortex: no significant correlation was seen (P value = 0.74, Spearman’s r = -0.04). 
4.4.7.4 Relationship between TCC levels and AD pathology  
Aβ load 
There was no significant correlation between Aβ load and TCC in AD tissue (32 
cases), by using Pearson’s correlation test, in the frontal (P value = 0.11, Pearson’s r = -
0.3), or in the temporal cortex (P value = 0.25, Pearson’s r = -0.2), as assessed by Pearson’s 
correlation test and shown in Figure 4-42. 
 
Figure 4-42: Correlation between TCC concentrations and Aβ load in AD group. A) Frontal 
cortex: no significant correlation was seen (P value = 0.11, Pearson’s r = -0.3). B) Temporal cortex: 
no significant correlation was seen (P value = 0.25, Pearson’s r = -0.2). The continuous line 
represents the best fit of the linear regression and the dashed lines represent 95% confidence interval 




Braak tangle staging 
Comparison of TCC levels across the three groups of Braak stages (0-II = 31 
Controls, III-IV = 5 AD, V-VI = 28 AD) was performed. In the frontal cortex, no significant 
difference was seen between three groups of Braak stages in the frontal cortex (P value = 
0.39), or in the temporal cortex (P = 0.25), as assessed by one-way ANOVA followed by 
post-hoc Tukey’s test for multiple comparison and shown in Figure 4-43. 
 
Figure 4-43: TCC concentration in different Braak stages. A) Frontal cortex: no significant 
difference was seen between groups, one-way ANOVA test (P value = 0.39). B) Temporal cortex: 
no significant difference was seen between the groups, one-way ANOVA test (P value = 0.25). 
4.4.6.5 Relationship between TCC levels and APOE genotype 
TCC levels was compared in the full cohort grouped according to the number of 
APOE ε4 alleles (35 negative, 21 heterozygous and 7 homozygous). There was no 
significant difference in clusterin levels between the groups according to APOE genotypes 
in frontal cortex (P value = 0.86), as shown in Figure 4-44 (A). There was no significant 
difference between groups in the temporal cortex (P value = 0.62) by using as one-way 





Figure 4-44: Concentration of TCC (ng /mg total protein) in controls and AD with or without 
an APOE 4 allele. A) Frontal cortex: no significant difference was seen between the groups (P 
value = 086). B) Temporal cortex: no significant difference was seen between the groups (P value 
= 0.62). 
4.5 Discussion  
In this set of experiments, various complement components were measured, as 
markers of neuroinflammation in the AD brain. Complement proteins represented by C1q 
and C3, the complement regulators CFH and clusterin, and the early activation marker 
(iC3b) and late activation product (TCC) were all measured in the frontal and temporal 
cortices of post-mortem human brain tissue. Few studies have previously investigated the 
complement system in post-mortem human brain tissue.  
Data concerning complement components measured by ELISA in post-mortem 
human brain tissue is limited, most of the previous work has been done by semiquantitative 
detection of mRNA, which is not a reflection of protein levels, in AD brain (423,563,564), 
by localization of the complement proteins in the plaques by immunohistochemical staining 
(408), in mice (392,400,565), or by in vitro studies to demonstrate complement proteins 
expression by glial cells in tissue culture (422), as previously mentioned.  
Proteins were measured in the present study by sandwich ELISA. After validation 
and testing of the specificity of in-house antibodies by western blotting (more details in 
Appendix III). Regional differences in brain tissue (between frontal and temporal cortex) 





 No significant differences were seen between control and AD tissue in C1q or 
TCC measurements in either of the brain areas tested. In contrast, in the temporal cortex 
significant increases were evident in C3 (P value = 0.02), CFH (P value = 0.03), iC3b (P 
value < 0.0001) and clusterin (P value = 0.048), in AD homogenates compared to age-
matched controls. In AD frontal cortex homogenates, iC3b (P value = 0.02) and clusterin 
(P value = 0.03) were also found to be significantly higher than controls. 
This findings indicate that the complement system dysregulation in AD is therefore 
more evident in the temporal cortex, which is a brain area affected early in the disease and 
earlier than the frontal cortex that was also studied. All of these results were adjusted 
according to total protein concentration in the homogenates, taking into consideration that 
the total protein concentration did not differ significantly between control and AD groups, 
results included in Chapter 3, (Section 3.4.2.1). 
The multifunctional lipoprotein; clusterin, is highly expressed protein in the brain 
tissue in control and AD groups. It was significantly increased in AD in both frontal and 
temporal cortices compared to age-matched controls. This compares to variable results that 
have been previously reported for clusterin expression in the frontal cortex, where it has 
been reported to be increased in the hippocampus and frontal cortex of AD brains by 
immunostaining and western blotting (566).  
Clusterin measurement by ELISA described here are consistent with a separate 
study from the Dementia Research Group where soluble and insoluble clusterin in seven 
brain areas including mid-frontal area were studied, however that study did not include the 
temporal cortex. That recent study showed that clusterin was significantly increased in the 
frontal cortex in the AD group compared to the control group. Furthermore, that study 
showed that their clusterin results correlated with soluble and insoluble Aβ distribution in 
different brain areas tested in the same cohort (438). Clusterin is known to facilitate Aβ 
clearance via BBB in mice (567). No correlation between clusterin with total Aβ was seen. 
In this study Aβ load used in analysis was calculated as the average of Aβ from (the frontal, 
temporal, and parietal cortices), by automated semi-quantitative analysis of computer 
assisted images from 30 random regions, as previously mentioned in (Section 2.3.3). 
An earlier study of clusterin by colleagues in Dementia Research Group found no 
difference between AD and control in the frontal or temporal areas (435). In that study, 




and it showed a significant increase in clusterin in brain tissue from the group that had no 
APOE allele 4 in the frontal cortex but not in the temporal cortex compared to APOE allele 
4 positive group  (435). 
iC3b was measured as an early marker of complement activation for both classical 
and alternative pathways. Its concentration was found to be significantly increased in the 
AD group compared to the control group (P = 0.02 & P < 0.0001), in the frontal and 
temporal cortices, respectively. This reinforces the evidence that indicates substantial 
activation of complement in AD brain.  
By comparison with another study, iC3b  was measured by ELISA in post-mortem 
human temporal cortex and a significant increase in AD group was reported (568). The 
cohort in this study was smaller in numbers but they tested five brain areas that did not 
include the frontal cortex. The protein level values found in this study are considerably 
higher than those reported in Loeffler’s study. Possible explanations for these differences 
include the different antibodies used, which may have had differences in their sensitivities 
or specificities, and/or differences due to the different lysis buffer used in brain 
homogenization. They used Triton X-100 lysis buffer which be less effective in extracting 
plaque-bound complement proteins and allowing the measurement of mostly soluble 
proteins whereas in this study SDS lysis buffer was used that may have more effectively 
released more of the target proteins. Additionally, they were unable to measure TCC in 
their sample, which might also relate to differences in lysis buffer or differences in 
antibodies used (568). 
CFH is a critical inhibitor to the alternative pathway that was proved to be 
associated with plaques in the brain (423). CFH was increased significantly in the temporal, 
but not in the frontal cortex in this study and that was not in accordance with a smaller 
previous study that detected CFH in the frontal cortex of nine cases and nine controls. This 
study found CFH did not differ significantly in AD compared to controls by western 
blotting, but a significant difference was seen by immunohistochemistry in AD frontal 
sections (423). Since CFH is the main regulator for the alternative pathway and leads to 
breakdown of C3 into its degradation products iC3b, it was interesting to see if CFH levels 
were correlated with iC3b. Notably, a significant positive correlation between CFH and 




Previously, in a study of complement in plasma, no differences were seen in TCC 
concentration in AD compared to control (399). TCC concentration was measured here but 
no significant differences were seen between any of the groups.  Others (Loeffler et al., as 
previously mentioned) have reported difficulties in detecting TCC in human brain tissue 
and as mentioned may be due to differences between their use Triton X-100 which might 
have been less effective in the release of TCC from various complexes to the SDS lysis 
used here. It is also possible that the highly expressed soluble clusterin protein in brain 
which acts as regulatory protein for the terminal complement pathway, may explain why 
there was no difference in TCC detected in lysed brain tissue. 
Recently, Hakobyan et al. investigated complement proteins as biomarkers for 
early AD progression. This was in a large cohort of 106 plasma samples from controls, 186 
AD cases, plus 189 plasma samples from mild cognitively impaired subjects (MCI) in 
which a set of complement analytes, including factor I, factor B, C4d, iC3b, clusterin and 
TCC, were measured using multiplex assays. In this study only clusterin was found to be 
significantly higher in plasma of AD compared to control, while three analytes (clusterin, 
factor I and TCC) were significantly different between MCI who had converted to dementia 
after one year, and MCI “non-convertors”. This indicates that those three analytes may 
predict the progression of AD pathology (399).  
Higher clusterin levels in plasma were associated with higher AD risk only in older 
participants of a previous study (395). Moreover, increased clusterin plasma level 
correlated with AD polygenic risk score and is thus potentially useful as a biomarker for 
the disease (396). Other plasma biomarkers studied in AD and correlated with brain 
atrophy, were C3 (P value = 0.006, r = 0.31) and CFI (P value = 0.04, r = 0.24) (398). 
Plasma samples, although more readily obtained in patients, are unlikely to 
sensitively reflect all of the metabolic state in the brain since some of the changes in the 
periphery may also include secondary system manifestations in response to the disease. 
CSF is thus more likely to offer a more representative type of samples to allow inferences 
of brain changes, however in contrast to taking blood, it is a more invasive and 
uncomfortable procedure and is thus less easily obtained. 
In CSF, variable results from the measurement of complement proteins in AD have 
been reported. In some studies decreased C1q levels have been found in AD and this 




be reduced in CSF of AD patients in another study and these correlated with cognitive 
decline in MCI patients and raised questions as to their usefulness as prognostic markers 
for the disease (402). A further CSF study investigated C3 and CFH in different 
neurodegenerative disease such as AD and PD. In this study a significant positive 
correlation was seen in C3 (P value < 0.001, r = 0.27) and CFH (P value = <0.0001, r = 
0.31) measurements in CSF of AD patients with cognitive impairment by MMSE (401). 
Overall, across all of the complement proteins investigated no effect of age in AD 
or control groups or in frontal or temporal brain tissue regions was seen. The mean age at 
death of the control group was 78.1 years, and 81.6 years in the AD group. There did not 
appear to be any previous data reporting an effect of ageing in humans on complement 
protein expression in post-mortem human brain tissue.  A study in mice, however, showed 
that C1q level was dramatically increased with age (570). It would be useful to study the 
age effect on C1q brain expression in a younger cohort of controls in addition to more older 
controls to try and get a broader overview of age-related changes. 
No effect of PMI on all complement proteins studied in either frontal or temporal 
cortical tissue was seen. Similarly, no association between complement proteins and 
gender, no difference between males and females was seen. Moreover, there was no 
significant relationship between APOE genotype with the expression of any of the 
complement proteins measured here although it must be acknowledged that the cohort size 
only allows for some indicative exploration of possible trends that much larger samples 
sizes would need to be further tested for to have more confidence in the findings. 
Complement proteins in AD brain are linked to Aβ pathology and may correlate 
with Aβ load. A trend towards a positive correlation was seen between C1q and Aβ load 
which had previously been measured in these AD cases, while a significantly positive 
correlation was observed between Aβ load with C3 in the frontal tissue, which supports a 
possible C1q and C3 binding to Aβ and more classical complement pathway activation in 
the frontal cortex. This is relevant to and consistent with earlier findings that showed high 
colocalization of C1q on Aβ in the frontal cortex (410). Yet, no other correlations was seen 
in temporal cortex homogenates. Moreover, other complement proteins did not correlate 
significantly with Aβ load. One limitation to the present analysis is that Aβ load used for 
correlation is in fact an average of Aβ load measurement in three brain areas, as mentioned 




It was interesting to see the differences in expression of the complement proteins 
according to Braak tangle staging that represent increasing levels of disease severity and is 
associated with tau pathology which correlates with cognitive state. C1q concentration was 
significantly increased with late Braak stages in the frontal cortex (V-VI), but not in the 
temporal cortex. No significant differences were seen between the groups in C3, CFH or 
TCC, while iC3b concentration was significantly increased with the later Braak stages (V-
VI) in the temporal cortex and in both regions for clusterin. Most of the changes seen in 
this study was evident in later Braak stages, more studies are needed to confirm these 
findings especially in earlier Braak stages to find potential biomarkers for AD. 
To the best of my knowledge this is the first study to investigate a range of 
complement proteins in different parts of the complement pathway, involving different 
brain areas in a larger than usual well characterised series of post-mortem confirmed cases. 
Previous studies have generally been limited to few complement markers and/or smaller 
sample size cohorts. 
4.6 Summary and conclusions 
➢ The complement system is dysregulated in post-mortem human brain tissue in 
Alzheimer’s disease. 
➢ No significant differences were seen in complement proteins, between frontal and 
temporal cortex in AD group or age-matched controls. 
➢ Early complement component: C1q was not  significantly different between 
controls and AD in any of brain areas tested, however, in the frontal cortex it was 
positively correlated with disease pathology (increased in late Braak stages). 
➢ C3 was significantly increased in AD of the temporal cortex only, however, it was 
also positively correlated with disease pathology (Aβ load) in the frontal cortex.  
➢ The early complement activation marker iC3b was significantly increased in AD 
homogenates of both the frontal and the temporal cortices. This indicates activation 




positively correlated with disease pathology in the temporal cortex (increased in 
late Braak stages). 
➢ Clusterin, the chaperone protein is significantly increased in AD homogenates of 
both the frontal and the temporal cortices and it is positively correlated with disease 




5. Chapter 5: Complement Genes and their 
Expression in Alzheimer’s Disease. 
5.1 Introduction 
As described in detail in Chapter 4, there is dysregulation in the complement 
cascade, which may cause imbalance that may promote chronic inflammation in AD.   It is 
therefore important to explore the breadth of complement disruption in AD which we next 
sought to do by examining complement gene expression. The study of this in post-mortem 
brains of AD cases was intended to complement that of the protein studies in the previous 
chapter and to help provide a wider understanding of the inflammatory response at the 
mRNA level.  
Quantifying mRNA also gives more information about the possible origin of 
changes seen in protein expression and helps to address the fact that there is not always a 
direct relationship between protein levels and mRNA expression. In post-mortem brain 
tissue, proteins are assumed to be more stable than RNA, the latter often being more 
transient, but by studying both together the intention is to provide additional information 
to the observed differences and to the absence of change in some components of the 
complement cascade in AD. Studies have shown that the correlation between expression 
levels of mRNA and protein are poor, and representing less than half of the explanatory 
power across many studies (571,572). 
There is some evidence to support the involvement of the complement system, 
potentially causative, rather than a consequence, genetic studies. Early GWAS identified 
some of the complement inhibitor encoding genes as potential genetic risk factors for AD. 
These include the Clusterin gene (CLU) which is considered to be one of the most important 
genetic risk factors for LOAD. Moreover, two different polymorphism identified in 
complement receptor 1 (CR1) gene, one of these polymorphisms is in the region believed 
to be the binding site of C1q molecule; the initiator of complement cascade activation 
(23,573). 
Some in vitro studies have demonstrated gene expression for complement proteins 
in microglial cell cultures and from other glial cells  as well as neurons, indicating that 




Given the findings that some complement proteins were altered in AD brain tissue 
(Chapter 4). Therefore, it was interesting to study the key genes encoding for complement 
proteins such as; C1q and C3 and regulators such as CFH, CR1 and CLU which have also 
been implicated in genetic studies for AD, as previously introduced in Section 1.3.2.1. To 
the best of my knowledge, very few studies have been carried so far to investigate the 
expression of complement genes in post-mortem human brain tissue in a quantitative 
manner. Therefore, this set of experiments examines the gene expression using quantitative 
PCR, of the same pivotal components in the complement pathways discussed in Chapter 4.  
Relative gene expression quantification by RT-PCR is considered an accurate and 
sensitive method to detect the differences in target genes in human samples. The 
verification of the quality of the RNA before doing downstream applications such as qPCR 
is important. However to try and minimise differences in RNA quality and/or quantity, 
relative gene expression and normalisation to calibrator genes, that are unaffected generally 
by the disease being studied were suggested to increase the likelihood of obtaining reliable 
and comparable results (575,576). 
For the purposes of standardisation of data, two calibrator genes (GAPDH and β-
ACT) were mainly selected for each target gene investigated (C1qA, C3, CFH and CLU). 
GAPDH and β-ACT are commonly used ubiquitously expressed genes that are expressed 
in many cell types and were appropriate to use here as complement gene expression is 
similarly expected to be seen in all cell types in the brain. The gene for neuron specific 
enolase (NSE) was also tested, to serve as a neuronal specific calibrator gene, to detect 
complement genes changes that might be relevant to neuronal cells. For one target gene 
(CR1) I used ribosomal gene RPL13. However, it was not possible to measure CR1 protein 
levels in AD brain in the previous chapter, we decided to measure CR1 gene expression in 
AD brain as an important complement gene which encodes for transmembrane 
glycoprotein expressed on astroglial cells derived from the brain (447).  
5.2 Study aim 
The aim of the experiments described in this chapter was to measure levels of 
mRNA expression and relative gene expression of a selected set of complement system 




The complement genes mRNA expression measured were those deemed of interest in 
Chapter 4 and included C1qA, C3, CFH and CLU in addition to CR1 gene. 
5.3 Methods 
5.3.1 Cohort description 
This cohort includes clinically and pathologically validated AD cases with LOAD 
diagnosis and age matched controls. Frontal and temporal brain tissue was used, more 
details the PCR cohort is provided below in Table 5-1. 
Table 5-1: Characteristics of the samples used in the PCR cohort. This table shows a comparison 
between the control and AD groups including numbers, age at death and PMI. 
 Control group AD group 
Number 
Frontal 16 Frontal 16 
Temporal 14 Temporal 15 
Age 
Range: 62-95 (years).  
Mean: 77.4 
SD: 11.3 
Range: 69-90 (years).  
Mean: 81.8 
SD: 4.5  
PMI 
Range: 3-55 (hours). 
Mean: 26.2 
SD: 16.2  
Range: 5-72 (hours).  
Mean: 39.2 
SD: 23.2  
5.3.2 qPCR experiments  
The detailed method for real-time polymerase chain reaction (RT-PCR) is provided 
in Section 2.8. In brief, a total RNA extraction was performed, then tested the quality and 
the concentration of RNA by using Agilent bioanalyzer 2100 and Nanodrop. The samples 
where then treated with DNase to eliminate any genomic DNA that may contaminate RNA 
samples and thus give false positive results. Additionally, an equal concentration of RNA 
was used to make cDNA by reverse transcription. Quantitative PCR was then carried out 
for selected genes and calibrator genes.  All samples were tested in triplicate in 384 well 




5.3.3 PCR efficiency experiment  
A pilot study was done to test PCR efficiency in different RNA samples. This 
experiment was done by creating a standard curve (series of 1 in 10 dilutions) from the 
cDNA to test different RNA quality in brain samples. PCR efficiency above 90%, means 
that no inhibitors were present in cDNA samples tested, good primer design and accurate 
sample processing. 
5.3.4 RNA purity 
A clean up experiment was done to RNA samples with 260/230 less than 1.5, 
according to the protocol explained in detail in Section 2.8.6 as measured by Nanodrop and 
assessed by unpaired t-test. All samples used in qPCR experiments had 260/230 and 
260/280 ratios between 1.8 and 2.2. 
5.3.5  Selection of primers for relative quantification 
All qPCR runs were carried out using probes (TaqMan assays on demand) for more 
specificity and selected to be small amplicon. All primers used were not more than 200 
base pairs in size, the range of amplicon sizes was (60 to 93 bp) and designed to span 
introns that will not detect any genomic DNA, all details of the primers listed in Table 2-10. 
5.3.6  Selection of calibrator genes for relative quantification 
Normalization of data to stable calibrator genes is mandatory to help limit errors 
that may occur such as differences in starting material or in RNA quality. Moreover, 
normalization to more than one calibrator gene is deemed good practice as it offers greater 
accuracy than selecting just one. In an initial set of experiments, we chose the most 
commonly used universal calibrator genes (577–579) as GAPDH and β-ACT and the neuron 
specific calibrator gene NSE.  In later experiments, ribosomal protein L13 (RPL13) was 




5.3.7 qPCR for complement genes 
Optimisation experiments were carried out to determine the ideal RNA 
concentrations to be used for reverse transcription and to measure the abundancy of 
expression of the calibrator genes before starting the experiments to measure genes of 
interest. An experiment using samples with different RIN values of RNA quality (highest 
= 8.6, middle = 5 and lowest = 2.6) was performed to assess the effect of RNA degradation 
on PCR efficiency and on the ability to detect gene expression. To perform this, the 
performance of each assay i.e. the PCR efficiency for different RIN values was monitored 
and Ct values were determined for all genes to detect the fold changes of expression of 
genes of interest in AD tissue relative to the expression in control group. 
5.3.8 Statistical analysis 
 The 2-ΔΔCT for relative quantification was used (581) as described in details in 
Section 2.7.11, then the geometric mean for each group was calculated and used to perform 
the statistical tests. Parametric tests i.e. the unpaired t-test was used for normally distributed 
data, and non-parametric tests i.e. Mann-Whitney test was used when data was not normally 
distributed. 
5.4 Results 
5.4.1 qPCR study cohort 
5.4.1.1 Primary analysis of PCR cohort (age at death and PMI)  
The age at death of the control and AD groups are listed in Table 5-1. There was 
no significant difference in age at death between groups (P value = 0.17), as assessed by 
unpaired t-test and shown in Figure 5-1. 
The PMI of the control and AD groups are listed in Table 5-1. There was no 
significant difference in PMI between control and AD groups (P value = 0.15), as assessed 





Figure 5-1: Comparison of age at death (years) and PMI (hours) in control and AD groups of 
PCR cohort. A) Age at death analysis: no significant difference was seen between the groups (P 
value = 0.17). B) PMI analysis: no significant difference was seen between the groups (P value 
0.15). The mean and SD are displayed. 
5.4.1.2 pH measurement in PCR cohort  
As an important factor for the quality of RNA extracted from post-mortem tissue, 
a comparison of pH measurement in control and AD groups was performed. pH 
measurement for 27 tissue sample were available out of 30 brains. No significant difference 
was seen between control (average ± SEM = 6.01 ± 0.07) and AD group (average ± SEM 




















Figure 5-2: Comparison of pH measurement in control and AD groups. No significant 





5.4.2 RNA integrity number RIN values in control and AD  
RNA quality was measured by using the 2100 Agilent bioanalyzer. RIN scoring 
was used to determine RNA integrity (544), RIN values for AD (mean ± SEM = 4.2 ± 0.4) 
were significantly lower than control group (mean ± SEM = 5.46 ± 0.46) in the frontal 
cortex (P value = 0.015). In the temporal cortex RIN values for AD (mean ± SEM = 3.5 ± 
0.31) were also significantly lower than control group (mean ± SEM = 5.9 ± 0.21); P value 
was < 0.0001, as assessed by unpaired t-test. No significant difference was seen in RNA 
quality between two brain areas tested in control group (P value = 0.83), as assessed by 
unpaired t-test, or in AD group by Mann Whitney test (P value = 0.28). 
5.4.3 PCR efficiency experiment  
This experiment was done to test the different RNA quality and its effect on PCR 
efficiency. That was done to different calibrator genes. For instance, GAPDH gene PCR 
efficiency was performed in a sample with RIN value = 7.2 and a sample with RIN value 
2.6, and it was (91.41% & 93.31%) respectively. 
5.4.4 RNA purity (clean-up experiment) 
A clean up experiment produced a significant improvement (P value < 0.0001) in 
the 260/230 ratio of RNA samples measured by Nanodrop as assessed by the unpaired t-

















Figure 5-3: Readings of RNA 260/230 by Nanodrop before and after the clean-up experiment. 




5.4.5 Expression of calibrator genes in control and AD 
Several calibrator genes were explored as part of this set of experiments. The Ct 
values of GAPDH, β-ACT, RPL13 and NSE were examined to assess which might be 
suitable to use and were analysed by comparison between control and AD in the frontal 
and temporal cortices.  
GAPDH Ct values were not significantly different between the AD and control 
groups in the frontal cortex (P value = 0.054), as assessed by unpaired t- test. A similar 
finding was evident for the temporal cortex (P value = 0.11), as assessed by Mann Whitney 
test. β-ACT Ct values were significantly different between AD and controls in the frontal 
cortex only (P value = 0.02), as assessed by Mann Whitney test. In contrast no significant 
difference was seen in the temporal cortex (P value = 0.67), as assessed by unpaired t-test. 
GAPDH was more stable than β-ACT. The latter was then excluded from the 
second set of experiments, in which (RPL13) gene was selected and used based on a recent 
study on assessing calibrator genes expression in AD (580). RPL13 gene encodes for the 
60S subunit of the ribosome and was shown to be stable as Ct values were not significantly 
different in AD group compared to control in the frontal or temporal cortex (P value = 0.12 
& 0.07) respectively, as assessed by unpaired t-test. 
NSE Ct values were significantly higher in the AD group compared to controls in 
the frontal cortex (P value = 0.004), as assessed by Mann Whitney test. Values were also 
significantly higher in the temporal cortex in AD (P value = 0.002), as assessed by unpaired 
t- test.  Although the original plan was to investigate complement genes expression relative 
to neuronal cells, NSE did not fulfil the requirements needed to serve as a calibrator gene 
and was excluded from the analysis due to the significant differences seen between control 
and AD. We also tested the use of the hypoxanthine phosphoribosyl transferase 1 gene 
(HPRT1), been proposed as another useful calibrator gene but its expression was too low 
to be used as a calibrator gene (late Ct values).  
5.4.6 Expression of complement mRNA in control and AD 
First, relative gene expression of C1qA, C3, CFH and CLU was measured. 




mean of both in the first set of experiments done. Later, more RNA was extracted from the 
tissue to measure another complement gene (CR1). CR1 gene expression was calibrated 
against GAPDH and RPL13 and to the geometric mean of both. The selection of RPL13 
was based on the possibility of being more stable than commonly used genes such as β-
ACT which was not the ideal calibrator gene in the previous set of experiments. The fold 
difference relative to control tissue was calculated and normalized to calibrator genes. The 
individual sample 2-ΔΔCT values were used to perform statistical tests. 
5.4.6.1 Expression of C1qA mRNA in control and AD 
C1qA mRNA expression was assessed by RT-PCR by using RNA extracted from 
the frontal and temporal cortices from AD cases and controls and calibrated against 
GAPDH and β-ACT expression.  
Frontal cortex 
No significant difference was seen in AD compared to control in C1qA mRNA 
expression in the frontal cortex relative to GAPDH (~1.8 -fold, P value = 0.17), or to β-
ACT (~1.6-fold, P value = 0.18). C1qA had significantly higher expression relative to the 
geometric mean of calibrator genes (~1.8-fold, P value = 0.04), as assessed by unpaired t-
test.  
Temporal cortex 
In contrast to the frontal cortex, a significant higher level of C1qA mRNA 
expression was seen in AD compared to control in the temporal cortex relative to GAPDH 
(~2-fold, P value = 0.03). In contrast there was no significant difference between the groups 
relative to β-ACT (~1.1-fold, P value = 0.79), or to the geometric mean of calibrator genes 





Figure 5-4: C1qA relative gene expression in frontal and temporal cortices to A) GAPDH 
calibrator gene: no significant difference was seen in AD compared to control in the frontal cortex 
(P value = 0.17). A significant increase was seen in the temporal cortex (*P value = 0.03). B) β-ACT 
calibrator gene: no significant difference was seen in AD compared to control in the frontal or the 
temporal cortex (P value = 0.18 & 0.79), respectively. The geometric mean and 95% confidence 
interval of the 2-ΔΔCT values are shown on the logarithmic scale (to the base 2). 
5.4.6.2 Expression of C3 mRNA in control and AD 
C3 mRNA expression was assessed by RT-PCR by using RNA extracted from the 
frontal and temporal cortices from AD cases and controls and using GAPDH and β-ACT as 
calibrator genes.  
Frontal cortex 
Significantly higher levels of C3 mRNA expression was seen in AD compared to 
control in the frontal cortex relative to GAPDH (~2.4 -fold, P value = 0.01). However, there 
was no significant difference between the groups relative to β-ACT mRNA (~1.7-fold, P 
value = 0.3). Similarly, there was no significant difference between C3 expression and the 
geometric mean of the calibrator genes (~2.0-fold, P value = 0.057), as assessed by 
unpaired t-test.  
Temporal cortex 
A significantly higher level of C3 mRNA expression was also seen in the temporal 
cortex, in AD compared to controls, relative to GAPDH (~2.7-fold, P value = 0.003). There 




P value = 0.8) and neither was there any difference (as assessed by unpaired t-test) with the 
geometric means of calibrator genes (~1.8-fold, P value = 0.1). 
 
Figure 5-5: C3 relative gene expression in the frontal and temporal cortices to A) GAPDH 
calibrator gene: a significant higher expression was seen in AD compared to control in the frontal 
and the temporal cortices (*P value = 0.01 & 0.003) respectively. B) β-ACT calibrator gene: no 
significant difference was seen between the groups in the frontal or the temporal cortex (P value = 
0.33 & 0.8) respectively. The geometric mean and 95% confidence interval of the 2-ΔΔCT values are 
shown on the logarithmic scale (to the base 2). 
5.4.6.3 Expression of CFH mRNA in control and AD 
CFH mRNA expression was assessed by RT-PCR by using RNA extracted from 
the frontal and temporal cortices from AD cases and control and calibrated against the 
expression of GAPDH and β-ACT.  
Frontal cortex 
No significant differences were seen in CFH mRNA expression between groups in 
the frontal cortex relative to GAPDH (~1.9-fold, P value = 0.058), or β-ACT (~1.4-fold, P 
value = 0.56), or to the geometric mean of calibrator genes (~1.6-fold, P value = 0.2), as 
assessed by unpaired t-test.  
Temporal cortex 
Similarly, no significant differences were seen between the two diagnostic groups 




(~1.2 -fold, P value = 0.8), or β-ACT (~0.61 -fold, P value = 0.38), or to the geometric mean 
of calibrator genes (~0.75-fold, P value = 0.54), as assessed by unpaired t-test.  
 
Figure 5-6: CFH relative gene expression in frontal and temporal cortices to A) GAPDH 
calibrator gene: no significant difference was seen in AD compared to control in the frontal or the 
temporal cortex (P value = 0.058 & 0.8) respectively. B) β-ACT calibrator gene: no significant 
difference was seen between the groups in the frontal or the temporal cortex (P value = 0.56 & 0.38) 
respectively. The geometric mean and 95% confidence interval of the 2-ΔΔCT values are shown on 
the logarithmic scale (to the base 2). 
5.4.6.4 Expression of CLU mRNA in control and AD 
CLU mRNA expression was assessed as with the others by RT-PCR by using RNA 
extracted from the frontal and temporal cortices from AD cases and controls and calibrated 
against GAPDH and β-ACT expression.   
Frontal cortex 
A significantly higher level of CLU mRNA expression was seen in AD compared 
to control in the frontal cortex relative to GAPDH (~2.5-fold, P value = 0.005) whilst there 
was a borderline significant difference relative to β-ACT (~2.6-fold, P value = 0.055). 
Moreover, CLU mRNA expression was significantly higher in AD (~2.5-fold, P value = 
0.005) using the geometric mean of calibrator genes, as assessed by unpaired t-test.  
Temporal cortex 
No significant difference was seen between the comparator groups in terms of CLU 




= 0.3), as assessed by unpaired t-test. Similarly, there was no difference, relative to β-ACT 
(~0.7 -fold, P value = 0.9), as assessed by Mann- Whitney test, nor was there a difference 
relative to the geometric mean of calibrator genes (~0.9-fold, P value = 0.9), as assessed 
by unpaired t-test. 
 
Figure 5-7: CLU relative gene expression in frontal and temporal cortices to A) GAPDH 
calibrator gene: a significant higher expression was seen in AD compared to control in the frontal 
cortex (*P value = 0.005), while no significant difference was seen between the groups in the 
temporal cortex (P value = 0.3). B) β-ACT calibrator gene: no significant difference was seen 
between the groups in the frontal or the temporal cortex (P value = 0.055 & 0.9) respectively. The 
geometric mean and 95% confidence interval of the 2-ΔΔCT values are shown on the logarithmic scale 
(to the base 2). 
5.4.6.5 Expression of CR1 mRNA in control and AD 
CR1 mRNA expression was assessed by RT-PCR by using RNA extracted from 
the frontal and temporal cortices from AD cases and controls, but this time was calibrated 
against GAPDH and RPL13 gene expression.  
Frontal cortex 
No significant differences were seen in CR1 mRNA expression between the 
diagnostic groups in the frontal cortex relative to GAPDH (~1.9-fold, P value = 0.08) or 
relative to RPL13 (~1.05-fold, P value = 0.87). Similarly, there was no difference relative 
to the geometric mean of calibrator genes (~1.4-fold, P value = 0.33), as assessed by 





A significantly higher level of CR1 mRNA expression was seen in AD group in 
the temporal cortex samples relative to GAPDH (~2.4 -fold, P value = 0.02). In contrast no 
significant difference was seen between the groups relative to RPL13 (~1.3-fold, P value = 
0.36), nor to the geometric mean of calibrator genes (~1.77-fold, P value = 0.06), as 
assessed by unpaired t-test.  
 
Figure 5-8: CR1 relative gene expression in frontal and temporal cortices to A) GAPDH 
calibrator gene: No significant difference was seen in AD compared to the frontal cortex (P value 
= 0.08). a significant higher expression was seen in the temporal cortex (*P value = 0.02). B) RPL13 
calibrator gene: no significant difference was seen between the groups in the frontal or the temporal 
cortex (P value = 0.88 & 0.36) respectively. The geometric mean and 95% confidence interval of 
the 2-ΔΔCT values are shown on the logarithmic scale (to the base 2). 
5.4.6.6 Correlation between CR1 mRNA expression and C1QA 
mRNA expression 
It was interesting to examine the association of CR1 and C1q as CR1 receptor binds 
to C1q (23,573). C1qA gene was found to have a significant positive relationship with CR1 
gene expression relative to the GAPDH calibrator in the frontal cortex (P value 0.001 and 
Pearson’s r = 0.56). No significant correlation was seen in the temporal cortex (P value 
0.12 and Pearson’s r = 0.34), however, a significant positive correlation was seen in 
controls from the temporal cortex (P value = 0.006 and Pearson’s r = 0.79) when the cohort 
was analysed separately according to diagnosis, but not in AD group of the temporal cortex 




Table 5-2: Summary table for the complement genes studied by qPCR. This table shows a 
summary for results of complement genes (C1qA, C3, CFH, CLU and CR1) tested by the unpaired 
t-test or Mann-Whitney test, when appropriate. 
















GAPDH 1.79 ± 0.88 0.17 GAPDH 1.96 ± 0.44 0.028* 
Β-ACT 1.65 ± 0.78 0.18 Β-ACT 1.0 ± 1.05 0.79 
C3 
GAPDH 2.42 ± 1.4 0.01* GAPDH 2.73 ± 1.14 0.003** 
Β-ACT 1.68 ± 1.16 0.33 Β-ACT 1.2 ± 1.0 0.8 
CFH 
GAPDH 1.9 ± 0.66 0.058 GAPDH 1.15 ± 0.23 0.78 
Β-ACT 1.37 ± 0.95 0.56 Β-ACT 0.6 ± 0.7 0.39 
CLU 
GAPDH 2.5 ± 0.7 0.005** GAPDH 1.3 ± 0.3 0.3 
Β-ACT 2.6 ± 1.7 0.055 Β-ACT 0.68 ± 1.09 0.9 
CR1 
GAPDH 1.95 ± 1.28 0.078 GAPDH 2.38 ± 0.5 0.021* 
RPL13 1.05 ± 0.18 0.78 RPL13 1.33 ± 0.2 0.365 
 
5.5 Discussion 
Studying gene expression by measuring the levels of mRNA in post-mortem brain 
tissue gives additional information about the possible origin of any observed changes seen 
in proteins expression, i.e. it is indicative of levels of protein production. However, levels 
of protein may also be subject to protein degradation or metabolism. Therefore, there is not 
necessarily a direct relationship between levels of gene expression and observed levels of 
protein but when they correlate it can point to closer regulation of protein levels at the level 
of the gene and give further insights as to the extent of cellular activity in disease and in 
relation to the gene of interest. 
Complement proteins are thought to be expressed locally in the brain (e.g. in situ 
hybridization studies (366). Such expression has been observed in several cell types 
including glial cells: i.e. microglia and astrocytes and neurons (360). To my knowledge, 
few studies have previously investigated quantitatively the levels of complement gene 




done using semiquantitative methods such as RNA gel blots and nonradioactive in situ 
hybridization (563,564,582). RT-PCR was used as an accurate and specific quantitative 
method for the measurement of gene transcription levels. Advantage of PCR over northern 
blot: RT-qPCR having the capacity to measure gene expression levels with a very wide 
linear dynamic range of quantification. Nevertheless, it is not feasible to directly compare 
the results of semiquantitative methods in other studies to the relative gene expression by 
RT-PCR as carried out in this study. 
The cohort of samples used in this study were age matched for controls and AD 
with no significant difference between the groups. PMI was also matched for controls and 
AD, with no significant difference between the groups. In Chapter 4, we demonstrated that 
complement protein expression was dysregulated in brain lysates of AD. In this set of 
experiments, mRNA expression of some of the corresponding complement genes was 
measured in AD brain compared to age matched controls. In this study, RNA extracted 
from brain tissue was variable in quality.  
RT-PCR usually analyses shorter regions of RNA and is therefore slightly more 
tolerant to partially degraded RNA, the yield and the purity of RNA sample may also have 
an effect on the results as well as the degradation of RNA. Therefore, pilot studies were 
done to test different RNA quality samples, cleaning up of RNA samples to improve 
260/230. Moreover, TaqMan primers were selected with small amplicon size to ensure 
accurate results. The samples were tested in triplicates and to avoid any pipetting errors, an 
electronic pipette was used to load samples and reagents in 384 wells plate to avoid 
variability between the plates. Further to this, I calculated PCR efficiency in the least and 
most highly degraded RNA samples and there was no difference seen. 
The relative quantification of genes of interests was carried out to minimise the 
impact of technical variations mentioned above. For this, universal calibrator genes 
GAPDH and B-ACT were used in the first set of experiments, while GAPDH and RPL13 
used for one marker. The calibrator gene stability was checked between the groups in PCR 
cohort and NSE was excluded for this reason. GAPDH did not differ significantly between 
the groups in the frontal or the temporal cortex, β-ACT was not stable in the frontal cortex 
but did not differ significantly in the temporal cortex. B-ACT was also excluded from the 
later set of experiments and replaced with RPL13 in CR1 experiments which was not 




It is challenging to find a stable and highly expressed calibrator gene, especially 
one that is not affected by the pathology of the disease under study and which is 
ubiquitously expressed. Even genes used as calibrators in other studies and tissues, despite 
being used regularly may not necessarily be always appropriate in all disease contexts. 
Moreover, in AD in particular, there can be a complex situation, particularly if a marker is 
expressed in several cell types, whereby the complex neuropathology may affect different 
cell types in opposing ways e.g. loss of neuronal cells concomitantly relative increases of 
some forms of non-neuronal cells such as activated astrocytes and microglia.  
The use of the neuronally expressed gene NSE as a calibrator gene was initially 
considered, but which was found to be significantly reduced in AD and thus not appropriate 
for calibration. In line with expectation, this study showed downregulation in NSE 
expression in the temporal cortex (when calibrated to GAPDH and to β-ACT) in AD 
compared with control in the temporal cortex. Indeed, since NSE is a marker of neurons 
and that the temporal cortex is one of the earliest brain regions affected by AD pathology, 
it may explain the observed the reductions of NSE in the temporal cortex. 
In the current study of complement genes, C1qA gene expression was upregulated 
significantly in the temporal cortex relative to GAPDH but not in the frontal cortex. This 
contrasts with a previous study that investigated C1q and C3 mRNA expression in six AD 
cases from the frontal cortex and reported that C1q was significantly upregulated relative 
to 28S rRNA in six AD patients compared to six controls as determined by semiquantitative 
northern blot analysis. The same study found no change in C3 gene expression (582). In 
this study, in addition to the observed change in C1qA in the temporal lobe, C3 gene 
expression was significantly upregulated in AD compared to control, relative to GAPDH 
in the frontal and temporal cortices. The differences between this findings and that of 
Fischer et al. may likely relate to the different methods used and where arguably the use of 
qPCR gives a more accurate quantitative measure. Moreover, the cohort sizes were 
different. Larger cohort was used in this study, thereby offering more statistical power. 
Another earlier study also assessed relative expression of C3 and C4 genes in just 
four control and six AD brains and which were calibrated against cyclophilin. In that study 
both genes were found to be significantly upregulated in the AD tissue that was taken from 
the temporal cortex. RNA samples extracted from human brain and blood monocytes were 
tested where it was suggested that very low expression detected in mononuclear cells 
purified from peripheral blood may have originated from or been caused by changes in 




In the previous chapter, C3 protein was measured by ELISA and was significantly 
higher levels in AD in the temporal cortex (P = 0.025). This is consistent with the observed 
increases in C3 gene expression and points to the fact that the rises in C3 might be tightly 
regulated at a gene level. In this study of CFH gene expression, there was no (even though 
it was borderline) significant increases in CFH transcription in the frontal cortex relative 
to GAPDH (P value 0.058). This agrees with  a previous study where no difference was 
seen in CFH mRNA in a cohort of nine controls and six AD cases from the frontal cortex 
(423). It is worth noting that iC3b is an activation product that is produced from the action 
of CFH with CFI and is not regulated by a specific gene that I can measure by RT-PCR. 
The same is applied to TCC which is a complex of multiple proteins (C5b, C6, C7, C8 and 
C9). 
CLU gene expression was found to be significantly upregulated in the frontal 
cortex in AD compared to control relative to GAPDH. Although there was a suggestion of 
similarly higher expression relative to β-ACT, this elevation did not reach the statistical 
significance (P value 0.055). These findings differ to those of a previous study involving 
20 AD brains and 19 controls (435). In that study CLU expression was found to be 
unchanged when calibrated against GAPDH but was significantly upregulated in the frontal 
and temporal cortices when calibrated against NSE. Yet, as mentioned, I excluded NSE due 
to its lack of suitability as a calibrator gene and so further studies are needed to re-assess 
how CLU expression might change in AD. 
Clusterin protein was significantly increased in AD tissue from frontal and 
temporal cortices, as shown in Chapter 4 (Section 4.4.6). This shows how clusterin protein 
levels appear to be more widely altered in AD than would otherwise be seen if just CLU 
gene expression had been studied alone. This discrepancy might be explained by the idea 
that the protein levels are better maintained than RNA in post-mortem tissue. Even though 
there is not a direct reflection of the changes to protein levels of clusterin in terms of gene 
expression. 
In terms of CR1 gene expression, it was upregulated but not significantly in the 
frontal cortex of AD tissue compared to that in controls, but which was significantly 
upregulated in the temporal cortex (P value 0.021), C1qA gene expression was also 
upregulated significantly in the temporal cortex. These changes pose and interesting 
question noting prior reports that CR1 polymorphism is a risk factor for LOAD (573) and 
that the variants might involve or affect the binding site of C1q to CR1 (443). Therefore, it 




correlation was seen in the frontal cortex, however, this was not evident in the temporal 
cortex when all cases and controls were examined together but only a positive correlation 
was found in controls and no such correlation was found for the AD group when analysed 
separately. This might suggest that only under control conditions the expression of these 
genes work more closely together than they do in AD which need some further examination 
in the future. 
This study involves one of the larger sample sizes to date and includes what could 
be argued to be a more sensitive and accurate method for the quantitative measurement of 
gene expression. It is therefore difficult to compare these results because of the different 
techniques and different sized cohorts studied. Further studies would be beneficial to 
confirm this findings, several of which are consistent with the direction of some changes 
observed in levels of the corresponding proteins from these genes. There were still some 
inconsistencies between brain regions and between the levels of expression between 
different calibrator genes used. This does bring to mind the issue as the limitations that 
qPCR of brain tissue has, with several cell types likely to be represented in any tissue 
homogenate. 
5.6 Summary and conclusion 
➢ The complement cascade genes encoding for the main proteins (C1qA and C3) and 
regulators (CFH, CLU and CR1) are expressed in different regions of post-mortem 
human brain tissue in AD and age-matched controls. 
➢ Two calibrator genes; GAPDH and RPL13 genes were not significantly different 
between AD and controls in the frontal and the temporal cortex. 
➢ NSE gene expression was downregulated in the frontal and the temporal cortices, 
therefore, it was not suitable to be used as an internal calibrator to study 
complement genes expression relative to the neuronal loss. 
➢ Β-ACT gene was significantly different in AD compared to controls in the frontal 
cortex, but its expression was stable in the temporal cortex.  
➢ C3 and CLU genes were upregulated in the AD brain of the frontal cortex compared 




➢ C1qA, C3 and CR1 genes were upregulated in the AD brain of the temporal cortex 
compared to age-matched controls. 
➢ A significant positive correlation was seen between CR1 and C1qA gene 







6. Chapter 6: Astrocyte Activation in 
Alzheimer’s Disease. 
6.1 Introduction 
Glial cells, including microglia and astrocytes, are fundamental in maintaining the 
defence mechanisms in the brain and are considered important contributors in chronic 
neuroinflammation (327). Upon exposure to a pathological condition; such as in chronic 
neurodegenerative diseases including AD, astrocytes become reactive (583), change their 
morphology and switch to a hypertrophic form that overexpresses GFAP (310).  
Astrocytes perform different functions in the human brain such as maintaining the 
structural integrity and homeostasis of the brain, which is an important part of the neuro-
vascular unit that maintains the function and integrity of the BBB. Astrocytes are essential 
for synaptic function, and they secrete neurotransmitters, neuromodulators and cytokines 
(316) (see Section 1.3.1.2) as well as help to regulate the blood flow in the brain (304). 
There is an ongoing need to better understand the role of astrocytes in AD 
pathogenesis, where their contribution is likely to be very complex. They are thought to be 
early responders to pathological changes before the significant neurodegeneration and 
cognitive decline has occurred. In AD, they can change morphology and their main 
function that can change between being neuroprotective or destructive, either by helping in 
Aβ degradation or promoting its production respectively (327,584). 
When over production of more aggregative forms of Aβ starts in AD, this 
eventually leads to deposition and subsequent amyloid plaque formation. 
Hyperphosphorylated tau pathology also occurs and is proposed to be a secondary event  
as a result of the aberrant Aβ pathology, which in turn leads to neuronal cell injury (20). 
The longer and more toxic Aβ peptide (Aβ42) accumulation has been found to stimulate 
glial cell activation (237), with both microglia and astrocytes contributing to Aβ clearance 
(73,238,585).  
There is evidence that astrocytes colocalize with senile plaques and react to Aβ 




the appearance of dystrophic neurites (587). Astrocytes also have been reported to respond 
to the presence of neurofibrillary tangles in order to clear them (150).  
"Astrogliosis" is  described as a hypertrophic state of astrocytes in the CNS 
(583,588). This includes an increase in the number and size and in the expression of GFAP, 
the marker of activated astrocytes and glial scar formation (292,293,589). 
GFAP is highly expressed in the brain and is a unique structural protein also called 
intermediate filament protein III (IF). It is expressed by mature astrocytes and ependymal 
cells (339) in the CNS, promoted by pro-inflammatory mediators such as Interleukin 6 (IL-
6) (590), and bacterial toxin lipopolysaccharides (LPS) (591). GFAP is responsible for the 
cytoskeletal structural support of glial cells; when astrocytes are activated, they are 
thickened and show elongated processes. GFAP is found only in the main branches of the 
astrocyte, therefore it is considered to be the main protein maintaining this structure (340). 
GFAP has been found to be increased in aged animal models, in brain injury, and 
in situations involving oxidative stress (592). It has been shown to be increased in AD brain 
tissue (295,346) as well as in CSF from AD patients but the latter was not correlated with 
the disease progression (344,345). It is known that a mild degree of gliosis is beneficial, 
while excessive gliosis when it occurs, negatively affects brain structural and functional 
recovery (593). In AD pathology, the levels of GFAP expression reported have been found 
to be inversly related to cognitive function (594). 
Given the importance of glial cells in AD pathogenesis and its progression, and in 
turn the role of the complement system in activation and control of glial cells, there is a 
complex relationship that needs further investigation and better understanding. There is 
already evidence of cross talk between glial cells and the complement system; reactive glial 
cells are a major source of complement component, whilst astrocytes and microglia are the 
primary source of C3 and C3aR, respectively (422). Recently it was shown in the brain 
tissue of a mouse model of AD, that there were interactions between astrocytes and 
microglia via the complement system, whereby GFAP positive cells and C3 complement 
factor were found in response to chronic Aβ deposition (376). 
In another recent study, researchers isolated astrocyte-derived exosomes from 




different complement components from C1q to terminal pathway components in AD 
patients (595). It is therefore important to investigate GFAP expression as a marker of 
mature astrocytes in post-mortem human brain tissue, not only to understand the 
involvement of astrocytes in AD pathology but also to explore its interaction with other 
neuroinflammatory aspects, such as the complement system.  
6.2 Study aim 
The aim of the experiments described in this chapter was to study GFAP in AD 
brain tissue and in relation to AD-associated pathology. This was done by IHC, quantitative 
analysis for GFAP protein using sandwich ELISA to measure the levels of GFAP protein 
in AD and age-matched controls in homogenized post-mortem brain tissue (frontal and 
temporal cortices). Another aim to measure GFAP gene expression by qPCR. 
Another aim of the study was the correlation of GFAP levels with AD pathological 
changes (Braak staging and Aβ load; using data that was previously measured by 
colleagues as a part of separate studies and as have been described in previous chapters). 
Further to this, the relationship between GFAP levels with other cohort variables such as 
age, gender, PMI and APOE genotypes was explored. A further aim was to explore the 
relationship between GFAP measurements and those of the complement proteins measured 
in Chapter 4 (C1q, C3, CFH, iC3b, clusterin and TCC) to explore the relationship between 
astrocyte activation and complement activation. 
6.3 Methods 
6.3.1 Immuno-peroxidase staining for GFAP in AD tissue 
Sections 7 μm in thickness were cut from paraffin-embedded blocks of the frontal 
cortex and stained with mouse monoclonal antibody against human GFAP (R&D systems), 





6.3.2 GFAP protein expression in human brain tissue  
6.3.2.1 Protein study cohort 
The details of the cohort used to measure GFAP by ELISA is the same as that used 
in the previous chapters and described in Table 3-1. Homogenized brain samples were 
obtained as described before in Section 2.2.3 from BA 8/9 frontal cortex and BA 21/22 
temporal cortex from clinically and pathologically validated AD cases with LOAD 
diagnosis (33 cases) and age matched controls (31 subjects). 
AD and control brain homogenates used were age-matched (control group mean ± 
SEM = 78.16 ± 1.98; AD group mean ± SEM = 81.64 ± 1.10) and PMI matched (control 
group mean ± SEM = 43.2 ± 5.25; AD group mean ± SEM = 49.8 ± 4.91). 
6.3.2.2 GFAP measurement by sandwich ELISA 
 GFAP protein level was measured in SDS homogenates, by sandwich ELISA 
using a protocol detailed in Section 2.5.2 and using a GFAP antibody pair kit (R&D 
systems). Following manufacturer's instructions, brain homogenates were diluted 1 in 20 
and tested in duplicate. Results were calculated from a seven-point standard curve and 
adjusted to total protein concentration in the homogenate. 
Results were first tested for normality by the Kolmogorov-Smirnov one-sample 
test.  For normally distributed data, the unpaired t-test was used and where data were not 
normally distributed, a non-parametric test (Mann-Whitney test) was used for analysis. 
Results were analysed statistically using Prism GraphPad version 6; linear correlations 
were assessed by using Pearson's correlation if normally distributed data or Spearman’s 
test if not. Comparison of groups was tested by one-way analysis of variance (ANOVA) 
followed by Tukey’s post-hoc test if normally distributed data or if not, Kruskal-Wallis test 
followed by post-hoc Dunn’s multiple comparison test. Statistical significance was defined 




6.3.3 GFAP gene expression in human brain tissue 
A total RNA extraction from brain tissue was performed, tested the quality and the 
concentration of RNA by using Agilent bioanalyzer 2100 and Nanodrop. Samples were 
then treated with DNase to eliminate any genomic DNA that may contaminate RNA 
samples giving false positive results. Then, an equal concentration of RNA was used to 
obtain cDNA by reverse transcription. Quantitative PCR for GFAP gene and calibrator 
genes (GAPDH and RPL13) was then carried out. All samples were tested in triplicate in 
384 wells plates to minimize variations between plates. 
6.3.3.1 qPCR study cohort 
The details of the PCR cohort used to measure GFAP mRNA expression is the 
same as that previously described in Table 5-1.  
6.3.3.2 Selection of primers for relative quantification 
RT-PCR was carried out using a hydrolysis probe for GFAP (TaqMan assays on 
demand), designed to span exon junctions and so that do not detect any genomic DNA. 
Details of the primer sequence is listed in (Table 2-8). 
6.3.3.3 Selection of calibrator genes for relative quantification 
As previously discussed in detail in the previous chapter, GAPDH and RPL13 were 
used as calibrator genes for relative GFAP gene expression.  
6.3.3.4 qPCR 
The detailed method for qPCR is outlined in Section 2.8. Ct values were 
determined to detect the fold change of expression of genes of interest in the AD tissue 




6.3.3.5 Statistical analysis 
The 2-ΔΔCT for relative quantification was used (581) as described in detail in 
Section 2.8.11, then the geometric mean for the control and AD groups were calculated and 
used to perform the statistical tests. A parametric test i.e. the unpaired t-test was used for 
normally distributed data, and a non-parametric test i.e. Mann-Whitney test was used when 
data were not normally distributed. 
6.4 Results 
6.4.1 Immunohistochemistry for GFAP 
Immunohistochemical staining was performed to visualise the location of the 
antibody to be used in the protein measurement assays. Frontal brain sections were stained 
with mouse monoclonal antibody against human GFAP (3μg/ml). As is evidence in Figure 
6-1, GFAP+ reactive astrocytes were evident in comparison to the negative control (no 
primary antibody) only secondary antibody.  
 
Figure 6-1: Illustrative GFAP immunohistochemical staining for astrocytes with anti GFAP 
mouse monoclonal antibody. A) Frontal sections: AD brain tissue showing astrocytes stained by 
mouse monoclonal antibody against human GFAP. B) Negative control section: secondary 




6.4.2 GFAP protein expression in AD brain tissue 
6.4.2.1 Comparison of GFAP expression between AD cases and 
controls 
On study of the frontal cortex, there was no significant increase found (P value = 
0.44) in GFAP concentration (ng/mg total protein) between controls (mean ± SEM = 282.4 
± 29.2) and AD (mean ± SEM = 296.9 ± 24.3). In contrast, there was a significant increase 
in AD tissue (mean ± SEM = 398.5 ± 34.8) compared to controls (mean ± SEM = 255.9 ± 
25.8) (P value = 0.002) in the temporal cortex (Figure 6-2). 
On comparing regions amongst the same diagnostic groups, no significant 
difference was seen between frontal and temporal cortex in the control group (P value = 
0.46).  In contrast to the controls, there was a significant increase in GFAP concentration 
in temporal tissue compared to the frontal in the AD group (P value = 0.019), as assessed 
by unpaired t-test. 
 
Figure 6-2: GFAP protein levels in human brain tissue (ng/mg total protein). A) Frontal 
cortex: no significant difference was seen between control and AD groups Mann-Whitney test (P 
value = 0.44) B) Temporal cortex: a significant increase was seen in AD tissue Mann-Whitney test 
(**P value = 0.002). 
6.4.2.2 Relationship between GFAP protein level, age at death, and 
gender 
Several factors are relevant in AD that might also have some bearing on levels of 




group ranged from 43 to 95 years (mean 78.1, SD 11), and the AD group ranged from 69 
to 96 years (mean 81.6, SD 6.3).  
Age did not correlate significantly with GFAP concentration in any of the cohort 
groups when analyzed by Pearson’s correlation test separately or when control and AD 
were combined (P value = 0.22, Pearson’s r = -0.03) in the frontal homogenates, or in the 
temporal homogenates when analyzed by Spearman’s correlation test (P value = 0.78, 
Spearman’s r = 0.15) (Figure 6-3). 
 In the temporal cortex, only the AD group showed a significant negative 
correlation between age at death and GFAP concentration (P value = 0.009, Pearson’s r = 
-0.44). Summary statistics for these data are also presented in Appendix II, Table 9-3. 
 
Figure 6-3: Correlation plots of GFAP concentration (ng/mg total protein) with age at death 
(years) in A) Frontal cortex: no significant correlation was seen (P value = 0.22, Pearson’s r = -
0.03). B) Temporal cortex: no significant correlation was seen (P value = 0.78, Spearman’s r = 
0.15). The continuous line represents the best fit of the linear regression and the dashed lines 
represent 95% confidence interval (CI) of the regression line. 
GFAP concentrations were compared according to gender in the control group: 
males (n = 19) and females (n = 12) and the AD group: males (n = 10) and females (n = 
23). No significant difference between different groups was seen in the frontal cortex when 
analyzed by Kruskal-Wallis test (P value = 0.15), while in the temporal cortex, there was a 
significant difference between the groups when analyzed by Kruskal-Wallis test (P value 
= 0.007), and post-hoc Dunn’s test for multiple comparison showed a significant higher 
GFAP levels in females in AD group compared to males in control group (Figure 6-4). 





Figure 6-4: Concentration of GFAP ng/mg total protein in males versus females. A) frontal 
cortex: no significant difference was seen between groups (P value = 0.15). B) Temporal cortex: 
a significant difference was seen between groups (**P value = 0.007), post-hoc test showed a 
significant difference between males in control group and females in AD group. 
6.4.2.3 Relationship between GFAP levels and PMI  
Examination of GFAP levels in relation to post-mortem interval was also assessed 
for both control and AD groups to explore if there might be issue with stability of the 
protein post-mortem. The PMI of the control group ranged from 3 to 106 hours (mean 43.2, 
SD 29.2), and the AD group ranged from 5 to 99 hours (mean 49.8, SD 28.2) and there was 
no significant difference between groups (p value = 0.34), as shown previously in Chapter 
3 (Section 3.4.1).  
A significant negative correlation was seen in the control group (P value = 0.02 & 
0.003) and Pearson’s r was ( -0.4 & -0.5) with PMI, in frontal and temporal cortex 
respectively, and in the AD group (P value = 0.048 & 0.006) with PMI, and Pearson's r (-
0.34 & -0.47), in frontal and temporal cortex, respectively. 
A significant negative correlation was also seen when the control and AD groups 
were combined to provide extra statistical power; as shown in Figure 6-5, for the frontal (P 
value = 0.007 & r = -0.33), as assessed by Pearson’s test and in the temporal cortex (P value 





Figure 6-5: Correlation plots of GFAP levels (ng/mg total protein) with PMI (hours) in A) 
Frontal cortex: a significant negative correlation with PMI (*P value = 0.007, Pearson’s r = -0.33). 
B) Temporal cortex: a significant negative correlation with PMI (*P value = 0.0005, Spearman’s r 
= -0.43). The continuous line represents the best fit of the linear regression and the dashed lines 
represent 95% confidence interval (CI) of the regression line. 
Post-mortem simulation study 
Given that there was evidence that the levels of protein were decreased over time 
due to post-mortem interval, pointing to protein degradation. To explore this further 
another experiment was done using a simulated post-mortem experiment where GFAP 
protein was measured in an AD case which was experimentally simulated for post-mortem 
delay involving several time points for up to 72 hours; as described in Section 2.2.4. Using 
Pearson’s test, a non-significant negative trend towards correlation was seen (P value = 
0.06, Pearson’s r = -0.72), as shown in Figure 6-6. 
 
Figure 6-6: Correlation plot of GFAP levels (ng/ml) with PMI (hours) in simulated AD brain 
for post-mortem delay. A negative correlation was seen but did not reach statistical significance (P 
value = 0.06, Pearson’s r = -0.72), RT; room temperature. The continuous line represents the best 
fit of the linear regression and the dashed lines represent 95% confidence interval (CI) of the 
regression line. 
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6.4.2.4 Relationship between GFAP level and AD pathology  
Aβ load 
Parenchymal Aβ load was available from the MRC and SWDBB database for 32 
of the 33 cases in the AD group. Correlation of GFAP levels with Aβ load was explored. 
No significant correlation was seen in the frontal cortex (P value = 0.44, Pearson’s r = -
0.14), or in the temporal cortex analyzed by Pearson’s correlation test (P value = 0.29, 
Pearson’s r = -0.12) with Aβ load, as shown in Figure 6-7. 
 
Figure 6-7: Correlation between GFAP levels with Aβ load in AD group. A) Frontal cortex: no 
correlation was seen (P value = 0.44, Pearson’s r = -0.14).  B) Temporal cortex: no correlation was 
seen (P value = 0.29, Pearson’s r = -0.12). The continuous line represents the best fit of the linear 
regression and the dashed lines represent 95% confidence interval (CI) of the regression line. 
Braak tangle staging 
Comparison of GFAP concentration across the three groups of Braak stages (0-II 
= 31 controls, III-IV = 5 AD, V-VI = 28 AD) was performed using one-way ANOVA test. 
In the frontal cortex there was no significant difference between groups (P value = 0.8). 
However, a significant difference was seen between the groups in the temporal cortex (P 
value = 0.001), group V-VI was significantly higher than group 0-II with post-hoc Tukey’s 





Figure 6-8: GFAP concentration in different Braak stages. A) Frontal cortex: no significant 
difference was seen between groups, one-way ANOVA test (P value = 0.8). B) Temporal cortex: 
a significant increase in Braak stage V-VI group was seen compared to 0-II group, one-way ANOVA 
test (*P value = 0.001). 
6.4.2.5 Relationship between GFAP level and APOE genotype 
GFAP levels was compared in the full cohort grouped according to the number of 
APOE ε4 genotypes (35 negative, 21 heterozygous and 7 homozygous: information taken 
from MRC brain bank database for SWDBB). These were analyzed using Kruskal-Wallis 
test. No significant difference was found in GFAP levels between the genotype groups in 
the frontal cortex (P value = 0.15) however there was a significant difference between the 
groups in the temporal cortex analyzed by using Kruskal-Wallis test (P value = 0.009). It 
was observed that the heterozygous group had significantly higher GFAP levels than the 
no ε4 allele group by post-hoc Dunn’s test. 
 
Figure 6-9: Concentration of GFAP (ng/mg total protein) in controls and AD with or without 
an APOE 4 allele. A) Frontal cortex: no significant difference was seen between the groups (P 
value = 0.15). B) Temporal cortex: heterozygous group was significantly higher than no ε4 allele 




6.4.2.6 Relationship between GFAP levels and complement proteins 
and regulators 
It was interesting to explore the association between astrocyte activation and 
complement activation in the AD brain. Data were tested for normality and Pearson’s 
correlation test was used for all analyses below in Table 6-1, except in the frontal control 
group with C1q and the frontal AD group with iC3b and TCC, where Spearman’s 
correlation test was used. 
In the frontal cohort, a significant positive correlation was identified between 
GFAP concentration and with iC3b concentration in the full cohort analysis. In contrast, in 
the temporal cortex, there were significant positive correlations in the AD group with C1q, 
CFH, clusterin and TCC. When cases and controls were combined to provide more 
statistical power and the temporal cohort was analysed, a significant positive correlation 
was also seen between GFAP levels and with four complement components (CFH, iC3b, 
clusterin and TCC).  
Table 6-1: Correlation between GFAP and complement proteins. P = P value, r = Pearson’s or 
Spearman’s test r value, the whole cohort (31 controls and 33 AD cases), was used in all analyses, 
except for C3 analysis (16 control and 16 AD cases) were analysed. 
 
Frontal cortex Temporal cortex 
Control AD Full cohort Control AD Full cohort 
C1q 
P = 0.15 
r = 0.26 
P = 0.46 
r = 0.26 
P = 0.12 
r = 0.19 
P = 0.75 
r = 0.05 
**P = 0.008 
 r = 0.45 
P = 0.25 
r = 0.15 
C3 
P = 0.17 
r = - 0.4 
P = 0.62 
r = - 0.14 
P = 0.38 
r = - 0.17 
P = 0.48 
r = - 0.2 
P = 0.058 
r = 0.51 
P = 0.2 
r = 0.25 
CFH 
P = 0.39 
r = 0.15 
P = 0.34 
r = - 0.16 
P = 0.87 
r = 0.02 
P = 0.88 
r = 0.02 
**P = 0.017 
r = 0.41 
**P = 0.03 
r = 0.26 
iC3b 
P = 0.39 
r = 0.15 
P = 0.07 
r = 0.31 
*P = 0.04 
 r = 0.25 
P = 0.22 
r = 0.23 
P = 0.08 
r = 0.3 
**P = 0.005 
r = 0.34 
Clusterin 
P = 0.58 
r = 0.11 
P = 0.95 
r = - 0.01 
P = 0.66 
r = 0.05 
P = 0.16 
r = 0.25 
**P = 0.007 
 r = 0.45 
***P = 0.0006 
r = 0.41 
TCC 
P = 0.12 
r = 0.29 
P = 0.14 
r = 0.26 
P = 0.08 
r = 0.21 
P = 0.13 
r = 0.27 
**P = 0.004 
r = 0.48 
***P = 0.0004 





6.4.3 Quantification of GFAP mRNA expression 
6.4.3.1 Expression of calibrator genes in control and AD 
GAPDH Ct values were first compared between the AD and control groups and 
were found to not be significantly different in the frontal cortex, as assessed by unpaired t-
test. Similarly, there were no significant differences found for the temporal cortex, as 
assessed by Mann-Whitney test. RPL13 Ct values were not significantly different in AD 
group compared to controls in the frontal or temporal cortex, as assessed by unpaired t-test.  
6.4.3.2 Expression of GFAP mRNA in control and AD 
GFAP gene expression was measured following calibration against GAPDH and 
RPL13 and to the geometric mean of both. The fold difference in AD samples relative to 
those from control tissue was calculated. The individual sample 2-ΔΔCT values were used to 
perform statistical tests. 
Frontal cortex 
In AD cases, a significantly higher level of GFAP mRNA expression was seen in 
comparison to controls in the frontal cortex relative to GAPDH (~4.6-fold, P value = 0.002), 
to RPL13 (~2.4-fold, P value = 0.03), and to the geometric mean of calibrator genes (~3.4-
fold, P value = 0.003), as assessed by unpaired t-test.  
Temporal cortex 
Similarly, in the AD group GFAP mRNA expression was significantly higher 
compared to control in the temporal cortex relative to GAPDH (~5.7-fold, P value = 0.002) 
and to the geometric mean of calibrator genes (~4.3-fold, P value = 0.0003), as assessed by 






Figure 6-10: GFAP relative gene expression in frontal and temporal cortices to A) GAPDH 
calibrator gene: a significant higher expression was seen in AD compared to control in the frontal 
cortex (*P value = 0.002), and in the temporal cortex (*P value = 0.002). B) RLP13 calibrator 
gene: a significant difference higher expression was seen in AD in the frontal and in the temporal 
cortex (*P value = 0.03 & 0.002 respectively). The geometric mean and 95% confidence interval of 
the 2-ΔΔCT values are shown on the logarithmic scale (to the base 2). 
6.4.3.2.1  Relationship between GFAP gene expression and age at 
death 
As with the study of GFAP protein levels it was worthwhile exploring the 
relationship between gene expression and age at death. The age of the control group ranged 
from 62 to 95 years (mean 77.4, SD 11), and the AD group ranged from 69 to 90 years 
(mean 81.6, SD 5.7). On examination, a significant positive correlation in GFAP gene 
expression was seen with age in the frontal cortex (P value = 0.014, Pearson’s r = 0.5). This 
significant correlation between age and GFAP gene was not seen in the temporal cortex (P 
value = 0.14, Pearson’s r = 0.24) (Figure 6-11).  
It was not possible to look at the gender effect because of the small numbers in 





Figure 6-11: Correlation plots of GFAP mRNA expression with log. (age at death).  A) Frontal 
cortex: a significant positive correlation in GFAP concentration with age (*P = 0.014, r = 0.47).  B) 
Temporal cortex: no significant correlation in GFAP concentration with age (P = 0.14, r = 0.24). 
Data transformed to log scale. The continuous line represents the best fit of the linear regression and 
the dashed lines represent 95% confidence interval (CI) of the regression line. 
6.4.3.2.2 Relationship between GFAP gene expression and PMI  
As with the GFAP protein levels and given the observed inverse correlation of 
GFAP levels with PMI I undertook a similar comparison with GFAP expression. The PMI 
of the control group ranged from 3 to 55 hours (mean 26.7, SD 6.9), and AD group ranged 
from 5 to 71 hours (mean 35, SD 5.9). In this analysis no significant correlation was seen 
between PMI and GFAP gene expression in either the frontal (P value = 0.9, Pearson’s r = 
0.001), or the temporal cortex (P value = 0.82 Pearson’s r = -0.04) (Figure 6-12). 
 
Figure 6-12: Correlation plots of GFAP gene expression with log. (PMI). A) Frontal cortex: no 
significant correlation with PMI (P value = 0.9, Pearson’s r = 0.001). B) Temporal cortex: no 
significant correlation with PMI (P value = 0.82, Pearson’s r = - 0.04). Data was transformed to the 
log scale. The continuous line represents the best fit of the linear regression and the dashed lines 




6.4.3.2.3  Relationship between GFAP mRNA expression and AD 
pathology 
Aβ load 
It was interesting to explore the relationship between GFAP and AD pathology at 
the level of gene expression. On investigation, no significant correlation was seen in the 
frontal cortex (P value = 0.22, Pearson’s r = -0.35), or in the temporal cortex (P value = 
0.25, Pearson’s r = -0.33) between levels of GFAP expression and Aβ load (Figure 6-13). 
 
Figure 6-13: Correlation between GFAP expression and Aβ load in AD group:  A) Frontal 
cortex: no significant correlation was seen (P value = 0.22, Pearson’s r = -0.35). B) Temporal 
cortex: no significant correlation was seen (P value = 0.25, Pearson’s r = -0.33). Data was 
transformed to the log scale. The continuous line represents the best fit of the linear regression and 
the dashed lines represent 95% confidence interval (CI) of the regression line. 
Braak stages and APOE genotype analyses 
It worth noting that the numbers were too few in each group for Braak stages and 
APOE genotype analysis in contrast to the analyses of GFAP protein levels around AD 
pathology when the full cohort was tested, therefore numbers were enough to run statistical 
tests. 
6.5 Discussion 
6.5.1 GFAP protein levels in post-mortem brain tissue 
GFAP is a marker of mature astrocytes in neurodegenerative diseases such as AD. 




matched controls. No significant difference was seen in GFAP levels in frontal 
homogenates between AD and age matched controls, however a significant increase was 
seen in the temporal homogenates. These results are in accordance with an earlier study by 
Ross et al., who compared GFAP in different post-mortem brain areas in AD and controls 
(n = 10 in each group) (346). In their study, they measured GFAP concentration in four 
brain areas (frontal, parietal, occipital, and temporal). They reported similar results for 
frontal and temporal areas to those described here where the sample size of this study was 
larger. 
The regional differences in levels of GFAP in the cases and control groups between 
the frontal and temporal cortex was also investigated and no difference was seen in the 
control group while significantly higher levels were seen in temporal AD compared to 
frontal AD homogenates. This supported similar findings in a smaller study of AD-
associated increases in the temporal cortex, which were more than 3-fold higher than the 
frontal cortex (295).  
It has been suggested that GFAP concentration is increased in AD brain and 
inversely related to the cognitive function (594). In another contradictory study, Wharton 
et al. found no difference in GFAP levels in temporal cortex in demented versus non-
demented brains (596). Their results was different from the current findings which can be 
explained by different antibodies used or due to using Triton-X 100 as a detenrgant, while 
in the current stydy, SDS homogenates were used to measure GFAP. In CSF, GFAP was 
increased in AD patients and correlated with severity of dementia (344). 
Furthermore, astrocyte count (which GFAP is marker of) correlated positively with 
age in post-mortem brain sections (597,598). Yet, others have found no association 
between age and GFAP levels in human brain (295). The failure to detect an association 
with age by Ross et.al may be due to the small sample size and narrower age range (76 to 
94 years) to this study (the AD group was 69 to 96 years) and a significant negative 
correlation was seen between GFAP concentration and age only in the temporal cortex of 
the AD group, while no significant correlations were seen in the other groups.  
No differences in GFAP concentration was seen between males and females in the 
frontal cortex, while in the temporal cortex, the female AD group showed significantly 
higher GFAP levels than what were present in males in the control group. Other studies 




in four different brain areas including both the frontal and temporal cortices in AD cases 
(597). 
Interestingly, findings in this study show that PMI appears to affect GFAP protein 
levels (but not GFAP expression – see below) in human brain over time; a significant 
negative correlation between GFAP concentration was seen with PMI in both the frontal 
and temporal cortices. Another experiment was performed using simulated post-mortem 
delay samples to explore this further and similarly found that GFAP was decreased with 
increased PMI. On this latter experiment, GFAP levels decreased with long PMI, however 
this did not reach the statistical significance, it worth noting that this experiment was only 
conducted on a single sample and thus should be confirmed with a larger sample size.  
In a previous study, GFAP levels measured by western blotting were found not to 
be affected by PMI but over a PMI range of 4 to 18 hours (599). This findings related to a 
wider PMI range, as was the range of the simulated PM study and thus the findings by 
Chandana may have not been conducted over a sufficiently long post-mortem time frame 
to see the further loss of GFAP protein. In contrast, immunoreactivity of GFAP was found 
to be increased with increased PMI in mice, they concluded that there was an increase in 
GFAP epitopes, and this may reflect that some cells in the brain do not die immediately, 
however there might be some differences in human and mice astrocytes (600). Comparing 
immunoreactivity in mice with protein levels in humans may not be appropriate, therefore 
further investigations need to be done to examine GFAP expression with PM delay by 
immunostaining in human brain sections. It is possible to consider normalizing the results 
to PMI changes or using a multivariate analysis statistical method to take an account of the 
potential confounding factors. 
It has been suggested that GFAP the marker of reactive astrocytes may be related 
to the burden of tau pathology i.e. as represented by Braak staging (95,601). In this study, 
there was no observed change in GFAP concentration in different Braak stages in the 
frontal cortex, however GFAP levels were significantly higher in later Braak stages (V-VI) 
in the temporal cortex. This observation is in accordance with another study of the temporal 
cortex (596). Additionally, some GFAP isoforms have been found to be increased with late 
Braak stages; GFAP+ cells were found to be closely associated with AD plaques in human 
post-mortem hippocampal AD brain tissue (341).  
However, the contribution of glial activation and its role in the pathogenesis of AD 




whereby Aβ acts as a stimulus (237) although activated astrocytes can also degrade Aβ 
(73). By examining this relationship, no correlation was seen between GFAP concentration 
and Aβ load in the brain areas tested similar to some other studies (602,603).  
In a previous study, they also investigated the relationship between GFAP and 
APOE genotype and found no association in the frontal cortex samples but contrasted with 
what was observed in the temporal cohort where GFAP concentration was significantly 
higher in the heterozygotes compared to the ε4 negative allele group. The APOE ε4 allele 
is the main risk factor for LOAD and an association between increased astroglial activation 
with APOE ε4 can conceivably add to pathology.  However, no similar association with 
APOE ε4 was found, potentially due to the smaller numbers of the APOE ε4 group. Yet, 
given the interaction between ApoE with glial cells, especially astrocytes (as previously 
discussed in detail in Section 1.3.1.2), and that of ApoE in the transport of Aβ whilst 
astroglia also have a possible role in Aβ degradation, there is clearly a complex relationship 
that should be further investigated. It is possible however, given that the observed 
association with APOE ε4 heterozygotes and not homozygotes, that one might expect to 
see in a dose-dependent manner reflects a statistical false positive. 
6.5.2 GFAP protein levels in relation to complement system proteins 
The association between the complement proteins measured in Chapter 4 with 
GFAP measurements was investigated to explore the relationship between astrocyte 
activation (that GFAP levels serve as a proxy for) and measures of complement cascade 
activation in different parts of the brain. 
 A significant positive correlation in GFAP levels with a number of mediators of 
complement activation and regulation (i.e. iC3b, CFH, clusterin and TCC) was seen in the 
temporal cortex. In the frontal cortex GFAP was positively correlated with only iC3b. This 
indicates that the complement system dysregulation is interacting more closely with 
astrocyte activation in the temporal cortex area that is affected early in disease progression 
and that for the cases studied here the complement pathology had yet to fully manifest in 





6.5.3 GFAP expression in post-mortem brain tissue  
GFAP gene expression was measured in this study by qPCR and calibrated against 
the calibrator genes GAPDH and RPL13. Relative GFAP gene expression was found to be 
increased significantly in both the frontal and the temporal cortex in AD compared to 
matched controls. GFAP gene expression has been studied previously using 
semiquantitative methods and reported to correlate with senile plaque density in eight post-
mortem aged brains in the temporal, not frontal cortex (604). What is notable about these 
observations is that the increases in gene expression in temporal lobe may relate to the 
observed increases in GFAP protein seen in the same brain region. Yet, the increases in 
gene expression seen in the frontal do not seem to translate into similar protein elevations 
in the frontal cortex. 
GFAP has previously been proposed to be affected by age at death; mRNA 
expression was found to increase with age in mice (605,606) and in human brain (607). 
Similarly others have found GFAP expression to be increased with age in rat and human 
brain (607). It may be the case that the observed effect of PMI on GFAP levels over time 
had a greater effect on frontal cortex levels of GFAP than temporal cortex levels and so 
differences were not affected, however the case and control groups were well matched. A 
multivariant analysis statistical method should be considered to take an account of the 
potential confounding factors. 
In this study, a significant positive correlation with age at death was seen in the 
frontal cortex and was not statistically significant in the temporal, no effect of PMI was 
seen here and no correlation with Aβ load in any of brain areas tested and this was similar 
to the protein finding.  
6.6 Summary and conclusions 
➢ GFAP protein level was significantly increased in AD tissue in the temporal cortex, 
but not frontal cortex, compared to aged-matched controls. 
➢ GFAP protein in AD showed higher levels in the temporal cortex compared to the 





➢ GFAP protein level, but not GFAP expression, was significantly affected by 
delayed post-mortem interval in brain tissue (there was a negative correlation with 
PMI in the frontal and temporal cortex). 
➢ GFAP gene expression was significantly higher in both frontal and temporal brain 
areas relative to age-matched controls. 
➢ Astrocyte activation, as per levels of the specific marker GFAP, correlated 
positively with complement system activation in the brain area that develops 
pathology earlier in AD, i.e. the temporal cortex than in the later affected frontal 
cortex. 





7. Chapter 7: Pro-inflammatory Cytokines in 
Alzheimer’s Disease. 
7.1 Introduction 
Cytokines have a crucial role in the brain under normal physiological conditions 
during the development of the CNS (462,608), and, also, under the pathological conditions 
which involve neuroinflammation. In normal healthy conditions, peripheral and central 
cytokines are not expressed or are expressed in low concentrations and their expression can 
be triggered by peripheral, systemic or CNS inflammation as seen in encephalomyelitis 
(609). Upon exposure to various inflammatory stimuli, peripheral cytokines can cross the 
BBB via an active transport system (464). Meanwhile, overexpression of cytokines has 
been implicated in many neuroinflammation-related pathologies such as AD (610).  
Cytokines serve as the link between the innate and the adaptive immune responses. 
They mediate the cross-talk between cells in the brain, such as glial-neuronal  and 
astrocyte-microglial interactions (611). They are involved in cell proliferation, apoptosis, 
leucocytic recruitment, and the initiation of inflammatory response in the brain (612), as 
well as in glial cell activation (611). Macrophages in the periphery, and activated microglia 
in CNS are the main source of pro-inflammatory cytokines (613), whilst many cytokines 
are produced by astrocytes and neurons (613,614). 
There is substantial evidence to suggest that pro-inflammatory cytokines such as 
IL-1β, IL-6 and TNF-α are implicated in the pathogenesis of AD (413,615,616). Their 
precise role remains uncertain, however, since they have been shown to be both 
neuroprotective and neurotoxic during the course of the disease (reviewed recently in 
(458)). It is likely that cytokines play a crucial role in both initial and chronic stages of AD. 
Different cytokines and their contribution in AD pathogenesis were introduced in Chapter 
1 in detail (See Section 1.3.3).  
The IL-1 family, including IL-1β, is thought to play a central role in the 
inflammatory response in the brain. It is mainly produced from the classically activated 
microglia (M1:pro-inflammatory phenotype) (243,244) on stimulation by Aβ; in turn, it 
stimulates the production of other pro-inflammatory cytokines (TNF-α and IL-6) from 




risk of AD (618). Nevertheless, the role of IL-1β is somewhat ambiguous in AD, and its 
production can be stimulated by beta amyloid deposition (486,619,620). Together, with 
S100β produced by reactive astrocytes, it affects Aβ aggregation (318,621). In contrast, 
other studies suggest IL-1β has a role in Aβ removal (622). Besides its interaction with Aβ, 
IL-1β has a role in synaptic function, as suggested by the substantial increase in the 
expression of the IL-1β gene during long-term potentiation of synaptic transmission (623).  
Similarly, blocking IL-1β in triple transgenic mice model of AD resulted in a 
reduction in hippocampal-dependant cognitive dysfunction, a significant decrease in tau 
pathology, reduced microglial activation, but minimal effect on  amyloid plaque load (497). 
In another study, however, IL-1β overexpression in AD mice models, unexpectedly, 
reduced plaque formation, despite inducing a strong neuroinflammatory response (490). 
TNF-α alpha is another important pro-inflammatory cytokine in AD pathogenesis 
and it has a complex role in the CNS during health and disease. It is involved in synapse 
formation, inflammatory response, glial cell activation and CNS regeneration; however its 
role is not clearly understood (614). Drugs targeting TNF-α have been proposed as 
modulators of disease progression and may improve cognitive function; soluble TNF-α 
inhibitors were protective in the 3xTgAD model and decreased amyloid pathology (503).  
Cytokine expression and function are closely related to microglial activation and 
morphology in AD; as the main immune cell in the CNS, microglia have a complex role in 
the pathogenesis of AD and exert a variety of functions (180). In vitro, pro-inflammatory 
cytokines were shown to be increased in a dose dependant manner when microglial cells 
were activated by Aβ (261).  
In contrast, anti-inflammatory cytokines such as IL-4 and IL-10 oppose  the action 
of pro-inflammatory cytokines in the brain (624–628). The balance between pro- and anti-
inflammatory cytokines and the presence of cytokine regulators determine the immune 
response and the role of microglia in AD pathology.  
In the periphery, pro-inflammatory cytokine levels are changed in the serum, CSF, 
and AD brain although the results have been contradictory. In CSF, pro-inflammatory 
cytokine levels has been reported as unchanged (629–631), or increased (632) in AD 
patients. In serum, unchanged (492,629,633), or increased (634–636) cytokine levels was 




mortem brain tissue, cytokine expression in the brain under normal conditions is low. In 
AD,  unchanged (637), decreased (630,638), or increased cytokine levels was seen in AD 
brain tissue (469), and the microvasculature (639). 
It is important to further study the levels of the pro-inflammatory cytokines in AD 
since there is still inconsistency in the published literature. Furthermore, comparisons of 
cytokine levels in the periphery and CSF with those in brain tissue is inadequate, as is the 
over-reliance on animal studies where often the stimulation of cytokines using acute 
challenges do not readily mimic the chronic neurodegenerative state of disease seen in 
disease. The measurement of pro-inflammatory cytokines in post-mortem brain can 
therefore be considered as an important complementary tissue source, with robust 
diagnosis, to try to add to our understanding of the role of the local inflammatory response 
in relation to AD pathology. 
7.2 Study aim 
The aim of the experiments described in this chapter was to study pro-
inflammatory cytokines in post-mortem homogenized brain tissue. This was attempted by 
quantitative analysis using sandwich ELISA to measure the levels of IL-1β , IL-6 and TNF-
α proteins in AD and age-matched controls in homogenized post-mortem brain tissue 
(frontal and temporal cortices). Another aim was to correlate these with known AD 
pathological changes in these samples (Braak staging and Aβ load; as described have 
previously been measured by colleagues as a part of separate studies). Furthermore, the 
relationship with or disease-associated variables such as age, gender, PMI and APOE 
genotypes was assessed.  
Unfortunately, due to the lack of sensitivity of available ELISAs, it was only 
possible to measure protein levels of IL-1β in this study but not TNF-α or IL-6. 
A further aim was to measure the gene expression by RT-PCR of pro-inflammatory 
cytokines (IL-1β and TNF-α) in post-mortem brain tissue, from the frontal and temporal 





7.3.1 Pro-inflammatory cytokines measurement in AD (IL-1β) 
Methods to detect pro-inflammatory cytokines are given in general methodology 
(Chapter 2). Specific kits and protocols were used in order to detect the pro-inflammatory 
cytokines (IL-1β, IL-6 and TNF-α), however most of these kits used were not sensitive 
enough to detect the cytokine expression in SDS brain homogenates. Antibody pairs were 
tested for IL-1β (DY 201), IL-6 (DY 206), and TNF-α (DY 210), by sandwich ELISA.  
Luminex-based cytokines assays for the detection of a panel of the selected cytokines was 
also tested, using a protocol detailed in (Section 2.10). None of these were found to be 
sufficiently sensitive to detect the proteins in brain tissue. 
The only kit sensitive enough to detect and measure IL-1β was the high sensitivity 
Quantikine ELISA kit. IL-1β was the only cytokine that was detectable with good 
sensitivity in the spike and recovery experiments. The method used on SDS homogenates 
was as detailed in (Section 2.5.4). Following manufacturer's instructions, pre-coated 
microplates with specific capture antibody against human IL-1β were used, brain 
homogenates (frontal and temporal cortices) were diluted 1 in 8 and tested in duplicate, 
then conjugated detection antibody was used. Results were calculated from a seven-point 
standard curve and adjusted to total protein concentration in the homogenate. 
Results were analysed statistically using Prism GraphPad version 6, after testing 
for normality. For group comparison in normally distributed data, the unpaired t-test was 
used and where data were not normally distributed, a non-parametric test (Mann-Whitney 
test) was used for analysis. Linear correlations were assessed by using Pearson's correlation 
if normally distributed data, or Spearman’s test if not. Comparison of groups was tested by 
one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test if normally 
distributed data, or if not, Kruskal-Wallis test followed by post-hoc Dunn’s multiple 
comparison test. Statistical significance was defined as p < 0.05. 
7.3.2 Measurement of IL-1β and TNF-α gene expression 
RNA was extracted and cDNA was obtained by reverse transcription of RNA as 
previously described in detail in Chapter 2, (Section 2.8). Quantitative PCR for IL-1β and 




7.3.2.1 PCR study cohort 
The details of the PCR cohort used to measure IL-1β and TNF-α mRNA expression 
is the same as that discussed in previous chapters and provided in Table 5-1.  
7.3.2.2 Selection of primers for relative quantification 
RT-PCR was carried out using a hydrolysis probe for IL-1β and TNF-α (TaqMan 
assays on demand), designed to span introns that do not detect any genomic DNA. Details 
of the primers are given in Chapter 2 (Table 2-8). 
7.3.2.3 Selection of reference genes for relative quantification  
As previously discussed in detail in Chapter 5, I decided to use GAPDH and RPL13 
as being the most stable reference genes in this cohort.  
7.3.2.4 qPCR 
The detailed method for qPCR experiments is outlined in (Section 2.8). Ct values 
were determined to detect the fold change of expression of IL-1β and TNF-α in the AD 
tissue relative to the mean expression in the control group from the frontal and temporal 
cortices. 
7.3.2.5 Statistical analysis for relative gene quantification  
The 2-ΔΔCT for relative quantification was used (581) as described in detail in 
(Section 2.8.11). The geometric mean for the control and AD groups were calculated and 
used to perform the statistical tests. A parametric test i.e. the unpaired t-test was used for 
normally distributed data, and a non-parametric test i.e. Mann-Whitney test was used when 





7.4.1 Interleukin 1β protein levels in control and AD brain tissue 
7.4.1.1 Comparison of IL-1β levels between AD cases and controls   
IL-1β protein was measured in frontal and temporal cortices from 31 controls and 
33 AD cases by sandwich ELISA and results were adjusted to total protein concentration 
for each case. The data were tested for normality and were normally distributed, therefore 
a parametric statistical test was used (unpaired t-test) for analysis. It worth noting that one 
control brain sample was excluded from the analysis; this sample had an unusually high 
signal in both frontal and temporal areas, and its OD reading was out of the standard curve.  
IL-1β levels (pg/mg total protein) was found to be significantly lower in AD (mean 
± SEM = 2.05 ± 0.17) compared with controls (mean ± SEM = 3.7 ± 0.5) in the frontal 
cortex (P value = 0.0015). Similarly, in the temporal cortex IL-1β concentration was 
significantly lower in AD tissue (mean ± SEM = 3.04 ± 0.35), compared to control (mean 
± SEM = 4.8 ± 0.5) and (P value = 0.0018), as shown in Figure 7-1. 
 
Figure 7-1: IL-1β protein levels in human brain tissue (pg/mg total protein). A significant 
reduction was seen in AD tissue compared to controls in A) Frontal cortex: (unpaired t-test **P 




Additionally, comparison of concentrations of IL-1β showed significantly higher 
levels in temporal cortex compared to frontal cortex in both the control and AD groups (P 
value = 0.03 & 0.008) respectively, as assessed by unpaired t-test.  
7.4.1.2 Relationship between IL-1β levels, age at death, and gender  
The potential factors that might affect protein levels, such as age and gender, were 
assessed. The age at death of the control group ranged from 43 to 95 years (mean 78.1, SD 
11), and the AD group ranged from 69 to 96 years (mean 81.6, SD 6.3).  
There was no evidence of a correlation between IL-1β concentration and age in 
any of the groups when analyzed separately or when control and AD were combined (P 
value = 0.93, Spearman’s r = -0.01) in the frontal or in the temporal cortex (P value = 0.11, 
Pearson’s r = -0.2) (Figure 7-2). Summary statistics for these data are also presented in 
Appendix II, Table 9-3. 
 
Figure 7-2: Correlation plots of IL-1β concentration (pg/mg total protein) with age (years) in 
A) Frontal cortex: no significant correlation was seen (P value = 0.93, Spearman’s r = -0.01). 
B) Temporal cortex: no significant correlation was seen (P value = 0.11, Pearson’s r = -0.2). The 
continuous line represents the best fit of the linear regression and the dashed lines represent 95% 
confidence interval (CI) of the regression line.   
IL-1β concentrations were also compared according to gender, in control males 
(n= 19) and females (n= 12) and in AD males (n= 10) and females (n= 23). A significant 
difference between the groups was seen in the frontal cortex when analyzed by ANOVA 




significantly higher IL-1β levels in males in control group compared to females in AD 
group, as shown in Figure 7-3.  
In the temporal cortex, a significant difference was also seen between the groups 
when analyzed by ANOVA test (P value = 0.006), and post-hoc Tukey’s test for multiple 
comparison showed a significant higher IL-1β level in males in control group compared to 
males in AD group, as shown in Figure 7-3. Summary statistics for these data are also 
presented in Appendix II, Table 9-4. 
 
Figure 7-3: Concentration of IL-1β in males versus females (pg/mg total protein). 
A) frontal cortex: A significant difference was seen between groups (**P value = 0.003). 
B) Temporal cortex: A significant difference was seen between groups (**P value = 0.006). 
7.4.1.3 Relationship between IL-1β levels and PMI  
Correlation of IL-1β concentration with PMI was assessed for both control and AD 
groups. The PMI of the control group ranged from 3 to 106 hours (mean 43.2, SD 29.2), 
and the AD group ranged from 5 to 99 hours (mean 49.8, SD 28.2).  
In the frontal cortex, no significant correlation was seen in the control or AD group 
(P value = 0.39 & 0.77), Pearson’s r = (-0.16 & -0.05) with PMI respectively, or when 
control and AD groups were combined (P value = 0.35, Spearman’s r = -0.12), as shown 




group (P value = 0.19, Pearson’s r = 0.2) with PMI, while a significant negative correlation 
was seen in the AD group (P value = 0.024, Pearson’s r = -0.4). No significant correlation 
was seen when control and AD groups were combined (P value = 0.058, Pearson’s r = -
0.23), as shown in Figure 7-4 (B). 
 
Figure 7-4: Correlation plots of IL-1β concentration (pg/mg total protein) with PMI (hours) 
in A) Frontal cortex: no significant correlation was seen with PMI (P value = 0.35, Spearman’s r 
= -0.12). B) Temporal cortex: no significant correlation was seen with PMI (P value = 0.058, 
Pearson’s r = -0.23). The continuous line represents the best fit of the linear regression and the 
dashed lines represent 95% confidence interval (CI) of the regression line. 
7.4.1.4 Relationship between IL-1β levels and AD pathology  
Aβ load 
Parenchymal Aβ load was available from the MRC and SWDBB database for 32 
of the 33 cases in the AD group. Correlation of IL-1β levels with Aβ load was explored. 
No significant correlation was seen in the frontal cortex (P value = 0.74, Pearson’s r = 
0.05), or in the temporal cortex (P value = 0.48, Pearson’s r = 0.12), with Aβ load, as shown 





Figure 7-5: Correlation between IL-1β concentrations and Aβ load in AD group. A) Frontal 
cortex: no correlation was seen (P value = 0.74, Pearson’s r = 0.05). B) Temporal cortex: no 
correlation was seen (P value = 0.48, Pearson’s r = 0.12). The continuous line represents the best fit 
of the linear regression and the dashed lines represent 95% confidence interval (CI) of the regression 
line. 
Braak tangle staging 
Comparison of IL-1β levels was made across the three groups of Braak stages (0-
II = 31 controls, III-IV = 5 AD, V-VI = 28 AD). In the frontal cortex, a significant 
difference was seen between groups (P value = 0.006), as assessed by one-way ANOVA 
test and shown in Figure 7-6 (A) such that group V-VI was significantly lower than group 
0-II with post-hoc Tukey’s test for multiple comparison. 
In the temporal cortex, IL-1β levels was also significantly different between 
groups, (P value = 0.002), as assessed by one-way ANOVA test and shown in Figure 7-6 
(B). Post hoc Tukey’s test showed a significant reduction in both group III-IV and V-VI 





Figure 7-6: IL-1β levels in different Braak stages. A) Frontal cortex: a significant difference 
was seen between groups, one-way ANOVA test (**P value = 0.006). B) Temporal cortex: a 
significant difference was seen between the groups, one-way ANOVA test (**P value = 0.002). 
7.4.1.5 Relationship between IL-1β levels and APOE genotype 
IL-1β concentration was compared in the full cohort grouped according to the 
number of APOE ε4 allele (35 negative, 21 heterozygous and 7 homozygous; information 
taken from MRC brain bank database for SWDBB), analyzed by using Kruskal-Wallis test; 
there was a significant difference between the groups in the frontal cortex (P value = 0.023), 
and post-hoc Dunn’s test showed a significant difference increase in negative ε4 allele 
group compared to heterozygous group as shown in Figure 7-7 (A). 
In the temporal cortex, there was a significant difference in IL-1β concentration by 
using Kruskal-Wallis test; there was a significant difference between the groups in the 
frontal cortex (P value = 0.01), and post-hoc Dunn’s test showed a significant increase in 
negative ε4 allele group compared to heterozygous and homozygous groups as shown in 






Figure 7-7: Concentration of IL-1β (pg/mg total protein) in controls and AD with or without 
an APOE 4 allele. A) Frontal cortex: a significant difference was seen between the groups (*P 
value = 0.023). B) Temporal cortex: a significant difference was seen between the groups (*P value 
= 0.01) by Kruskal-Wallis test. 
7.4.1.6 Relationship between IL-1β levels and cause of death  
Agonal state and the cause of death could have an effect on the inflammatory 
response in the brain. In this cohort, the cause of death was known for 48 subjects out of 
64 subjects. IL-1β levels were compared by dividing the groups according to the cause of 
death or any infectious comorbidity and no significant difference was seen between the 
groups in the frontal cortex (P value = 0.08). In the temporal cortex, there was a significant 
difference by Kruskal-Wallis test (P value = 0.03), however, no significant difference was 
seen between the groups with the post-hoc analysis by Dunn’s multiple comparison test, as 






Figure 7-8: IL-1β concentration (pg/ml): in brain tissue grouped by the cause of death (infectious 
or non-infectious causes of death) in: A) Frontal cortex: no significant difference was seen between 
groups by Kruskal-Wallis test (P value = 0.08). B) Temporal cortex: a significant difference was 
seen by Kruskal-Wallis test (*P value = 0.03), but no significant differences were seen by post-hoc 
Dunn’s test. 
7.4.1.7 Relationship between IL-1β levels and previously measured 
inflammatory markers 
The correlation between IL-1β and other inflammatory proteins in the same cohort 
were tested and results summarized in Table 7-1. 
Table 7-1: Correlation between IL-1β and inflammatory markers. P = P value, r = Pearson’s or 
Spearman’s test r value, the whole cohort (30 controls and 33 AD cases), was used in all analysis, 
except for C3 analysis (16 control and 16 AD cases) were analysed. 
 








P = 0.55 
r = 0.11 
P = 0.56 
r = -0.1 
P = 0.94 
r = -0.08 
P = 0.75 
r = -0.06 
*P = 0.047 
r = 0.34 
P = 0.45 
r = -0.09 
C1q 
*P = 0.01 
r = 0.43 
*P = 0.01 
r = 0.44 
P = 0.07 
r = 0.22 
P = 0.09 
r = 0.312 
P = 0.179 
r = 0.23 
P = 0.34 
r = 0.12 
C3 
P = 0.08 
r = -0.49 
P = 0.73 
r = 0.09 
P = 0.25 
r = 0.22 
P = 0.47 
r = - 0.2 
P = 0.19 
r = 0.36 
P = 0.25 
r = 0.19 
CFH 
P = 0.95 
r = -0.01 
***P = 0.0004 
r = 0.57 
P = 0.84 
r = 0.22 
P = 0.53 
r = 0.11 
*P = 0.01 
r = 0.4 
P = 0.42 
r = 0.1 
iC3b 
P = 0.46 
r = -0.13 
P = 0.44 
r = 0.13 
P = 0.35 
r = -0.11 
P = 0.60 
r = 0.1 
P = 0.79 
r = 0.04 
P = 0.46 
r = -0.09 
Clusterin 
*P = 0.01 
r = 0.44 
P = 0.41 
r = - 0.14 
P = 0.12 
r = 0.19 
P = 0.1 
r = 0.3 
P = 0.12 
r = 0.27 
P = 0.17 
r = 0.17 
TCC 
P = 0.22 
r = 0.23 
P = 0.08 
r = 0.3 
P = 0.09 
r = 0.21 
P = 0.34 
r = 0.17 
P = 0.28 
r = 0.19 
P = 0.39 




7.4.2 Quantification of IL-1β and TNF-α mRNA expression 
7.4.2.1 Expression of reference genes in control and AD 
As described in chapter 5 GAPDH and RPL13 were measured. GAPDH Ct values 
were not significantly different in the AD group compared to control in the frontal cortex 
or in the temporal cortex, and similarly RPL13 Ct values were not significantly different in 
AD group compared to controls in the frontal or temporal cortex.  
7.4.2.2 Expression of IL-1β mRNA in control and AD 
IL-1β gene expression was calibrated against GAPDH, RPL13 and to the geometric 
mean of both. The fold difference in AD relative to control tissue was calculated and 
normalized to GAPDH and RPL13. 
Frontal cortex 
No significant difference in IL-1β mRNA expression was seen in the AD group 
compared to the control group in the frontal cortex relative to GAPDH (~0.7-fold, P value 
= 0.33), although a significant lower expression was seen relative to RPL13 (~0.38-fold, P 
value = 0.015). In contrast, no significant difference was seen in AD compared to controls 
relative to the geometric mean of the calibrator genes (~0.51-fold, P value = 0.06), as 
assessed by unpaired t-test and shown in Figure 7-9 (A). 
Temporal cortex 
A similar pattern was observed in the temporal cortex. No significant difference in 
IL-1β mRNA expression was seen in AD compared to controls in the temporal cortex 
relative to GAPDH (~0.66 -fold, P value = 0.4), whilst a significantly lower expression was 
seen relative to RPL13 (~0.37-fold, P value = 0.012). Similar to that seen in the frontal 
cortex analysis, no significant difference was seen in AD compared to control relative to 
the geometric mean of calibrator genes (~0.49-fold, P value = 0.07), as assessed by 





Figure 7-9: IL-1β relative gene expression in frontal and temporal cortices to A) GAPDH 
calibrator gene: no significant difference was seen in AD compared to control in the frontal cortex 
(P value = 0.33), or in the temporal cortex (P value = 0.393). B) RLP13 calibrator gene: a 
significant lower expression was seen in AD in the frontal and in the temporal cortex (*P value = 
0.015 & 0.012 respectively). The geometric mean and 95% confidence interval of the 2-ΔΔCT values 
are shown on the logarithmic scale (to the base 2). 
7.4.2.3 TNF-α gene expression in AD 
TNF-α gene expression was calibrated against GAPDH, RPL13 and to the 
geometric mean of both. The fold difference in AD relative to control tissue was calculated 
and normalized to GAPDH and RPL13. 
Frontal cortex 
Unlike what was seen with IL-1β, there was no significant difference in TNF-α 
mRNA expression seen between the diagnostic groups in the frontal cortex relative to 
GAPDH (~1.4-fold, P value = 0.3), to RPL13 (~0.78-fold, P value = 0.17), or relative to 
the geometric mean of calibrator genes (~1.06-fold, P value = 0.47), as assessed by 
unpaired t-test and shown in Figure 7-10 (A).  
Temporal cortex 
Similar to the findings from the frontal cortex, there was no significant difference 
in TNF-α mRNA expression seen in ADs compared to controls in the temporal cortex 
relative to GAPDH (~1.0-fold, P value = 0.87), to RPL13 (~0.62-fold, P value = 0.16), or 
relative to the geometric mean of calibrator genes (~0.78-fold, P value = 0.53), as assessed 





Figure 7-10: TNF-α relative gene expression in frontal and temporal cortices to A) GAPDH 
calibrator gene: no significant difference was seen in AD compared to control in the frontal cortex 
(P value = 0.3), or in the temporal cortex (P value = 0.87). B) RLP13 calibrator gene: no significant 
difference was seen in AD in the frontal (P value = 0.17), or in the temporal cortex (P value = 0.16). 
The geometric mean and 95% confidence interval of the 2-ΔΔCT values are shown on the logarithmic 
scale (to the base 2). 
7.5 Discussion 
7.5.1 IL-1β protein levels in post-mortem brain tissue 
In this set of experiments, the aim was originally to measure pro-inflammatory 
cytokines (IL-1β and TNF-α), as markers of neuroinflammation in the frontal and temporal 
cortices of post-mortem human brain tissue from AD and aged-matched controls. Few 
studies have previously investigated these cytokines in depth in post-mortem tissue 
although related studies in other ex vivo tissue samples from AD and controls were 
suggestive of disease associated differences. Data concerning pro-inflammatory cytokine 
levels in AD has been contradictory and inconclusive to date, which might be expected in 
such a complex disease and where expression may change from one brain area to another 
or at a point in the disease. The use of post-mortem brain tissue allowed some examination 
of some of these aspects. 
Unfortunately, it was possible to only measure IL-1β protein concentration in this 
cohort. This was only possible by the use of a sufficiently specific and high sensitivity 
Quantikine ELISA kit; in which the detection limit of the kit was (0.063 pg/ml). This was 
needed as low levels were expected as other attempts to measure it by other kits proved 
unsuccessful and the lower limits of detection seemed inadequate. In this kit the antibodies 




in human brain tissue can be also achieved by high sensitivity kits due to their low levels 
in the brain and this needs to be approved in later studies. 
Contrary to the expectations of seeing an elevation in IL-1β in AD patients, 
indicative of the role of pro-inflammatory markers in AD, a significant decrease was seen 
in both brain areas tested, in the AD group compared to the age-matched controls. A 
significant positive correlation was seen between reducing levels of IL-1β in relation to 
increasing severity of tau-related pathology, however interestingly no similar significant 
correlation was observed between IL-1β and amyloid beta load. Although apparently 
counterintuitive, these data was reinforced with another unpublished study (Dr. Scott 
Miners- Dementia Research Group, Southmead) where a significant decrease in IL-1β 
levels was seen in AD compared with controls, in the superior temporal cortex (BA 41/42) 
in a different cohort (70 AD; 42 controls) using two different ELISA kits, one of them was 
the same as mine (high sensitivity quantikine kit for human IL-1β) and the same results 
were obtained. 
Other studies have looked at pro-inflammatory cytokines in AD brain. A smaller 
study (16 AD, 20 controls) in post-mortem brain tissue from BA9 and BA21, grey and 
white matter (the same brain areas in this study), using multiplex assays, showed a 
significant decrease in IL-1β as well as a decrease in IL-6 and TNF-α in demented 
compared to non-demented subjects (638).  
By comparison, other studies have found differing results. One earlier small study 
(10 control and 10 AD patients) investigated cytokines in the temporal cortex and found no 
significant difference in IL-1β levels between AD and controls  (637). In a longitudinal 
study, pro-inflammatory cytokines were tested in serum, CSF, and brain tissue of just 6 AD 
patients and 4 controls and where no significant differences were seen in IL-1β and IL-6 
concentration in all brain areas tested in AD tissue. However, in the same study, TNF-α 
level was significantly reduced in AD patients compared to controls in the frontal cortex 
(BA9) and temporal cortex (BA22), similar to Wood and colleagues but not found in this 
study. Moreover, no correlations were seen between cytokine measurements in serum and 
CSF and cognitive function or brain atrophy (630). Another study found increased levels 
of IL-1β in AD brain in the frontal and temporal cortices (640), and hippocampus 
(640,641). Different methodologies but also, most likely, the different cohort sizes may 
explain the slightly contradictory results. An explanation for lower levels of IL-1β found 




later AD stages. Immunosenescence: aging of the immune system and dysfunction of the 
adaptive immune response, together with the inflammatory response via pro-inflammatory 
cytokines might result in differences under more severe pathological conditions such as 
severe, late and chronic stages of AD (642). A simpler explanation might also just be that 
this cohort is one of the largest to date and which therefore was more representative that 
some of the earlier studies that were less than half the size. 
A meta-analysis study of cytokines in AD has shown that pro-inflammatory 
cytokines are increased significantly in the blood of AD patients, suggesting that peripheral 
inflammation is present in AD pathogenesis, while no significant differences were seen in 
the anti-inflammatory cytokines (636). In a more recent study of cytokines in the peripheral 
circulation, IL-1β was increased while no difference in IL-6 and TNF-α levels were seen 
in AD compared to age-matched controls (492). These findings similarly support the 
involvement of peripheral inflammation in AD (643), however, it also suggests that there 
may be different responses relevant both peripherally and centrally. 
There have also been similarly contradictory data of IL-1β and TNF-α levels in 
peripheral samples such as CSF of AD patients. In one study of 42 AD patients and 20 age-
matched controls, no difference was seen in interleukins and TNF-α expression (631). 
These findings were similar to another smaller study of 8 AD patients and 9 controls, where 
no significant difference was seen in AD and no correlations were found between pro-
inflammatory cytokines in serum or CSF and with cognitive function.  Notably, IL-1β was 
undetectable in half of the patients in a study of CSF  (630), suggesting that any cytokine 
changes that might occur may be limited to the brain tissue. Yet, in a third study in CSF, in 
contrast, IL-1β was significantly increased in 11 sporadic AD patients and 12 healthy age-
matched controls (P value= 0.047); IL-6 was also elevated in AD group (P value = 0.008) 
(632).  
Another meta-analysis study, has discussed the inconsistency in cytokine data in 
AD and proposed that the role of pro-inflammatory cytokines might be limited to the 
progression of the disease from MCI to AD (644). The presence of such contradictory data 
has also suggested to be due to high variations between individuals (472). In a very recent 
study using a panel of pro- and anti-inflammatory cytokines that included IL-1β, IL-6 and 
TNF-α on CSF samples from different types of dementia, a significant increase was seen 




In this study, there was no correlation in IL-1β protein levels with age in brain 
tissue. Similarly, no effect of age was seen on pro-inflammatory cytokines in the serum of 
healthy individuals (646) or in CSF of AD patients (631).  
The inhibitory reaction of pro-inflammatory cytokines can be mediated by anti-
inflammatory cytokines as IL-10 and TGF-β as well as the regulatory mechanism via IL-
1Ra.  Anti-inflammatory cytokines and their expression have not been measured in this 
cohort due to time constraints and this is worthy of further investigations to get a broader 
perspective of the level of cytokine involvement in dementia, particularly in brain tissue. 
Additionally, inflammasome activation and microglial activation are closely related to 
cytokine expression. Thus, microglial activation markers, which have not been assessed in 
this cohort, would be worthy of future study to investigate the association between 
cytokines, complement and microglial activation. Interestingly, in this study a significant 
correlation was found between IL-1β levels and GFAP levels as a specific marker of mature 
astrocytes which needs further investigations. 
For the assessment for possible association between IL-1β protein and disease 
severity, all cases were grouped by Braak stages; there was a significant increase in Group 
I also compared to Group III that has the more advanced cases with Braak V and VI in the 
temporal cortex. This suggests there is a differential expression in the end-stage of the 
disease and could indicate either a failing of the inflammatory response via cytokines as a 
result of AD progression or that the damage has gone beyond a point where even an 
inflammatory response might be helpful and so it is downregulated which appears to be 
supported by these findings of IL-1β expression whilst the TNF-α expression was 
comparable to controls. 
7.5.2 IL-1β protein levels in relation to complement system activation 
Interestingly, a positive correlation was found here between IL-1β protein level 
and some of the complement proteins measured in the AD group. In the AD group, in both 
the frontal and the temporal cortex, a strong positive correlation was seen between IL-1β 
and the regulatory complement protein (CFH) the understanding of which is not yet clear. 
The release of inflammatory cytokines and activation of the complement system are 
important events in the immune responses. There is some evidence that sublethal 
complement system activation can mediate NLRP3 inflammasome-induced IL-1β 




action was evident (648,649). The interaction between the two systems together with 
microglial activation in the chronic inflammation in the brain should be considered for 
further studies. 
7.5.3 IL-1β and TNF-α mRNA expression in post-mortem brain tissue  
IL-1β and TNF-α expression were both measured in this study by quantitative RT-
PCR (qPCR) calibrated against validated calibrator genes; GAPDH and RPL13. Relative 
IL-1β expression was decreased significantly in both the frontal and the temporal cortex in 
AD compared to matched controls in relation to RPL13 but not to GAPDH. No significant 
difference was seen in TNF-α mRNA expression against either calibrator gene.  
IL-1β and TNF-α gene expression have been studied previously using another 
qPCR approach using SYBR green methods in the temporal and cerebellum of 10 AD 
patients. In this study an increase in TNF-α mRNA expression was reported in cerebellum, 
not in the temporal cortex. This observed upregulation in the cerebellum may be involved 
in its protection from AD pathology, while in the same study IL-1β mRNA showed 
significantly higher gene expression in the temporal cortex more than the cerebellum (616). 
It is worth highlighting that surprisingly SYBR green is considered to have less sensitivity 
than the TaqMan method used in the current study (650), although other studies suggest 
that the methods can be comparable if enough attention is given to optimisation(651). 
 Anti-inflammatory cytokines such as IL-3 and IL-10 are negative regulators for 
IL-1β, Morimoto et al., also showed a positive correlation in mRNA expression between 
IL-1β with IL-10 and IL-13; however, there was insufficient time for me to measure anti-
inflammatory genes expression in AD brain. 
7.6 Summary and conclusions 
➢ IL-1β protein is significantly reduced in AD tissue in both the frontal and temporal 
cortices compared to age matched controls. 
➢ IL-1β protein is significantly higher in the temporal cortex compared to the frontal 




➢ IL-1β protein level is not affected by age or delayed post-mortem interval in brain 
tissue. 
➢ IL-1β concentration correlated positively with complement proteins in the frontal 
cortex (C1q, CFH and clusterin), and with CFH in the temporal cortex. 
➢ IL-1β gene expression was significantly lower in both frontal and temporal brain 
areas relative to RPL13, but not relative to GAPDH, and which was consistent with 
measurements of IL-1β levels 
➢ It was not possible to accurately measure TNF-α and IL-6 protein levels in this 
study. 
➢ TNF-α gene expression was not significantly different in either frontal or temporal 




8. Chapter 8: Discussion. 
8.1 General discussion and concluding remarks 
Many studies have suggested links between neuroinflammation and AD (201,220–
222). Understanding the origin of changes in AD brain leading to the pathology is key for 
successful therapeutic approaches. The role of neuroinflammation in AD progression has 
been controversial. Both detrimental and protective effects have been reported, which are 
likely to depend on the cellular or molecular alterations and the cross-talk among different 
cell types in the brain (354,652,653). 
Various animal models have been generated to mimic some aspects of the changes 
that happen in AD without reproducing the complexity arising from different human-
related environmental and genetic factors. These do not develop the same level of neuronal 
loss as is seen in humans, which is a cardinal feature of the disease (654). Plasma samples 
are more readily obtained in patients than CSF and appear to be a favoured route to 
exploring biomarkers. Despite that, they have limitations as to the extent to which they 
sensitively and accurately reflect the complete metabolic state in the brain. CSF is, in 
contrast, more likely to provide a better representation of brain changes; however, obtaining 
this is more invasive procedure and thus less preferable for patients and research study 
participants.  
Studying neuroinflammation in post-mortem brain tissue gives some very 
important information about the events in AD pathogenesis. These have the advantage of 
using tissue where there is the most accurate diagnosis possible as to the cause of a 
dementia and ensuring the diagnosis is accurate. Yet, it is worth mentioning that also post-
mortem brain studies have many practical difficulties due to the variability in pre- and post-
mortem conditions such as the age, PMI, genetic heterogeneity, the cause of death and the 
agonal state at the time of death. 
A cohort of clinically and pathologically validated AD cases (33 subjects) with 
LOAD diagnosis and age matched controls (31 subjects) was selected. The study cohort 
was matched as close as possible regarding age at death and PMI. Studies were carried out 
on SDS homogenates of grey matter from two brain areas: the frontal cortex (BA 8/9) and 




brain regions coverage to most similar studies undertaken to date. The comparison groups 
and tissue were evenly balanced in terms of total protein concentration.  
8.1.1 Is a disruption in the BBB seen in AD brain compared with normal 
ageing in this cohort? 
As described in Chapter 3, the extent of BBB disruption in AD brains was explored 
by measuring fibrinogen levels in the post-mortem homogenates of this cohort. No 
significant difference between AD and age-matched controls was seen in the frontal or the 
temporal cortex, which was somewhat unexpected given evidence that BBB disruption is 
an early pathological feature of AD (547). However, this finding is also somewhat helpful 
for the purposes of project as it suggests that the protein changes reported in this thesis 
would be more likely to have originated from the brain itself and not from peripheral 
incursion. There is evidence, however, from the literature that the BBB is disrupted with 
normal ageing, with fibrinogen being described as increasing in both mice and human brain 
with age (142,143,556). Furthermore, changes in fibrinogen levels are probably evident in 
the white matter (557) whilst another study, suggested that fibrinogen is a marker of small 
vessel disease, not AD (558). Thus, it is possible the lack of differences between AD and 
controls is not as unexpected as some might assume, that the accuracy of diagnosis in the 
AD cohort has excluded vascular cases more than might occur in a clinical study and that 
the age association on BBB disruption occurs equally between the cases and controls that 
were well matched. 
It is likely that BBB disruption is not a contributing factor to findings reported in 
this thesis. Yet, it is worth commenting on previous studies that have highlighted 
interactions between fibrinogen levels and ApoE, with a significant increase in fibrinogen 
levels reported in those individuals homozygous for APOE ε4 (133). I found a non-
significant trend (P = 0.057) towards an increase in fibrinogen levels in those individuals 
with the APOE ε4 allele and thus it is reasonable to acknowledge that a larger cohort size 
would need to be examined as an association might be detectable. Furthermore, the APOE 
ε4 allele is more common in AD than controls, and so it may be that its relationship with 




8.1.2 Is the complement system dysregulated in AD? Which brain area 
shows the most change? 
In Chapter 4, various complement components were described. These were all 
measured in the frontal and temporal cortices of post-mortem human brain tissue. This 
findings indicate that several elements, suggesting a wider effect in the complement system, 
are dysregulated in AD. The observed changes tended to be more significant in the temporal 
cortex, which is a brain area affected earlier than the frontal lobe in the disease 
(95,655,656). 
 
Figure 8-1: Schematic figure of results of complement proteins changes in AD brain. This 
figure shows dysregulated complement proteins among the classical and alternative complement 
pathways in AD brains compared to age-matched controls in F= frontal cortex, and T= temporal 




It was interesting to investigate the relationship between the pathological changes 
of AD (Aβ load and tau in the form of Braak tangle staging) with complement protein 
levels. A significant positive correlation was seen between Aβ load and C3 in the frontal 
tissue, which may indicate a possible association between C3 and Aβ that may point to 
activation of the classical complement pathway in AD. A trend towards positive correlation 
was also seen with C1q in the frontal cortex. This is consistent with an earlier finding that 
showed high levels of colocalization of C1q with Aβ (410). Moreover, different 
complement proteins were significantly increased in late Braak stages (V-VI) such as iC3b 
and clusterin. These findings suggest that complement dysregulation may increases as the 
disease pathology becomes more extensive. 
Two main findings in this part of this study were the upregulation of both iC3b and 
clusterin in AD in both brain areas tested. In terms of iC3b, this is produced by the action 
of CFH and CFI on C3b. Normally iC3b/CR3 signalling increases microglial activation 
and promotes the clearance of apoptotic cells and the sequential production of cytokines 
and synaptic pruning;  in line with this, blocking this pathway rescued synapses in AD mice 
(374,392,415). The microglial receptor CR3 has also been shown to mediate Aβ 
phagocytosis (106,427). The increase of iC3b in this cohort may be related to this 
microglial pathway and microglial activation, which, was beyond the scope of this study 
because unavailability of validated ELISAs to measure microglial activation. It was 
interesting to look at the correlation between iC3b and CFH, a significant positive 
correlation between the two proteins in all groups analysed, notably CFH is responsible for 
the production of iC3b.  
In plasma, clusterin was previously suggested as one of the main complement 
components found to give some promising results as a predictor for cognitive decline and 
also for the conversion from MCI to AD, in addition to the complement proteins CFI and 
TCC (399). Clusterin, a highly expressed chaperone protein in the brain, was significantly 
increased in AD homogenates in both the frontal and temporal cortices. It has many roles 
in the brain and is thought to be protective by helping in the clearance of Aβ (379,437). An 
interesting finding in this study was that there was a positive correlation between clusterin 
and TCC suggesting an ongoing terminal complement pathway inhibition. The increase in 
clusterin could be a compensatory mechanism to facilitate Aβ clearance, or to inhibit the 
complement activation in the brain. It is worth noting that the imbalance between 
complement protein production and complement cascade inhibitors, may contribute to the 




8.1.3 What are the changes of complement genes expression seen in AD 
brain? Are these consistent with changes in the complement proteins? 
As described in Chapter 5, the expression of various complement genes (C1qA, 
C3, CFH, CR1 and CLU) was measured in the frontal and the temporal cortices of (15) AD 
and (15) control brains. There were the same brain areas as were tested in the protein 
studies. Studying relative gene expression by measuring the levels of mRNA gives 
additional information about the possible origin of any observed changes seen in proteins 
However, it is necessary to acknowledge factors in RNA extraction, including the choice 
of appropriate stable calibrator gene, especially in post-mortem brain tissue that might have 
a bearing on analysis. To date, most data for gene expression in post-mortem brain tissue 
was obtained by semiquantitative measurement such as northern blot (564,582) although 
these pre-date the developments in technology that qPCR now offers. It is therefore difficult 
to compare with these results because of the different techniques and different sized cohorts 
studied and thus methods used in this study were done before on human brain tissue (435). 
Multiple calibrator genes were selected and tested for the stability in this cohort to 
be used for relative gene quantification by qPCR. That gave a conclusion that there may be 
no single ideal calibrator gene to study gene expression in AD. This is because one of the 
limitations of using qPCR on homogenates from brain tissue is that several cell types are 
likely to be represented in one sample. Thus, the calibrator gene expression might be 
affected by the extensive neuronal loss as well as the glial cell activation seen in AD cases 
that do not occur in non-demented cases. Those calibrator genes found to be most stable in 
this cohort were used to help calibrate and normalize the analysis between the diagnostic 
groups as much as possible. GAPDH was found to be the most stable in the whole cohort 
compared to β-ACT, therefore, in the second set of experiments β-ACT was replaced with 
RPL13, the expression of which was not significantly different between the groups and thus 
fulfilling the properties of an acceptable calibrator gene. 
RNA quality was found to be a problem in this study, as it has also been found in 
other studies of post-mortem brain tissues (657). It is known that RNA can be easily 
degraded, and many factors can be involved in the degradation such as PMI, pH of the 
tissue, the agonal state, handling and storage of the tissue and repeated freeze-thaw cycles 
(657–659). The relationship between RNA quality and those factors were explored and no 




significant difference was seen between frontal and temporal RNA quality, which was 
similar to that of another study (658).  
In order to overcome the low quality of RNA, preliminary PCR experiments were 
carried out comparing different RNA qualities, also the PCR efficiency for the target genes 
was tested in different samples and no effect was seen in RNA quality. In a previous study, 
the effect of RNA quality on PCR efficiency was minimal (575). Several practices were 
adopted to try to minimize the errors in the PCR experiment: (1) TaqMan probes were 
chosen for more accurate and reliable results. (2) Primers chosen were of a small amplicon 
size; not more than 200 base pairs. (3) More than one calibrator gene was tested for each 
PCR experiment. (4) Normalization to the most stable calibrator gene between groups was 
used. (5) Accuracy of measurement for the starting material of RNA. All of these increased 
this confidence in my ability to interpret the PCR results. 
The results of complement gene expression in this study confirmed previous 
reports that complement is expressed locally from brain tissue (564,582) and suggests that 
the complement system is also dysregulated at the molecular level of the disease. In the 
frontal cortex C3 and CLU genes were significantly upregulated while in the temporal 
cortex, C1qA, C3 and CR1 were upregulated relative to GAPDH expression. Interestingly, 
other calibrator genes used for normalization did not show any significant results in relative 
gene expression. qPCR also showed that CFH gene expression was not changed in AD 
brain. However, the discrepancy between protein data described in Chapter 4 and 
complement genes results was evident, for example CLU gene was only upregulated in the 
frontal cortex, while clusterin protein was significantly increased in both frontal and 
temporal cortices. On the contrary, C3 gene was found to be upregulated in both brain areas 
tested, while its protein level was increased significantly in the temporal cortex only. This 
means that there appears to be no direct reflection of the changes to protein levels in terms 
of gene expression and shows the limitations of just doing gene expression studies alone 
without looking at the protein levels as well. 
Despite the limitation discussed previously, to the best of my knowledge, this study 
is one of the largest cohorts measuring complement gene expression by a method that is 
commonly used for its sensitivity and specificity for the accurate measurement of gene 
expression. Further studies would be beneficial to confirm the current findings, several of 




corresponding proteins, although with some inconsistencies between brain regions and 
between the levels of expression between different calibrator genes used. 
8.1.4 Is astrocyte activation seen in AD brain? Which brain area shows 
more activation? Is there any detectable relationship with the presence of 
APOE ε4? 
Although the microglia are known to be central to complement activation and 
inflammation in AD, astrocytes are also known to play an important, although not as well 
defined, role in neuroinflammatory events in the AD process. In Chapter 6, GFAP was 
explored as a marker of activated astrocytes in AD brain tissue, in terms of its localization 
by IHC, protein measurement and relative GFAP gene expression in the protein and PCR 
cohorts previously described.  
GFAP level was found to be significantly increased in the temporal, but not in the 
frontal homogenates. On comparing regions amongst the same diagnostic groups, 
significantly higher levels of GFAP were seen in the temporal cortex, compared to the 
frontal, that was found in the AD group only, meaning that in AD, astrocyte activation is 
increased in the early affected brain area with pathology. Furthermore, significantly higher 
GFAP levels were seen in the temporal cortex in later Braak stages (V-VI), which means 
that not only is astrocyte activation more evident in the temporal cortex, it is also positively 
correlated with the disease severity. 
Relative GFAP gene expression was measured and calibrated the PCR results 
against two calibrator genes GAPDH and RPL13 genes. GFAP gene was found to be 
upregulated in both the frontal and the temporal cortex in AD, compared to matched 
controls, and the results were consistent when calibrated against both calibrator genes 
tested. The temporal cortex result was in accord with another study that had used less 
accurate semiquantitative methods i.e. densitometric evaluation of northern blots (604). 
GFAP expression is thought to be increased by age in mouse (606), in rat and human brain 
(607). In this study, a significant positive correlation was found with age, but only in the 
frontal cortex, further studies would be needed to confirm this finding.   
Interestingly, a significant negative effect of PMI on GFAP protein levels was seen 




expression. This suggests that protein degradation may be an issue over time and in relation 
to post-mortem rather than less protein arising from reduced gene expression. This was not 
seen in a previous study in which GFAP levels were measured by Western Blot (599), 
however, the PMI of this cohort was longer than in that study. To investigate this further, 
another experiment involving a post-mortem simulation was done. I found the same pattern 
of decreasing GFAP level with increased PMI, although this decline was not statistically 
significant, but it did involve a small number of samples that further studies would need to 
address to properly confirm the current findings.  
The relationship between GFAP and APOE genotype was also explored. GFAP 
concentration was significantly higher in the ε4 heterozygotes in comparison to samples 
without an ε4 allele in the temporal cortex. This was not evident in the frontal cortex. There 
may be a complex relationship that warrants further investigation as the APOE ε4 allele is 
the main risk factor for LOAD. Both also have possible roles in Aβ clearance and an 
association between increased astroglial activation and APOE ε4 might exacerbate 
pathology.  
8.1.5 Is there any correlation between complement proteins studied in the 
cohort and astrocyte marker? 
To the best of my knowledge, this is the first study to assess the relationship 
between GFAP and complement proteins. In relation to complement system proteins, 
GFAP levels in temporal cortex area were positively correlated with complement proteins 
(i.e. iC3b, and TCC) and regulators (i.e. CFH, and clusterin) especially in the AD group. 
This suggests close interaction between the complement system activation and astrocyte 
activation in AD brain in the temporal cortex. However, a similar positive correlation of 
GFAP levels was seen only with iC3b protein levels in the frontal cortex. 
8.1.6 Is IL-1β protein level altered in AD brain? Which brain area shows 
more changes?  
In Chapter 7, the aim was to measure several pro-inflammatory cytokines. 
Unfortunately, it was only possible to measure IL-1β protein levels after many trials and 
also the relative gene expression of IL-1β and TNF-α. Previous studies of pro-inflammatory 




methods and arguably lower sensitivity. Due to this, as well as the disease complexity, 
inconsistent and conflicting results from plasma and CSF have been reported 
(519,521,522,525). Furthermore, a limited number of post-mortem studies had been carried 
out to investigate pro-inflammatory cytokines. A high sensitivity ELISA kit was able to 
detect the mature form of IL-1β. 
In this protein cohort, surprisingly, a significant decrease of IL-1β levels in AD 
brain homogenates was seen compared to age-matched controls in both the frontal and the 
temporal cortices. These findings need to be replicated in a larger cohort. However, this 
reduction was consistent with a large unpublished study on superior temporal cortex (BA 
41/42) by colleagues in the Dementia Research Group at the University of Bristol. On 
examining the regional differences in the brain, IL-1β protein has showed a significantly 
higher levels in the temporal cortex compared to the frontal cortex in both control and AD 
groups.  
It worth noting that IL-1β and other pro-inflammatory cytokines (IL-6 and TNF-
α) were also decreased in AD brain in a smaller study of 16 AD and 20 controls in post-
mortem brain tissue from the same brain areas (BA9 and BA21) used in this study, using 
multiplex assays (638). Another early study showed no significant difference in IL-1β 
levels between AD and controls using IHC (637), while others showed an increase in IL-
1β brain in the frontal and temporal cortices (640), and hippocampus (640,641). 
Although many differing results were encountered by multiple smaller studies with 
different methodologies; this may be explained by an exhausted or failed inflammatory 
response in which pro-inflammatory cytokines production might change under more severe 
pathological conditions such as severe and late stages of AD (642). These conflicting 
results may also reflect individual variations in cytokine profile (472) or the imbalance 
between pro- and anti-inflammatory cytokines. It was not possible to investigate any anti-
inflammatory cytokines in AD brain due to the time constraints and this is worthy of further 
investigations to get a broader perspective of the level of cytokine involvement in AD. 
Additionally, relative gene expression analysis of IL-1β revealed a significant 
decrease in both the frontal and the temporal cortex in AD compared to matched controls 
in relation to RPL13 but not when calibrated against GAPDH. In contrast, TNF-α mRNA 




8.1.7 Is there any correlation between IL-1β proteins studied in the cohort 
and astrocyte or complement markers? 
Interestingly, these results also revealed a strong positive correlation between IL-
1β and one components of the complement system; the regulatory complement protein 
CFH in AD groups in both brain areas tested, although the understanding of which is not 
yet clear. This suggests the existence of an interaction between the complement system and 
this should be considered for further studies. Moreover, a positive correlation was also seen 
between IL-1β and GFAP protein levels in the temporal AD cortex. 
8.2 Limitations of the current study 
8.2.1 Limitations of the protein studies 
• The study included two brain areas (frontal and temporal cortices) with different 
pathology as previously mentioned. It would be more informative if a third brain 
area with less pathology could have been included, such as cerebellum, which we 
thought would be ‘spared’ from the disease. However, recent evidence has shown 
that the cerebellum is also affected in the early involvement of AD pathology (122) 
and in brain atrophy (123). More recent understanding of the widespread nature of 
AD pathology reveals the difficulty in finding brain areas which are universally 
spared and thus suitable for use as a true control brain region. 
• The Aβ parenchymal load, previously measured in a different project and used for 
the analysis of possible correlation between neuroinflammatory markers and brain 
pathology, is in fact an average of Aβ load measurement in three brain areas in the 
cerebral cortex (frontal, temporal and parietal) and intended to give a summary 
estimate of Aβ load. It would be more accurate to have had the opportunity to 
undertake direct measurements of soluble Aβ in some of the same homogenates 
used in this study, or from corresponding tissues from the same brain area that 
would be needed for the preparation of additional specific guanidine-extracted 
homogenates to allow the measurement of Aβ fractions.  
• The present study was also limited by the sample size. Although it was not a small 




a bigger cohort could give even more power and confidence in interpreting the 
results. That became more obvious especially when subdividing the groups into 
smaller groups for further analyses and in relation to the APOE comparisons. 
• Issues with time and budget limited the scope to increase the use of IHC or to use 
double immunostaining to allow examination of the co-localisation of the 
complement proteins in the brain with specific cells producing these proteins 
and/or neuropathological hallmarks of AD e.g. Aβ plaques and tangles. This must 
be considered as one of the aims of the future work. 
8.2.2 Limitations of the gene studies 
• The RNA studies were subject to reduced quality of RNA in the post-mortem 
human brain tissue due to their long-term storage following donation as well as 
handling of samples over time. This would be in addition to the different ante- and 
post-mortem variables that may affect the results of the qPCR.  
• These studies were also limited by the sample size, a bigger cohort could give more 
valid and less inconsistent data.  
Despite these limitations discussed here, this is one of the largest cohorts selected 
to study the inflammatory markers by methods which could be argued to be sensitive and 
accurate for the quantitative measurement of proteins and genes. However, further studies 
would be needed to confirm these preliminary results. Moreover, the data retrieved from 
human AD brain may be more relevant than other results obtained from cell or animal 
models which may not reflect the human pathological changes in AD brain. 
8.3 Future work 
Further possible investigations prompted by investigations could consider: 
• Extension of this study to investigate the other forms of dementias such as vascular 
dementia, to see if the same patterns were seen regarding the inflammatory 




vascular dysfunction. There was an intention to expand the research into vascular 
dementias, however, that was not possible due to time and financial related issues. 
• Studying the effect of ageing on inflammatory markers by testing brain samples 
from deceased younger persons, such as those donated in sudden death brain banks 
in Edinburgh. This would give more information about the immune response in the 
human brain with the normal ageing rather than with AD pathology alone. 
•  Studying microglial activation markers, in conjunction with complement and 
inflammation in AD and optimizing sensitive assays to measure this important 
contributor to neuroinflammation. 
• An opportunity to further research the extent of neuronal loss and synaptic changes 
with the inflammatory markers in AD brain, to highlight possible roles of 
complement proteins for example C1q and C3 in neuronal loss. 
• Validating previous findings in a larger sized cohort, by using IHC methods and 
exploring the use of different methods of homogenization with different detergents 
such as Triton-X, rather than SDS to explore if these might increase the yield of 
some of the markers that were not detectable for this work. 
• Replicating pro-inflammatory cytokine experiments to see if the reduction in IL-
1β levels is a consistent finding in AD brain and also to look at anti-inflammatory 





9. Chapter 9: Appendices. 
9.1 Appendix I: Study cohort 
9.1.1 Control cohort 
Table 9-1: Summary of demographic and neuropathological characteristics for the control 
cohort used in this study. BB No.= Brain bank number (SWDBB). Gender (M= male, F = female). 
PMI (post-mortem delay). Braak stage = (0, I, II). APOE genotype (2.3 for example = ε2/ε3). 











Control 1 62 M 4 0 3.4 
Control 16 95 F 46 II 2.3 
Control 36 78 F 24 II 3.3 
Control 50 71 M 25 I 3.3 
Control 66 64 M 12 II 3.4 
Control 69 64 M 16 0 3.3 
Control 72 72 M 42 I 3.3 
Control 73 80 M 106 II 3.3 
Control 74 90 M 45 II 2.3 
Control 75 83 M 86 II 3.3 
Control 79 81 F 103 II 3.3 
Control 81 64 M 23 II 3.3 
Control 84 77 M 55 I 3.3 
Control 95 73 M 36 II 3.3 
Control 98 88 F 62 II 3.3 
Control 106 88 F 72 0 3.3 
Control 110 93 F 18 II 3.3 
Control 112 80 F 92 0 3.3 
Control 122 82 M 30 II 3.3 
Control 128 90 M 48 II 3.3 
Control 130 75 M 48 II 3.3 
Control 141 89 F 15 II 3.3 
Control 147 73 M 33 I 2.3 
Control 206 73 F 59 I 3.3 
Control 259 89 M 91 II 3.4 
Control 295 82 M 3 II 3.3 
Control 328 43 F 12 No No 
Control 333 84 F 17 I 2.3 
Control 336 82 F 37 II 4.4 
Control 390 82 M 56 II 3.3 




9.1.2 AD cohort 
Table 9-2: Summary of demographic and neuropathological characteristics for the AD cohort 
used in this study. BB No.= Brain bank number (SWDBB). Gender (M= male, F = female). PMI 
(post-mortem delay). Braak stage = (III, IV, V, VI). Aβ= amyloid beta load average %. APOE 
















AD 196 78 F 77 VI 2.4 4.4 
AD 205 78 F 9 V 1.09 3.4 
AD 212 81 F 80 III 1.67 3.4 
AD 224 96 M 53 V 0.51 2.3 
AD 241 87 F 67 V 5.77 2.4 
AD 242 79 F 70 III 2.24 3.3 
AD 243 88 F 79 VI No 3.3 
AD 278 78 F 35 VI 7.03 3.3 
AD 288 83 F 43 V 1.68 3.4 
AD 302 70 F 25 VI 1.35 3.4 
AD 370 74 F 12 VI 3.37 3.4 
AD 400 79 M 28 VI 2.1 3.4 
AD 405 85 M 66 VI 8.07 3.4 
AD 424 90 F 21 IV 1.62 4.4 
AD 451 84 F 20 V 5.47 3.4 
AD 470 79 F 72 V 0.91 3.4 
AD 498 83 F 5 V 1.69 3.3 
AD 512 77 F 26 VI 3.1 3.4 
AD 561 74 M 24 V 3.33 3.4 
AD 572 79 M 84 V 2.37 3.4 
AD 573 89 F 39 V 1.67 4.4 
AD 579 84 M 64 V 1.69 3.4 
AD 584 85 F 85 VI 2.53 3.4 
AD 586 80 F 71 VI 4.43 3.3 
AD 665 88 F 75 V 1.087 3.4 
AD 670 83 F 85 VI 3.13 4.4 
AD 691 83 M 99 IV 2.42 3.4 
AD 697 87 M 36 VI 5.65 4.4 
AD 717 85 M 49.5 VI 0.82 3.3 
AD 725 69 M 12 V 3.38 3.4 
AD 731 88 F 88 IV 3.55 3.3 
AD 737 67 F 24.25 VI 3.06 4.4 





9.2 Appendix II: Cohort variables analysis with inflammatory markers 
9.2.1 Age at death correlations for inflammatory markers 
Table 9-3: Statistical analysis of age at death (years) correlation with inflammatory markers 
measured in the thesis. P = P value, r = Pearson’s test r value if data was normally distributed or 
Spearman’s r when data was not normally distributed. 
 
Frontal cortex Temporal cortex 
Control AD Full cohort Control AD Full cohort 
C1q 
P = 0.25 
r = 0.21 
P = 0.53 
r = -0.11 
P = 0.22 
r = 0.15 
P = 0.54 
r = 0.11 
P = 0.13  
r = 0.27 
P = 0.97 
r = -0.004 
C3 
*P = 0.01 
 r = 0.59 
**P = 0.08 
 r = 0.63 
P = 0.27 
r = -0.22 
P = 0.9 
r = -0.03 
P = 0.2 
r = -0.3 
P = 0.9 
r = 0.01 
CFH 
P = 0.54 
r = -0.1 
*P = 0.04  
 r = -0.35 
P = 0.15 
r = -0.18 
P = 0.9 
r = -0.002 
P = 0.47 
r = -0.12 
P = 0.7 
r = -0.05  
iC3b 
P = 0.2 
r = 0.2 
P = 0.3 
r = -0.18 
P = 0.4  
r = 0.1 
P = 0.8 
r = 0.03 
P = 0.3 
r = -0.17 
P = 0.8 
r = -0.02 
Clusterin 
*P = 0.01 
  r = 0.4 
P = 0.29 
r = -0.18 
P = 0.18 
r = 0.16 
P = 0.053 
r = 0.3 
P = 0.7 
r = -0.07 
P = 0.15 
r = 0.18 
TCC 
P = 0.4 
r = 0.12 
P = 0.9 
r = 0.006 
P = 0.6 
r = 0.06 
P = 0.3 
r = 0.15 
P = 0.55 
r = -0.1 
P = 0.79 
r = 0.03 
GFAP 
P = 0.4 
r = 0.15 
P = 0.9 
r = -0.006 
P = 0.2 
r = 0.15 
P = 0.9 
r = -0.006 
**P = 0.009 
  r = -0.45 
P = 0.79 
r = -0.03 
IL-1β 
P = 0.5 
r = 0.13 
P = 0.34 
r = 0.17 
P = 0.9 
r = -0.01 
P = 0.9 
r = -0.02 
P = 0.11 
r = -0.28 
P = 0.11 






9.2.2 Gender comparison for inflammatory markers 
Table 9-4: Gender differences in inflammatory markers tested in the thesis. P value is 
presented. For all assays, control group (M = 19, F =12) and AD group (M = 10, F = 23). In C3 
assay only, control group (M = 13, F =3) and AD group (M = 3, F = 13). 
P value 
Frontal cortex Temporal cortex 
Control 
(19 M vs 12 F) 
AD 
(10 M vs 23 F) 
Control 
(19 M vs 12 F) 
AD 
(10 M vs 23 F) 
C1q 0.18 0.48 0.33 0.76 
C3 0.22 0.29 0.18 0.3 
CFH 0.36 0.47 0.53 M < F *0.04 
iC3b 0.6 0.89 0.69 0.26 
Clusterin 0.56 0.76 0.5 0.49 
TCC 0.86 0.1 0.4 0.8 
GFAP 0.25 0.052 0.1 0.22 
IL-1β F < M *0.017 0.78 0.12 0.28 
 
9.3 Appendix III: Western blotting for some complement antibody 
validation 
 Western blot was used to test the specificity of some antibodies to detect the 




9.3.1 SDS-PAGE and WB for C1q protein in AD brain 
 
Figure 9-1: SDS-PAGE and Western blotting for C1q antibody. The figure shows 8 wells 
(1,2,3,4 are not-reduced samples, C1q recombinant protein, 2 AD samples and one plasma sample) 
and (5,6,7,8 are reduced samples, C1q recombinant protein, 2 AD samples and one plasma sample). 
 
9.3.2 SDS-PAGE and WB for clusterin protein in AD brain 
 
 
Figure 9-2: SDS-PAGE and Western blotting for clusterin antibody. The figure shows 8 wells 
(1,2,3,4 are not-reduced samples, 3 AD samples and one plasma sample) and (5,6,7,8 are reduced 




9.3.3 SDS-PAGE and WB for CFH protein in AD brain 
 
Figure 9-3: SDS-PAGE and Western blotting for CFH antibody. The figure shows 8 wells 
(1,2,3,4 are not-reduced samples, CFH protein, 2 AD samples and one plasma sample) and (5,6,7,8 
are reduced samples, CFH protein, 2 AD samples and one plasma sample). 
 
9.4 Appendix IV: Microglia 
9.4.1  Immunohistochemical staining method for microglia 
Sections that were 7 μm in thickness were cut from paraffin-embedded blocks from 
the frontal cortex (male patient diagnosed with AD, aged 83 years at death and Braak stage 
V) and stained with (3μg/ml) goat polyclonal antibody against human ionized calcium 
binding adaptor molecule 1 (Iba1, Abcam), at 4οC overnight, and donkey polyclonal anti-
goat antibody with dilution 1 in 1000 (Jackson- ImmunoResearch), was used as a secondary 
antibody for 1 hour at RT. Sections were stained by using the protocol outlined in Section 
2.9.1 in the general methodology chapter (Chapter 2). 
9.4.2  Results 
Frontal brain sections were stained with a goat polyclonal antibody against human 
Iba1; which labels microglia and macrophage-specific calcium-binding protein involved in 
the process of phagocytosis by activated microglia. Some activated microglia were seen in 
AD sections, in comparison to the negative control (no primary antibody); there, the 





Figure 9-4: Representative image of Iba1 IHC staining for microglia with anti Iba1 goat 
polyclonal antibody. Frontal sections: A) AD brain tissue of AD male patient aged 83 years at 
death, Braak stage V:  showing Iba1 labelled microglia stained by goat polyclonal antibody. B) 
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